검색어를 입력하세요.
로그인해야 이용 가능합니다.
|
[의료] |
진단 데이터셋 공개데이터 진단 데이터셋 공개데이터
|
데이터 기본 이용료
|
| 데이터등록일 | 데이터 수정일 | 데이터 이용기한 | 판매제공처 |
|---|---|---|---|
| 2023-07-06 | 2023-07-06 | 무기한 | 비네아 |
| 데이터 제공포맷 | 데이터 제공방식 | 데이터 파일용량 | 데이터 상품구분 |
| json/zip | 다운로드 | 89.00 KB | dataset |
[데이터 출처] BMC Infectious Diseases, JAMA Network Open, Frontiers in Immunology 등 주요 의학 저널 3종에 게재된 호흡기 감염병의 진단에 관련된 의학 학술논문, 의료보고서 [데이터 가공 방식] 의학 논문 및 보고서의 메타데이터, 추출 키워드 데이터셋 분석 [데이터 범위] 분자진단법, 항원/항체법, 세포배양법 등의 호흡기 감염병 진단에 관한 2017~2021년 의학 자료 *2017년 이전과 2021년 이후 데이터는 순차적으로 추가될 예정입니다.
|
ID
|
카테고리ID
|
카테고리명
|
키워드명
|
키워드속성
|
대체키워드명
|
키워드출처
|
키워드대역어
|
논문ID
|
논문DOI명
|
논문제목
|
논문저자
|
논문발행연월
|
논문유형
|
논문출처
|
논문초록
|
논문URL
|
저널ID
|
저널ISSN명
|
저널제목
|
저널발행기관명
|
저널ImpactFactor명
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1065566 | 897 | 진단 | Affect | Term | affect | abstract | abnormality | 22268 | 10.1001/jamanetworkopen.2021.4117 | Association of Vitamin D Levels, Race/Ethnicity, and Clinical Characteristics With COVID-19 Test Results | David O. Meltzer@@@Thomas J. Best@@@Hui Zhang@@@Tamara Vokes@@@Vineet M. Arora@@@Julian Solway | 202103 | Research | PMC | Key Points Question Are differences in vitamin D levels greater than levels traditionally considered sufficient (30 ng/mL) associated with having test results positive for coronavirus disease 2019 (COVID-19) in White and in Black individuals? Findings In this cohort study of 4638 individuals with a measured vitamin D level in the year before undergoing COVID-19 testing, the risk of having positive results in Black individuals was 2.64-fold greater with a vitamin D level of 30 to 39.9 ng/mL than a level of 40 ng/mL or greater and decreased by 5% per 1-ng/mL increase in level among individuals with a level of 30 ng/mL or greater. There were no statistically significant associations of vitamin D levels with COVID-19 positivity rates in White individuals. Meaning These findings suggest that randomized clinical trials to determine whether increasing vitamin D levels to greater than 30 to 40 ng/mL affect COVID-19 risk are warranted, especially in Black individuals. This cohort study examines the associations of vitamin D levels, race, and other characteristics with positive COVID-19 test results. Importance Deficient (ie, <20 ng/mL) or insufficient (ie, 20 to <30 ng/mL) 25-hydroxyvitamin D (also known as calcifediol ) levels are more common in Black individuals than White individuals and are associated with increased coronavirus disease 2019 (COVID-19) risk. Whether COVID-19 risk is associated with differences in vitamin D levels of 30 ng/mL or greater is not known. Objective To examine whether COVID-19 test results are associated with differences in vitamin D levels of 30 ng/mL or greater, including for White individuals and for Black individuals. Design, Setting, and Participants This retrospective cohort study was conducted at an academic medical center in Chicago, Illinois. Participants included individuals with data on vitamin D level within 365 days before COVID-19 testing, which was conducted from March 3 to December 30, 2020. Data were analyzed from September 11, 2020, to February 5, 2021. Exposures The last vitamin D level before COVID-19 testing was categorized as less than 20 ng/mL (ie, deficient), 20 to less than 30 ng/mL (ie, insufficient), 30 to less than 40 ng/mL, or 40 ng/mL or greater. Treatment was defined by vitamin D type and dose 14 days before COVID-19 testing and treatment changes after last vitamin D level. Main Outcomes and Measures The main outcome was a positive result for COVID-19 in polymerase chain reaction testing. Multivariable analyses tested whether previously measured vitamin D level was associated with having test results positive for COVID-19 in White individuals and in Black individuals, controlling for months and treatment changes since the vitamin D level was measured, as well as demographic characteristics and comorbidity indicators. Results A total of 4638 individuals (mean [SD] age 52.8 [19.5] years; 3205 [69%] women) had data for a vitamin D level within 1 year before COVID-19 testing, including 2288 (49%) Black individuals, 1999 (43%) White individuals, and 351 individuals (8%) who were another race/ethnicity (eg, Asian, Mideast Indian, >1 race). Stratified by vitamin D level, 1251 individuals (27%) had less than 20 ng/mL, 1267 individuals (27%) had 20 to less than 30 ng/mL, 1023 individuals (22%) had 30 to less than 40 ng/mL, and 1097 individuals (24%) had 40 ng/mL or greater. Lower vitamin D levels were more common in Black individuals (<20 ng/mL: 829 of 2288 Black individuals [36%]) than White individuals (<20 ng/mL: 315 of 1999 White individuals [16%]). A total of 333 individuals (7%) had test results positive for COVID-19, including 102 White individuals (5%) and 211 Black individuals (9%). Multivariate analysis controlling for time since last vitamin D level measurement was used to estimate the outcomes associated with levels 14 days before COVID-19 testing. A positive test result for COVID-19 was not significantly associated with vitamin D levels in White individuals but was associated with vitamin D levels in Black individuals (compared with ≥40 ng/mL: <20 ng/mL incidence rate ratio [IRR], 2.55 [95% CI, 1.26-5.15]; P =?.009; 20 to <30 ng/mL IRR, 1.69 [95% CI, 0.75-3.84]; P =?.21; 30 to <40 ng/mL IRR, 2.64 [95% CI, 1.24-5.66]; P =?.01). Stratified by vitamin D level, estimated COVID-19 positivity rates in Black individuals were 9.72% (95% CI, 6.74%-13.41%) for individuals with a vitamin D level less than 20 ng/mL, 6.47% (95% CI, 3.33%-10.28%) for individuals with a vitamin D level of 20 to less than 30 ng/mL, 10.10% (95% CI, 6.00%-15.47%) for individuals with a vitamin D level of 30 to less than 40 ng/mL, and 3.82% (95% CI, 1.78%-6.68%) for individuals with a vitamin D level of 40 ng/mL or higher. Multivariate analysis in individuals with a vitamin D level of 30 ng/mL or greater found that the IRR of a positive COVID-19 test result was 0.97 (95% CI, 0.94-0.99; P =?.008) per 1-ng/mL increase in vitamin D overall and 0.95 (95% CI, 0.91-0.98; P =?.003) per 1-ng/mL increase in vitamin D in Black individuals. Conclusions and Relevance In this single-center retrospective cohort study, COVID-19 risk increased among Black individuals with vitamin D level less than 40 ng/mL compared with those with 40 ng/mL or greater and decreased with increasing levels among individuals with levels greater than 30 ng/mL. No significant associations were noted for White individuals. Randomized clinical trials should examine whether increasing vitamin D level to greater than 40 ng/mL affects COVID-19 risk. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7980095/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1065579 | 897 | 진단 | clinical trial | Term | clinical trial | abstract | 임상시험 | 22268 | 10.1001/jamanetworkopen.2021.4117 | Association of Vitamin D Levels, Race/Ethnicity, and Clinical Characteristics With COVID-19 Test Results | David O. Meltzer@@@Thomas J. Best@@@Hui Zhang@@@Tamara Vokes@@@Vineet M. Arora@@@Julian Solway | 202103 | Research | PMC | Key Points Question Are differences in vitamin D levels greater than levels traditionally considered sufficient (30 ng/mL) associated with having test results positive for coronavirus disease 2019 (COVID-19) in White and in Black individuals? Findings In this cohort study of 4638 individuals with a measured vitamin D level in the year before undergoing COVID-19 testing, the risk of having positive results in Black individuals was 2.64-fold greater with a vitamin D level of 30 to 39.9 ng/mL than a level of 40 ng/mL or greater and decreased by 5% per 1-ng/mL increase in level among individuals with a level of 30 ng/mL or greater. There were no statistically significant associations of vitamin D levels with COVID-19 positivity rates in White individuals. Meaning These findings suggest that randomized clinical trials to determine whether increasing vitamin D levels to greater than 30 to 40 ng/mL affect COVID-19 risk are warranted, especially in Black individuals. This cohort study examines the associations of vitamin D levels, race, and other characteristics with positive COVID-19 test results. Importance Deficient (ie, <20 ng/mL) or insufficient (ie, 20 to <30 ng/mL) 25-hydroxyvitamin D (also known as calcifediol ) levels are more common in Black individuals than White individuals and are associated with increased coronavirus disease 2019 (COVID-19) risk. Whether COVID-19 risk is associated with differences in vitamin D levels of 30 ng/mL or greater is not known. Objective To examine whether COVID-19 test results are associated with differences in vitamin D levels of 30 ng/mL or greater, including for White individuals and for Black individuals. Design, Setting, and Participants This retrospective cohort study was conducted at an academic medical center in Chicago, Illinois. Participants included individuals with data on vitamin D level within 365 days before COVID-19 testing, which was conducted from March 3 to December 30, 2020. Data were analyzed from September 11, 2020, to February 5, 2021. Exposures The last vitamin D level before COVID-19 testing was categorized as less than 20 ng/mL (ie, deficient), 20 to less than 30 ng/mL (ie, insufficient), 30 to less than 40 ng/mL, or 40 ng/mL or greater. Treatment was defined by vitamin D type and dose 14 days before COVID-19 testing and treatment changes after last vitamin D level. Main Outcomes and Measures The main outcome was a positive result for COVID-19 in polymerase chain reaction testing. Multivariable analyses tested whether previously measured vitamin D level was associated with having test results positive for COVID-19 in White individuals and in Black individuals, controlling for months and treatment changes since the vitamin D level was measured, as well as demographic characteristics and comorbidity indicators. Results A total of 4638 individuals (mean [SD] age 52.8 [19.5] years; 3205 [69%] women) had data for a vitamin D level within 1 year before COVID-19 testing, including 2288 (49%) Black individuals, 1999 (43%) White individuals, and 351 individuals (8%) who were another race/ethnicity (eg, Asian, Mideast Indian, >1 race). Stratified by vitamin D level, 1251 individuals (27%) had less than 20 ng/mL, 1267 individuals (27%) had 20 to less than 30 ng/mL, 1023 individuals (22%) had 30 to less than 40 ng/mL, and 1097 individuals (24%) had 40 ng/mL or greater. Lower vitamin D levels were more common in Black individuals (<20 ng/mL: 829 of 2288 Black individuals [36%]) than White individuals (<20 ng/mL: 315 of 1999 White individuals [16%]). A total of 333 individuals (7%) had test results positive for COVID-19, including 102 White individuals (5%) and 211 Black individuals (9%). Multivariate analysis controlling for time since last vitamin D level measurement was used to estimate the outcomes associated with levels 14 days before COVID-19 testing. A positive test result for COVID-19 was not significantly associated with vitamin D levels in White individuals but was associated with vitamin D levels in Black individuals (compared with ≥40 ng/mL: <20 ng/mL incidence rate ratio [IRR], 2.55 [95% CI, 1.26-5.15]; P =?.009; 20 to <30 ng/mL IRR, 1.69 [95% CI, 0.75-3.84]; P =?.21; 30 to <40 ng/mL IRR, 2.64 [95% CI, 1.24-5.66]; P =?.01). Stratified by vitamin D level, estimated COVID-19 positivity rates in Black individuals were 9.72% (95% CI, 6.74%-13.41%) for individuals with a vitamin D level less than 20 ng/mL, 6.47% (95% CI, 3.33%-10.28%) for individuals with a vitamin D level of 20 to less than 30 ng/mL, 10.10% (95% CI, 6.00%-15.47%) for individuals with a vitamin D level of 30 to less than 40 ng/mL, and 3.82% (95% CI, 1.78%-6.68%) for individuals with a vitamin D level of 40 ng/mL or higher. Multivariate analysis in individuals with a vitamin D level of 30 ng/mL or greater found that the IRR of a positive COVID-19 test result was 0.97 (95% CI, 0.94-0.99; P =?.008) per 1-ng/mL increase in vitamin D overall and 0.95 (95% CI, 0.91-0.98; P =?.003) per 1-ng/mL increase in vitamin D in Black individuals. Conclusions and Relevance In this single-center retrospective cohort study, COVID-19 risk increased among Black individuals with vitamin D level less than 40 ng/mL compared with those with 40 ng/mL or greater and decreased with increasing levels among individuals with levels greater than 30 ng/mL. No significant associations were noted for White individuals. Randomized clinical trials should examine whether increasing vitamin D level to greater than 40 ng/mL affects COVID-19 risk. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7980095/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1154976 | 897 | 진단 | high risk | Term | high risk | abstract | None | 25010 | 10.1186/s12879-022-07513-0 | Anti-SARS-CoV2 antibody-mediated cytokine release syndrome in a patient with acute promyelocytic leukemia | Ahmed N Hegazy@@@Jan Kr?nke@@@Stefan Angermair@@@Stefan Schwartz@@@Carl Weidinger@@@Ulrich Keller@@@Sascha Treskatsch@@@Britta Siegmund@@@Thomas Schneider | 202206 | Case Reports | PMC | {{{ Abstract }}} !!{{ Background: }} Passive immunization against SARS-CoV-2 limits viral burden and death from COVID-19; however, it poses a theoretical risk of disease exacerbation through antibody-dependent enhancement (ADE). ADE after anti-SARS-CoV2 antibody treatment has not been reported, and therefore the potential risk and promoting factors remain unknown. !!{{ Case presentation: }} A 75-year-old female was admitted to the emergency room with recurrent, unexplained bruises and leukocytopenia, anemia, and thrombocytopenia. Evaluation of a bone marrow biopsy established the diagnosis of an acute promyelocytic leukemia (APL). SARS-CoV-2 RT-PCR testing of nasal and throat swabs on admission was negative. During the routine SARS-CoV-2 testing of inpatients, our patient tested positive for SARS-CoV-2 on day 14 after admission without typical COVID-19 symptoms. Due to disease- and therapy-related immunosuppression and advanced age conferring a high risk of progressing to severe COVID-19, casirivimab and imdevimab were administered as a preemptive approach. The patient developed immune activation and cytokine release syndrome (CRS) occurring within four hours of preemptive anti-SARS-CoV2 antibody (casirivimab/imdevimab) infusion. Immune activation and CRS were evidenced by a rapid increase in serum cytokines (IL-6, TNFα, IL-8, IL-10), acute respiratory insufficiency, and progressive acute respiratory distress syndrome. !!{{ Discussion and conclusion: }} The temporal relationship between therapeutic antibody administration and the rapid laboratory, radiological, and clinical deterioration suggests that CRS was an antibody-related adverse event, potentially exacerbated by APL treatment-mediated differentiation of leukemic blasts and promyelocytes. This case highlights the need for careful assessment of life-threatening adverse events after passive SARS-CoV-2 immunization, especially in the clinical context of patients with complex immune and hematological landscapes. !!{{ Keywords: }} Acute promyelocytic leukemia; Antibody-dependent enhancement; Case report; Coronavirus disease 2019; Cytokine release syndrome; SARS-CoV2; Viral infection. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188919/ | 2 | 1471-2334 | BMC Infectious Diseases | London : BioMed Central | |
| 1154984 | 897 | 진단 | Inpatients | Term | inpatient | abstract | None | 25010 | 10.1186/s12879-022-07513-0 | Anti-SARS-CoV2 antibody-mediated cytokine release syndrome in a patient with acute promyelocytic leukemia | Ahmed N Hegazy@@@Jan Kr?nke@@@Stefan Angermair@@@Stefan Schwartz@@@Carl Weidinger@@@Ulrich Keller@@@Sascha Treskatsch@@@Britta Siegmund@@@Thomas Schneider | 202206 | Case Reports | PMC | {{{ Abstract }}} !!{{ Background: }} Passive immunization against SARS-CoV-2 limits viral burden and death from COVID-19; however, it poses a theoretical risk of disease exacerbation through antibody-dependent enhancement (ADE). ADE after anti-SARS-CoV2 antibody treatment has not been reported, and therefore the potential risk and promoting factors remain unknown. !!{{ Case presentation: }} A 75-year-old female was admitted to the emergency room with recurrent, unexplained bruises and leukocytopenia, anemia, and thrombocytopenia. Evaluation of a bone marrow biopsy established the diagnosis of an acute promyelocytic leukemia (APL). SARS-CoV-2 RT-PCR testing of nasal and throat swabs on admission was negative. During the routine SARS-CoV-2 testing of inpatients, our patient tested positive for SARS-CoV-2 on day 14 after admission without typical COVID-19 symptoms. Due to disease- and therapy-related immunosuppression and advanced age conferring a high risk of progressing to severe COVID-19, casirivimab and imdevimab were administered as a preemptive approach. The patient developed immune activation and cytokine release syndrome (CRS) occurring within four hours of preemptive anti-SARS-CoV2 antibody (casirivimab/imdevimab) infusion. Immune activation and CRS were evidenced by a rapid increase in serum cytokines (IL-6, TNFα, IL-8, IL-10), acute respiratory insufficiency, and progressive acute respiratory distress syndrome. !!{{ Discussion and conclusion: }} The temporal relationship between therapeutic antibody administration and the rapid laboratory, radiological, and clinical deterioration suggests that CRS was an antibody-related adverse event, potentially exacerbated by APL treatment-mediated differentiation of leukemic blasts and promyelocytes. This case highlights the need for careful assessment of life-threatening adverse events after passive SARS-CoV-2 immunization, especially in the clinical context of patients with complex immune and hematological landscapes. !!{{ Keywords: }} Acute promyelocytic leukemia; Antibody-dependent enhancement; Case report; Coronavirus disease 2019; Cytokine release syndrome; SARS-CoV2; Viral infection. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188919/ | 2 | 1471-2334 | BMC Infectious Diseases | London : BioMed Central | |
| 1219676 | 897 | 진단 | substantial reductions | Action | substantial reduction | abstract | None | 556 | 10.1001/jamanetworkopen.2021.21675 | Association of COVID-19 Mitigation Measures With Changes in Cardiorespiratory Fitness and Body Mass Index Among Children Aged 7 to 10 Years in Austria | Gerald Jarnig@@@Johannes Jaunig@@@Mireille N. M. van Poppel | 202108 | Article | PMC | This cohort study examines the association of COVID-19 mitigation measures with changes in cardiorespiratory fitness measures and body mass index among primary schoolchildren aged 7 to 10 years in Austria. Key Points Question Were COVID-19 mitigation measures associated with changes in cardiorespiratory fitness measures and body mass index among primary schoolchildren in Austria? Findings In this cohort study of 764 primary schoolchildren aged 7 to 10 years, COVID-19 mitigation measures were associated with substantial reductions in cardiorespiratory fitness measures and increases in body mass index SD scores and the proportion of children with overweight or obesity. Meaning The findings suggest that collaborative efforts are needed to improve children’s health and fitness to prevent long-term negative health outcomes. Importance Previous studies have shown reductions in self-reported physical activity levels in children associated with implementation of COVID-19 mitigation measures, and data on objectively assessed health parameters are limited. Objective To examine the association of COVID-19 mitigation measures with changes in cardiorespiratory fitness (CRF) measures and body mass index (BMI) among primary schoolchildren. Design, Setting, and Participants This cohort study included children aged 7 to 10 years from 12 randomly selected primary schools in urban and rural districts of Klagenfurt, Austria. Baseline CRF and BMI measurements were obtained in September 2019 before COVID-19 mitigation measures were implemented, and follow-up measurements were obtained in June and September 2020. Exposures COVID-19 mitigation measures. Main Outcomes and Measures Cardiorespiratory fitness was measured with a 6-minute endurance run test. Height and weight were objectively measured. Standard deviation scores were calculated for CRF and BMI. Changes over time were analyzed using analyses of variance. Secondary analyses were performed for subgroups stratified by sex. Results A total of 764 children (383 girls [50.1%]) aged 7 to 10 years had all measurements completed. From September 2019 to September 2020, CRF SD scores changed by ?1.06 (95% CI, ?1.13 to ?1.00), with a similar decrease in both boys and girls. Body mass index SD scores had increased by 0.12 (95% CI, 0.06-0.16) in June 2020 and by 0.16 (95% CI, 0.12-0.20) in September 2020 compared with September 2019. The increase in BMI SD scores (from September 2019 to September 2020) was greater among boys (0.23; 95% CI, 0.18-0.29) than among girls (0.09; 95% CI, 0.04-0.15). During the 1-year period, the percentage of children with overweight or obesity increased from 20.3% (155 children) to 24.1% (184 children) (difference, 3.8% [29 children]). Conclusions and Relevance In this cohort study of children in Austria, COVID-19 mitigation measures were associated with decreases in CRF measures and increases in BMI. The findings suggest that collaborative efforts are needed to reverse these changes in children’s health to prevent long-term negative health outcomes. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391099/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1219677 | 897 | 진단 | variance | Term | variance | abstract | None | 556 | 10.1001/jamanetworkopen.2021.21675 | Association of COVID-19 Mitigation Measures With Changes in Cardiorespiratory Fitness and Body Mass Index Among Children Aged 7 to 10 Years in Austria | Gerald Jarnig@@@Johannes Jaunig@@@Mireille N. M. van Poppel | 202108 | Article | PMC | This cohort study examines the association of COVID-19 mitigation measures with changes in cardiorespiratory fitness measures and body mass index among primary schoolchildren aged 7 to 10 years in Austria. Key Points Question Were COVID-19 mitigation measures associated with changes in cardiorespiratory fitness measures and body mass index among primary schoolchildren in Austria? Findings In this cohort study of 764 primary schoolchildren aged 7 to 10 years, COVID-19 mitigation measures were associated with substantial reductions in cardiorespiratory fitness measures and increases in body mass index SD scores and the proportion of children with overweight or obesity. Meaning The findings suggest that collaborative efforts are needed to improve children’s health and fitness to prevent long-term negative health outcomes. Importance Previous studies have shown reductions in self-reported physical activity levels in children associated with implementation of COVID-19 mitigation measures, and data on objectively assessed health parameters are limited. Objective To examine the association of COVID-19 mitigation measures with changes in cardiorespiratory fitness (CRF) measures and body mass index (BMI) among primary schoolchildren. Design, Setting, and Participants This cohort study included children aged 7 to 10 years from 12 randomly selected primary schools in urban and rural districts of Klagenfurt, Austria. Baseline CRF and BMI measurements were obtained in September 2019 before COVID-19 mitigation measures were implemented, and follow-up measurements were obtained in June and September 2020. Exposures COVID-19 mitigation measures. Main Outcomes and Measures Cardiorespiratory fitness was measured with a 6-minute endurance run test. Height and weight were objectively measured. Standard deviation scores were calculated for CRF and BMI. Changes over time were analyzed using analyses of variance. Secondary analyses were performed for subgroups stratified by sex. Results A total of 764 children (383 girls [50.1%]) aged 7 to 10 years had all measurements completed. From September 2019 to September 2020, CRF SD scores changed by ?1.06 (95% CI, ?1.13 to ?1.00), with a similar decrease in both boys and girls. Body mass index SD scores had increased by 0.12 (95% CI, 0.06-0.16) in June 2020 and by 0.16 (95% CI, 0.12-0.20) in September 2020 compared with September 2019. The increase in BMI SD scores (from September 2019 to September 2020) was greater among boys (0.23; 95% CI, 0.18-0.29) than among girls (0.09; 95% CI, 0.04-0.15). During the 1-year period, the percentage of children with overweight or obesity increased from 20.3% (155 children) to 24.1% (184 children) (difference, 3.8% [29 children]). Conclusions and Relevance In this cohort study of children in Austria, COVID-19 mitigation measures were associated with decreases in CRF measures and increases in BMI. The findings suggest that collaborative efforts are needed to reverse these changes in children’s health to prevent long-term negative health outcomes. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391099/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1219678 | 897 | 진단 | was measured | Action | was measured | abstract | None | 556 | 10.1001/jamanetworkopen.2021.21675 | Association of COVID-19 Mitigation Measures With Changes in Cardiorespiratory Fitness and Body Mass Index Among Children Aged 7 to 10 Years in Austria | Gerald Jarnig@@@Johannes Jaunig@@@Mireille N. M. van Poppel | 202108 | Article | PMC | This cohort study examines the association of COVID-19 mitigation measures with changes in cardiorespiratory fitness measures and body mass index among primary schoolchildren aged 7 to 10 years in Austria. Key Points Question Were COVID-19 mitigation measures associated with changes in cardiorespiratory fitness measures and body mass index among primary schoolchildren in Austria? Findings In this cohort study of 764 primary schoolchildren aged 7 to 10 years, COVID-19 mitigation measures were associated with substantial reductions in cardiorespiratory fitness measures and increases in body mass index SD scores and the proportion of children with overweight or obesity. Meaning The findings suggest that collaborative efforts are needed to improve children’s health and fitness to prevent long-term negative health outcomes. Importance Previous studies have shown reductions in self-reported physical activity levels in children associated with implementation of COVID-19 mitigation measures, and data on objectively assessed health parameters are limited. Objective To examine the association of COVID-19 mitigation measures with changes in cardiorespiratory fitness (CRF) measures and body mass index (BMI) among primary schoolchildren. Design, Setting, and Participants This cohort study included children aged 7 to 10 years from 12 randomly selected primary schools in urban and rural districts of Klagenfurt, Austria. Baseline CRF and BMI measurements were obtained in September 2019 before COVID-19 mitigation measures were implemented, and follow-up measurements were obtained in June and September 2020. Exposures COVID-19 mitigation measures. Main Outcomes and Measures Cardiorespiratory fitness was measured with a 6-minute endurance run test. Height and weight were objectively measured. Standard deviation scores were calculated for CRF and BMI. Changes over time were analyzed using analyses of variance. Secondary analyses were performed for subgroups stratified by sex. Results A total of 764 children (383 girls [50.1%]) aged 7 to 10 years had all measurements completed. From September 2019 to September 2020, CRF SD scores changed by ?1.06 (95% CI, ?1.13 to ?1.00), with a similar decrease in both boys and girls. Body mass index SD scores had increased by 0.12 (95% CI, 0.06-0.16) in June 2020 and by 0.16 (95% CI, 0.12-0.20) in September 2020 compared with September 2019. The increase in BMI SD scores (from September 2019 to September 2020) was greater among boys (0.23; 95% CI, 0.18-0.29) than among girls (0.09; 95% CI, 0.04-0.15). During the 1-year period, the percentage of children with overweight or obesity increased from 20.3% (155 children) to 24.1% (184 children) (difference, 3.8% [29 children]). Conclusions and Relevance In this cohort study of children in Austria, COVID-19 mitigation measures were associated with decreases in CRF measures and increases in BMI. The findings suggest that collaborative efforts are needed to reverse these changes in children’s health to prevent long-term negative health outcomes. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391099/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1219679 | 897 | 진단 | weight | Term | weight | abstract | 중량 | 556 | 10.1001/jamanetworkopen.2021.21675 | Association of COVID-19 Mitigation Measures With Changes in Cardiorespiratory Fitness and Body Mass Index Among Children Aged 7 to 10 Years in Austria | Gerald Jarnig@@@Johannes Jaunig@@@Mireille N. M. van Poppel | 202108 | Article | PMC | This cohort study examines the association of COVID-19 mitigation measures with changes in cardiorespiratory fitness measures and body mass index among primary schoolchildren aged 7 to 10 years in Austria. Key Points Question Were COVID-19 mitigation measures associated with changes in cardiorespiratory fitness measures and body mass index among primary schoolchildren in Austria? Findings In this cohort study of 764 primary schoolchildren aged 7 to 10 years, COVID-19 mitigation measures were associated with substantial reductions in cardiorespiratory fitness measures and increases in body mass index SD scores and the proportion of children with overweight or obesity. Meaning The findings suggest that collaborative efforts are needed to improve children’s health and fitness to prevent long-term negative health outcomes. Importance Previous studies have shown reductions in self-reported physical activity levels in children associated with implementation of COVID-19 mitigation measures, and data on objectively assessed health parameters are limited. Objective To examine the association of COVID-19 mitigation measures with changes in cardiorespiratory fitness (CRF) measures and body mass index (BMI) among primary schoolchildren. Design, Setting, and Participants This cohort study included children aged 7 to 10 years from 12 randomly selected primary schools in urban and rural districts of Klagenfurt, Austria. Baseline CRF and BMI measurements were obtained in September 2019 before COVID-19 mitigation measures were implemented, and follow-up measurements were obtained in June and September 2020. Exposures COVID-19 mitigation measures. Main Outcomes and Measures Cardiorespiratory fitness was measured with a 6-minute endurance run test. Height and weight were objectively measured. Standard deviation scores were calculated for CRF and BMI. Changes over time were analyzed using analyses of variance. Secondary analyses were performed for subgroups stratified by sex. Results A total of 764 children (383 girls [50.1%]) aged 7 to 10 years had all measurements completed. From September 2019 to September 2020, CRF SD scores changed by ?1.06 (95% CI, ?1.13 to ?1.00), with a similar decrease in both boys and girls. Body mass index SD scores had increased by 0.12 (95% CI, 0.06-0.16) in June 2020 and by 0.16 (95% CI, 0.12-0.20) in September 2020 compared with September 2019. The increase in BMI SD scores (from September 2019 to September 2020) was greater among boys (0.23; 95% CI, 0.18-0.29) than among girls (0.09; 95% CI, 0.04-0.15). During the 1-year period, the percentage of children with overweight or obesity increased from 20.3% (155 children) to 24.1% (184 children) (difference, 3.8% [29 children]). Conclusions and Relevance In this cohort study of children in Austria, COVID-19 mitigation measures were associated with decreases in CRF measures and increases in BMI. The findings suggest that collaborative efforts are needed to reverse these changes in children’s health to prevent long-term negative health outcomes. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391099/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1219680 | 897 | 진단 | Year | Term | year | title | None | 556 | 10.1001/jamanetworkopen.2021.21675 | Association of COVID-19 Mitigation Measures With Changes in Cardiorespiratory Fitness and Body Mass Index Among Children Aged 7 to 10 Years in Austria | Gerald Jarnig@@@Johannes Jaunig@@@Mireille N. M. van Poppel | 202108 | Article | PMC | This cohort study examines the association of COVID-19 mitigation measures with changes in cardiorespiratory fitness measures and body mass index among primary schoolchildren aged 7 to 10 years in Austria. Key Points Question Were COVID-19 mitigation measures associated with changes in cardiorespiratory fitness measures and body mass index among primary schoolchildren in Austria? Findings In this cohort study of 764 primary schoolchildren aged 7 to 10 years, COVID-19 mitigation measures were associated with substantial reductions in cardiorespiratory fitness measures and increases in body mass index SD scores and the proportion of children with overweight or obesity. Meaning The findings suggest that collaborative efforts are needed to improve children’s health and fitness to prevent long-term negative health outcomes. Importance Previous studies have shown reductions in self-reported physical activity levels in children associated with implementation of COVID-19 mitigation measures, and data on objectively assessed health parameters are limited. Objective To examine the association of COVID-19 mitigation measures with changes in cardiorespiratory fitness (CRF) measures and body mass index (BMI) among primary schoolchildren. Design, Setting, and Participants This cohort study included children aged 7 to 10 years from 12 randomly selected primary schools in urban and rural districts of Klagenfurt, Austria. Baseline CRF and BMI measurements were obtained in September 2019 before COVID-19 mitigation measures were implemented, and follow-up measurements were obtained in June and September 2020. Exposures COVID-19 mitigation measures. Main Outcomes and Measures Cardiorespiratory fitness was measured with a 6-minute endurance run test. Height and weight were objectively measured. Standard deviation scores were calculated for CRF and BMI. Changes over time were analyzed using analyses of variance. Secondary analyses were performed for subgroups stratified by sex. Results A total of 764 children (383 girls [50.1%]) aged 7 to 10 years had all measurements completed. From September 2019 to September 2020, CRF SD scores changed by ?1.06 (95% CI, ?1.13 to ?1.00), with a similar decrease in both boys and girls. Body mass index SD scores had increased by 0.12 (95% CI, 0.06-0.16) in June 2020 and by 0.16 (95% CI, 0.12-0.20) in September 2020 compared with September 2019. The increase in BMI SD scores (from September 2019 to September 2020) was greater among boys (0.23; 95% CI, 0.18-0.29) than among girls (0.09; 95% CI, 0.04-0.15). During the 1-year period, the percentage of children with overweight or obesity increased from 20.3% (155 children) to 24.1% (184 children) (difference, 3.8% [29 children]). Conclusions and Relevance In this cohort study of children in Austria, COVID-19 mitigation measures were associated with decreases in CRF measures and increases in BMI. The findings suggest that collaborative efforts are needed to reverse these changes in children’s health to prevent long-term negative health outcomes. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391099/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1245365 | 897 | 진단 | clinical trial registry | Term | clinical trial registry | abstract | None | 2869 | 10.1186/s12879-021-06829-7 | Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials | Cathrine Axfors@@@Perrine Janiaud@@@Andreas M. Schmitt@@@Janneke van’t Hooft@@@Emily R. Smith@@@Noah A. Haber@@@Akin Abayomi@@@Manal Abduljalil@@@Abdulkarim Abdulrahman@@@Yeny Acosta-Ampudia@@@Manuela Aguilar-Guisado@@@Farah Al-Beidh@@@Marissa M. Alejandria@@@Rachelle N. Alfonso@@@Mohammad Ali@@@Manaf AlQahtani@@@Alaa AlZamrooni@@@Juan-Manuel Anaya@@@Mark Angelo C. Ang@@@Ismael F. Aomar@@@Luis E. Argumanis@@@Alexander Averyanov@@@Vladimir P. Baklaushev@@@Olga Balionis@@@Thomas Benfield@@@Scott Berry@@@Nadia Birocco@@@Lynn B. Bonifacio@@@Asha C. Bowen@@@Abbie Bown@@@Carlos Cabello-Gutierrez@@@Bernardo Camacho@@@Adrian Camacho-Ortiz@@@Sally Campbell-Lee@@@Damon H. Cao@@@Ana Cardesa@@@Jose M. Carnate@@@German Jr. J. Castillo@@@Rossana Cavallo@@@Fazle R. Chowdhury@@@Forhad U. H. Chowdhury@@@Giovannino Ciccone@@@Antonella Cingolani@@@Fresthel Monica M. Climacosa@@@Veerle Compernolle@@@Carlo Francisco N. Cortez@@@Abel Costa Neto@@@Sergio D’Antico@@@James Daly@@@Franca Danielle@@@Joshua S. Davis@@@Francesco Giuseppe De Rosa@@@Justin T. Denholm@@@Claudia M. Denkinger@@@Daniel Desmecht@@@Juan C. D?az-Coronado@@@Juan A. D?az Ponce-Medrano@@@Anne-Fran?oise Donneau@@@Teresita E. Dumagay@@@Susanna Dunachie@@@Cecile C. Dungog@@@Olufemi Erinoso@@@Ivy Mae S. Escasa@@@Lise J. Estcourt@@@Amy Evans@@@Agnes L. M. Evasan@@@Christian J. Fareli@@@Veronica Fernandez-Sanchez@@@Claudia Galassi@@@Juan E. Gallo@@@Patricia J. Garcia@@@Patricia L. Garcia@@@Jesus A. Garcia@@@Mutien Garigliany@@@Elvira Garza-Gonzalez@@@Deonne Thaddeus V. Gauiran@@@Paula A. Gaviria Garc?a@@@Jose-Antonio Giron-Gonzalez@@@David G?mez-Almaguer@@@Anthony C. Gordon@@@Andr? Gothot@@@Jeser Santiago Grass Guaqueta@@@Cameron Green@@@David Grimaldi@@@Naomi E. Hammond@@@Heli Harvala@@@Francisco M. Heralde@@@Jesica Herrick@@@Alisa M. Higgins@@@Thomas E. Hills@@@Jennifer Hines@@@Karin Holm@@@Ashraful Hoque@@@Eric Hoste@@@Jose M. Ignacio@@@Alexander V. Ivanov@@@Maike Janssen@@@Jeffrey H. Jennings@@@Vivekanand Jha@@@Ruby Anne N. King@@@Jens Kjeldsen-Kragh@@@Paul Klenerman@@@Aditya Kotecha@@@Fiorella Krapp@@@Luciana Labanca@@@Emma Laing@@@Mona Landin-Olsson@@@Pierre-Fran?ois Laterre@@@Lyn-Li Lim@@@Jodor Lim@@@Oskar Ljungquist@@@Jorge M. Llaca-D?az@@@Concepci?n L?pez-Robles@@@Salvador L?pez-C?rdenas@@@Ileana Lopez-Plaza@@@Josephine Anne C. Lucero@@@Maria Lundgren@@@Juan Mac?as@@@Sandy C. Maganito@@@Anna Flor G. Malundo@@@Rub?n D. Manrique@@@Paola M. Manzini@@@Miguel Marcos@@@Ignacio Marquez@@@Francisco Javier Mart?nez-Marcos@@@Ana M. Mata@@@Colin J. McArthur@@@Zoe K. McQuilten@@@Bryan J. McVerry@@@David K. Menon@@@Geert Meyfroidt@@@Ma. Angelina L. Mirasol@@@Beno?t Misset@@@James S. Molton@@@Alric V. Mondragon@@@Diana M. Monsalve@@@Parastoo Moradi Choghakabodi@@@Susan C. Morpeth@@@Paul R. Mouncey@@@Michel Moutschen@@@Carsten M?ller-Tidow@@@Erin Murphy@@@Tome Najdovski@@@Alistair D. Nichol@@@Henrik Nielsen@@@Richard M. Novak@@@Matthew V. N. O’Sullivan@@@Julian Olalla@@@Akin Osibogun@@@Bodunrin Osikomaiya@@@Salvador Oyonarte@@@Juan M. Pardo-Oviedo@@@Mahesh C. Patel@@@David L. Paterson@@@Carlos A. Pe?a-Perez@@@Angel A. Perez-Calatayud@@@Eduardo P?rez-Alba@@@Anastasia Perkina@@@Naomi Perry@@@Mandana Pouladzadeh@@@Inmaculada Poyato@@@David J. Price@@@Anne Kristine H. Quero@@@Md. M. Rahman@@@Md. S. Rahman@@@Mayur Ramesh@@@Carolina Ram?rez-Santana@@@Magnus Rasmussen@@@Megan A. Rees@@@Eduardo Rego@@@Jason A. Roberts@@@David J. Roberts@@@Yhojan Rodr?guez@@@Jes?s Rodr?guez-Ba?o@@@Benjamin A. Rogers@@@Manuel Rojas@@@Alberto Romero@@@Kathryn M. Rowan@@@Fabio Saccona@@@Mehdi Safdarian@@@Maria Clariza M. Santos@@@Joe Sasadeusz@@@Gitana Scozzari@@@Manu Shankar-Hari@@@Gorav Sharma@@@Thomas Snelling@@@Alonso Soto@@@Pedrito Y. Tagayuna@@@Amy Tang@@@Geneva Tatem@@@Luciana Teofili@@@Steven Y. C. Tong@@@Alexis F. Turgeon@@@Januario D. Veloso@@@Balasubramanian Venkatesh@@@Yanet Ventura-Enriquez@@@Steve A. Webb@@@Lothar Wiese@@@Christian Wik?n@@@Erica M. Wood@@@Gaukhar M. Yusubalieva@@@Kai Zacharowski@@@Ryan Zarycha | 202111 | Meta-Analysis | PMC | Background Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials (Open Science Framework, https://doi.org/10.17605/OSF.IO/GEHFX ). Methods In this collaborative systematic review and meta-analysis, clinical trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform), the Cochrane COVID-19 register, the LOVE database, and PubMed were searched until April 8, 2021. Investigators of trials registered by March 1, 2021, without published results were contacted via email. Eligible were ongoing, discontinued and completed randomized clinical trials that compared convalescent plasma with placebo or no treatment in COVID-19 patients, regardless of setting or treatment schedule. Aggregated mortality data were extracted from publications or provided by investigators of unpublished trials and combined using the Hartung?Knapp?Sidik?Jonkman random effects model. We investigated the contribution of unpublished trials to the overall evidence. Results A total of 16,477 patients were included in 33 trials (20 unpublished with 3190 patients, 13 published with 13,287 patients). 32 trials enrolled only hospitalized patients (including 3 with only intensive care unit patients). Risk of bias was low for 29/33 trials. Of 8495 patients who received convalescent plasma, 1997 died (23%), and of 7982 control patients, 1952 died (24%). The combined risk ratio for all-cause mortality was 0.97 (95% confidence interval: 0.92; 1.02) with between-study heterogeneity not beyond chance (I 2 =?0%). The RECOVERY trial had 69.8% and the unpublished evidence 25.3% of the weight in the meta-analysis. Conclusions Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care. Supplementary Information The online version contains supplementary material available at 10.1186/s12879-021-06829-7. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605464/ | 2 | 1471-2334 | BMC Infectious Diseases | London : BioMed Central | |
| 1115969 | 897 | 진단 | proportion | Term | proportion | abstract | None | 23613 | 10.1001/jamanetworkopen.2022.11497 | Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab | Andreas Tolf@@@Anna Wiberg@@@Malin M?ller@@@Faisal Hayat Nazir@@@Ivan Pavlovic@@@Ida Laur?n@@@Sara Mangsbo@@@Joachim Burman | 202205 | Article | PMC | {{{ Abstract }}} !!{{ Importance: }} B-cell-depleting monoclonal antibodies are widely used for treatment of multiple sclerosis but are associated with an impaired response to vaccines. !!{{ Objective: }} To identify factors associated with a favorable vaccine response to tozinameran. !!{{ Design, setting, and participants: }} This prospective cohort study was conducted in a specialized multiple sclerosis clinic at a university hospital from January 21 to December 1, 2021. Of 75 patients evaluated for participation who received a diagnosis of multiple sclerosis with planned or ongoing treatment with rituximab, 69 were included in the study, and data from 67 were analyzed. !!{{ Exposures: }} Sex, age, number of previous rituximab infusions, accumulated dose of rituximab, previous COVID-19 infection, time since last rituximab treatment, CD19+ B-cell count before vaccination, CD4+ T-cell count, and CD8+ T-cell count were considered potential factors associated with the main outcome. !!{{ Main outcomes and measures: }} Serological vaccine responses were measured by quantitation of anti-spike immunoglobulin G (IgG) antibodies, anti-receptor-binding domain (RBD) IgG antibodies, and their neutralizing capacities. Cellular responses to spike protein-derived SARS-CoV-2 peptide pools were assessed by counting interferon gamma spot-forming units in a FluoroSpot assay. !!{{ Results: }} Among 60 patients with ongoing rituximab treatment (49 women [82%]; mean (SD) age, 43 [10] years), the median (range) disease duration was 9 (1-29) years, and the median (range) dose of rituximab was 2750 (500-10 000) mg during a median (range) time of 2.8 (0.5-8.3) years. The median (range) follow-up from the first vaccination dose was 7.3 (4.3-10.0) months. Vaccine responses were determined before vaccination with tozinameran and 6 weeks after vaccination. By using established cutoff values for anti-spike IgG (264 binding antibody units/mL) and anti-RBD IgG (506 binding antibody units/mL), the proportion of patients with a positive response increased with the number of B cells, which was the only factor associated with these outcomes. A cutoff for the B-cell count of at least 40/μL was associated with an optimal serological response. At this cutoff, 26 of 29 patients (90%) had positive test results for anti-spike IgG and 21 of 29 patients (72%) for anti-RBD IgG, and 27 of 29 patients (93%) developed antibodies with greater than 90% inhibition of angiotensin-converting enzyme 2. No factor associated with the cellular response was identified. Depending on the peptide pool, 21 of 25 patients (84%) to 22 of 25 patients (88%) developed a T-cell response with interferon gamma production at the B-cell count cutoff of at least 40/μL. !!{{ Conclusions and relevance: }} This cohort study found that for an optimal vaccine response from tozinameran, rituximab-treated patients with multiple sclerosis may be vaccinated as soon as possible, with rituximab treatment delayed until B-cell counts have reached at least 40/μL. An additional vaccination with tozinameran should be considered at that point. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096596/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1111538 | 897 | 진단 | study participant | Term | study participant | abstract | None | 23484 | 10.1001/jamanetworkopen.2022.21616 | Long-term Immune Response to SARS-CoV-2 Infection Among Children and Adults After Mild Infection | Costanza Di Chiara@@@Anna Cantarutti@@@Paola Costenaro@@@Daniele Don?@@@Francesco Bonfante@@@Chiara Cosma@@@Martina Ferrarese@@@Sandra Cozzani@@@Maria Raffaella Petrara@@@Francesco Carmona@@@Cecilia Liberati@@@Paolo Palma@@@Giovanni Di Salvo@@@Anita De Rossi@@@Mario Plebani@@@Andrea Padoan@@@Carlo Giaquinto | 202207 | Article | PMC | {{{ Abstract }}} !!{{ Importance: }} Understanding the long-term immune response against SARS-CoV-2 infection in children is crucial to optimize vaccination strategies. Although it is known that SARS-CoV-2 antibodies may persist in adults 12 months after infection, data are limited in the pediatric population. !!{{ Objective: }} To examine long-term anti-SARS-CoV-2 spike receptor-binding domain (S-RBD) IgG kinetics in children after SARS-CoV-2 infection. !!{{ Design, setting, and participants: }} In this single-center, prospective cohort study, patients were enrolled consecutively from April 1, 2020, to August 31, 2021, at the COVID-19 Family Cluster Follow-up Clinic, Department of Women's and Children's Health, University Hospital of Padua. A cohort of 252 COVID-19 family clusters underwent serologic follow-up at 1 to 4, 5 to 10, and more than 10 months after infection with quantification of anti-S-RBD IgG by chemiluminescent immunoassay. !!{{ Exposures: }} SARS-CoV-2 infection. !!{{ Results: }} Among 902 study participants, 697 had confirmed SARS-CoV-2 infection, including 351 children or older siblings (mean [SD] age, 8.6 [5.1] years) and 346 parents (mean [SD] age, 42.5 [7.1] years). Among 697 cases, 674 (96.7%) were asymptomatic or mild. Children had significantly higher S-RBD IgG titers than older patients across all follow-up time points, with an overall median S-RBD IgG titer in patients younger than 3 years 5-fold higher than adults (304.8 [IQR, 139.0-516.6] kBAU/L vs 55.6 [24.2-136.0] kBAU/L, P < .001). Longitudinal analysis of 56 study participants sampled at least twice during follow-up demonstrated the persistence of antibodies up to 10 months from infection in all age classes, despite a progressive decline over time. !!{{ Conclusions and relevance: }} In this cohort study of Italian children and adults following SARS-CoV-2 infection different kinetics of SARS-CoV-2 antibodies were found across several age classes of individuals with asymptomatic or mild COVID-19, which could help in optimizing COVID-19 vaccination strategies and prevention policies. This work provides further evidence of sustained immune response in children up to 1 year after primary SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280400/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1111539 | 897 | 진단 | Study participants | Term | study participant | abstract | None | 23484 | 10.1001/jamanetworkopen.2022.21616 | Long-term Immune Response to SARS-CoV-2 Infection Among Children and Adults After Mild Infection | Costanza Di Chiara@@@Anna Cantarutti@@@Paola Costenaro@@@Daniele Don?@@@Francesco Bonfante@@@Chiara Cosma@@@Martina Ferrarese@@@Sandra Cozzani@@@Maria Raffaella Petrara@@@Francesco Carmona@@@Cecilia Liberati@@@Paolo Palma@@@Giovanni Di Salvo@@@Anita De Rossi@@@Mario Plebani@@@Andrea Padoan@@@Carlo Giaquinto | 202207 | Article | PMC | {{{ Abstract }}} !!{{ Importance: }} Understanding the long-term immune response against SARS-CoV-2 infection in children is crucial to optimize vaccination strategies. Although it is known that SARS-CoV-2 antibodies may persist in adults 12 months after infection, data are limited in the pediatric population. !!{{ Objective: }} To examine long-term anti-SARS-CoV-2 spike receptor-binding domain (S-RBD) IgG kinetics in children after SARS-CoV-2 infection. !!{{ Design, setting, and participants: }} In this single-center, prospective cohort study, patients were enrolled consecutively from April 1, 2020, to August 31, 2021, at the COVID-19 Family Cluster Follow-up Clinic, Department of Women's and Children's Health, University Hospital of Padua. A cohort of 252 COVID-19 family clusters underwent serologic follow-up at 1 to 4, 5 to 10, and more than 10 months after infection with quantification of anti-S-RBD IgG by chemiluminescent immunoassay. !!{{ Exposures: }} SARS-CoV-2 infection. !!{{ Results: }} Among 902 study participants, 697 had confirmed SARS-CoV-2 infection, including 351 children or older siblings (mean [SD] age, 8.6 [5.1] years) and 346 parents (mean [SD] age, 42.5 [7.1] years). Among 697 cases, 674 (96.7%) were asymptomatic or mild. Children had significantly higher S-RBD IgG titers than older patients across all follow-up time points, with an overall median S-RBD IgG titer in patients younger than 3 years 5-fold higher than adults (304.8 [IQR, 139.0-516.6] kBAU/L vs 55.6 [24.2-136.0] kBAU/L, P < .001). Longitudinal analysis of 56 study participants sampled at least twice during follow-up demonstrated the persistence of antibodies up to 10 months from infection in all age classes, despite a progressive decline over time. !!{{ Conclusions and relevance: }} In this cohort study of Italian children and adults following SARS-CoV-2 infection different kinetics of SARS-CoV-2 antibodies were found across several age classes of individuals with asymptomatic or mild COVID-19, which could help in optimizing COVID-19 vaccination strategies and prevention policies. This work provides further evidence of sustained immune response in children up to 1 year after primary SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280400/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1115974 | 897 | 진단 | response | Term | response | title,abstract | 반응 | 23613 | 10.1001/jamanetworkopen.2022.11497 | Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab | Andreas Tolf@@@Anna Wiberg@@@Malin M?ller@@@Faisal Hayat Nazir@@@Ivan Pavlovic@@@Ida Laur?n@@@Sara Mangsbo@@@Joachim Burman | 202205 | Article | PMC | {{{ Abstract }}} !!{{ Importance: }} B-cell-depleting monoclonal antibodies are widely used for treatment of multiple sclerosis but are associated with an impaired response to vaccines. !!{{ Objective: }} To identify factors associated with a favorable vaccine response to tozinameran. !!{{ Design, setting, and participants: }} This prospective cohort study was conducted in a specialized multiple sclerosis clinic at a university hospital from January 21 to December 1, 2021. Of 75 patients evaluated for participation who received a diagnosis of multiple sclerosis with planned or ongoing treatment with rituximab, 69 were included in the study, and data from 67 were analyzed. !!{{ Exposures: }} Sex, age, number of previous rituximab infusions, accumulated dose of rituximab, previous COVID-19 infection, time since last rituximab treatment, CD19+ B-cell count before vaccination, CD4+ T-cell count, and CD8+ T-cell count were considered potential factors associated with the main outcome. !!{{ Main outcomes and measures: }} Serological vaccine responses were measured by quantitation of anti-spike immunoglobulin G (IgG) antibodies, anti-receptor-binding domain (RBD) IgG antibodies, and their neutralizing capacities. Cellular responses to spike protein-derived SARS-CoV-2 peptide pools were assessed by counting interferon gamma spot-forming units in a FluoroSpot assay. !!{{ Results: }} Among 60 patients with ongoing rituximab treatment (49 women [82%]; mean (SD) age, 43 [10] years), the median (range) disease duration was 9 (1-29) years, and the median (range) dose of rituximab was 2750 (500-10 000) mg during a median (range) time of 2.8 (0.5-8.3) years. The median (range) follow-up from the first vaccination dose was 7.3 (4.3-10.0) months. Vaccine responses were determined before vaccination with tozinameran and 6 weeks after vaccination. By using established cutoff values for anti-spike IgG (264 binding antibody units/mL) and anti-RBD IgG (506 binding antibody units/mL), the proportion of patients with a positive response increased with the number of B cells, which was the only factor associated with these outcomes. A cutoff for the B-cell count of at least 40/μL was associated with an optimal serological response. At this cutoff, 26 of 29 patients (90%) had positive test results for anti-spike IgG and 21 of 29 patients (72%) for anti-RBD IgG, and 27 of 29 patients (93%) developed antibodies with greater than 90% inhibition of angiotensin-converting enzyme 2. No factor associated with the cellular response was identified. Depending on the peptide pool, 21 of 25 patients (84%) to 22 of 25 patients (88%) developed a T-cell response with interferon gamma production at the B-cell count cutoff of at least 40/μL. !!{{ Conclusions and relevance: }} This cohort study found that for an optimal vaccine response from tozinameran, rituximab-treated patients with multiple sclerosis may be vaccinated as soon as possible, with rituximab treatment delayed until B-cell counts have reached at least 40/μL. An additional vaccination with tozinameran should be considered at that point. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096596/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1115977 | 897 | 진단 | sclerosis | Term | sclerosis | title | None | 23613 | 10.1001/jamanetworkopen.2022.11497 | Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab | Andreas Tolf@@@Anna Wiberg@@@Malin M?ller@@@Faisal Hayat Nazir@@@Ivan Pavlovic@@@Ida Laur?n@@@Sara Mangsbo@@@Joachim Burman | 202205 | Article | PMC | {{{ Abstract }}} !!{{ Importance: }} B-cell-depleting monoclonal antibodies are widely used for treatment of multiple sclerosis but are associated with an impaired response to vaccines. !!{{ Objective: }} To identify factors associated with a favorable vaccine response to tozinameran. !!{{ Design, setting, and participants: }} This prospective cohort study was conducted in a specialized multiple sclerosis clinic at a university hospital from January 21 to December 1, 2021. Of 75 patients evaluated for participation who received a diagnosis of multiple sclerosis with planned or ongoing treatment with rituximab, 69 were included in the study, and data from 67 were analyzed. !!{{ Exposures: }} Sex, age, number of previous rituximab infusions, accumulated dose of rituximab, previous COVID-19 infection, time since last rituximab treatment, CD19+ B-cell count before vaccination, CD4+ T-cell count, and CD8+ T-cell count were considered potential factors associated with the main outcome. !!{{ Main outcomes and measures: }} Serological vaccine responses were measured by quantitation of anti-spike immunoglobulin G (IgG) antibodies, anti-receptor-binding domain (RBD) IgG antibodies, and their neutralizing capacities. Cellular responses to spike protein-derived SARS-CoV-2 peptide pools were assessed by counting interferon gamma spot-forming units in a FluoroSpot assay. !!{{ Results: }} Among 60 patients with ongoing rituximab treatment (49 women [82%]; mean (SD) age, 43 [10] years), the median (range) disease duration was 9 (1-29) years, and the median (range) dose of rituximab was 2750 (500-10 000) mg during a median (range) time of 2.8 (0.5-8.3) years. The median (range) follow-up from the first vaccination dose was 7.3 (4.3-10.0) months. Vaccine responses were determined before vaccination with tozinameran and 6 weeks after vaccination. By using established cutoff values for anti-spike IgG (264 binding antibody units/mL) and anti-RBD IgG (506 binding antibody units/mL), the proportion of patients with a positive response increased with the number of B cells, which was the only factor associated with these outcomes. A cutoff for the B-cell count of at least 40/μL was associated with an optimal serological response. At this cutoff, 26 of 29 patients (90%) had positive test results for anti-spike IgG and 21 of 29 patients (72%) for anti-RBD IgG, and 27 of 29 patients (93%) developed antibodies with greater than 90% inhibition of angiotensin-converting enzyme 2. No factor associated with the cellular response was identified. Depending on the peptide pool, 21 of 25 patients (84%) to 22 of 25 patients (88%) developed a T-cell response with interferon gamma production at the B-cell count cutoff of at least 40/μL. !!{{ Conclusions and relevance: }} This cohort study found that for an optimal vaccine response from tozinameran, rituximab-treated patients with multiple sclerosis may be vaccinated as soon as possible, with rituximab treatment delayed until B-cell counts have reached at least 40/μL. An additional vaccination with tozinameran should be considered at that point. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096596/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1115978 | 897 | 진단 | serological response | Term | serological response | abstract | None | 23613 | 10.1001/jamanetworkopen.2022.11497 | Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab | Andreas Tolf@@@Anna Wiberg@@@Malin M?ller@@@Faisal Hayat Nazir@@@Ivan Pavlovic@@@Ida Laur?n@@@Sara Mangsbo@@@Joachim Burman | 202205 | Article | PMC | {{{ Abstract }}} !!{{ Importance: }} B-cell-depleting monoclonal antibodies are widely used for treatment of multiple sclerosis but are associated with an impaired response to vaccines. !!{{ Objective: }} To identify factors associated with a favorable vaccine response to tozinameran. !!{{ Design, setting, and participants: }} This prospective cohort study was conducted in a specialized multiple sclerosis clinic at a university hospital from January 21 to December 1, 2021. Of 75 patients evaluated for participation who received a diagnosis of multiple sclerosis with planned or ongoing treatment with rituximab, 69 were included in the study, and data from 67 were analyzed. !!{{ Exposures: }} Sex, age, number of previous rituximab infusions, accumulated dose of rituximab, previous COVID-19 infection, time since last rituximab treatment, CD19+ B-cell count before vaccination, CD4+ T-cell count, and CD8+ T-cell count were considered potential factors associated with the main outcome. !!{{ Main outcomes and measures: }} Serological vaccine responses were measured by quantitation of anti-spike immunoglobulin G (IgG) antibodies, anti-receptor-binding domain (RBD) IgG antibodies, and their neutralizing capacities. Cellular responses to spike protein-derived SARS-CoV-2 peptide pools were assessed by counting interferon gamma spot-forming units in a FluoroSpot assay. !!{{ Results: }} Among 60 patients with ongoing rituximab treatment (49 women [82%]; mean (SD) age, 43 [10] years), the median (range) disease duration was 9 (1-29) years, and the median (range) dose of rituximab was 2750 (500-10 000) mg during a median (range) time of 2.8 (0.5-8.3) years. The median (range) follow-up from the first vaccination dose was 7.3 (4.3-10.0) months. Vaccine responses were determined before vaccination with tozinameran and 6 weeks after vaccination. By using established cutoff values for anti-spike IgG (264 binding antibody units/mL) and anti-RBD IgG (506 binding antibody units/mL), the proportion of patients with a positive response increased with the number of B cells, which was the only factor associated with these outcomes. A cutoff for the B-cell count of at least 40/μL was associated with an optimal serological response. At this cutoff, 26 of 29 patients (90%) had positive test results for anti-spike IgG and 21 of 29 patients (72%) for anti-RBD IgG, and 27 of 29 patients (93%) developed antibodies with greater than 90% inhibition of angiotensin-converting enzyme 2. No factor associated with the cellular response was identified. Depending on the peptide pool, 21 of 25 patients (84%) to 22 of 25 patients (88%) developed a T-cell response with interferon gamma production at the B-cell count cutoff of at least 40/μL. !!{{ Conclusions and relevance: }} This cohort study found that for an optimal vaccine response from tozinameran, rituximab-treated patients with multiple sclerosis may be vaccinated as soon as possible, with rituximab treatment delayed until B-cell counts have reached at least 40/μL. An additional vaccination with tozinameran should be considered at that point. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096596/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1111540 | 897 | 진단 | sustained | Action | sustained | abstract | None | 23484 | 10.1001/jamanetworkopen.2022.21616 | Long-term Immune Response to SARS-CoV-2 Infection Among Children and Adults After Mild Infection | Costanza Di Chiara@@@Anna Cantarutti@@@Paola Costenaro@@@Daniele Don?@@@Francesco Bonfante@@@Chiara Cosma@@@Martina Ferrarese@@@Sandra Cozzani@@@Maria Raffaella Petrara@@@Francesco Carmona@@@Cecilia Liberati@@@Paolo Palma@@@Giovanni Di Salvo@@@Anita De Rossi@@@Mario Plebani@@@Andrea Padoan@@@Carlo Giaquinto | 202207 | Article | PMC | {{{ Abstract }}} !!{{ Importance: }} Understanding the long-term immune response against SARS-CoV-2 infection in children is crucial to optimize vaccination strategies. Although it is known that SARS-CoV-2 antibodies may persist in adults 12 months after infection, data are limited in the pediatric population. !!{{ Objective: }} To examine long-term anti-SARS-CoV-2 spike receptor-binding domain (S-RBD) IgG kinetics in children after SARS-CoV-2 infection. !!{{ Design, setting, and participants: }} In this single-center, prospective cohort study, patients were enrolled consecutively from April 1, 2020, to August 31, 2021, at the COVID-19 Family Cluster Follow-up Clinic, Department of Women's and Children's Health, University Hospital of Padua. A cohort of 252 COVID-19 family clusters underwent serologic follow-up at 1 to 4, 5 to 10, and more than 10 months after infection with quantification of anti-S-RBD IgG by chemiluminescent immunoassay. !!{{ Exposures: }} SARS-CoV-2 infection. !!{{ Results: }} Among 902 study participants, 697 had confirmed SARS-CoV-2 infection, including 351 children or older siblings (mean [SD] age, 8.6 [5.1] years) and 346 parents (mean [SD] age, 42.5 [7.1] years). Among 697 cases, 674 (96.7%) were asymptomatic or mild. Children had significantly higher S-RBD IgG titers than older patients across all follow-up time points, with an overall median S-RBD IgG titer in patients younger than 3 years 5-fold higher than adults (304.8 [IQR, 139.0-516.6] kBAU/L vs 55.6 [24.2-136.0] kBAU/L, P < .001). Longitudinal analysis of 56 study participants sampled at least twice during follow-up demonstrated the persistence of antibodies up to 10 months from infection in all age classes, despite a progressive decline over time. !!{{ Conclusions and relevance: }} In this cohort study of Italian children and adults following SARS-CoV-2 infection different kinetics of SARS-CoV-2 antibodies were found across several age classes of individuals with asymptomatic or mild COVID-19, which could help in optimizing COVID-19 vaccination strategies and prevention policies. This work provides further evidence of sustained immune response in children up to 1 year after primary SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280400/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1115980 | 897 | 진단 | T-cell Response | Action | t-cell response | abstract | T세포 반응 | 23613 | 10.1001/jamanetworkopen.2022.11497 | Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab | Andreas Tolf@@@Anna Wiberg@@@Malin M?ller@@@Faisal Hayat Nazir@@@Ivan Pavlovic@@@Ida Laur?n@@@Sara Mangsbo@@@Joachim Burman | 202205 | Article | PMC | {{{ Abstract }}} !!{{ Importance: }} B-cell-depleting monoclonal antibodies are widely used for treatment of multiple sclerosis but are associated with an impaired response to vaccines. !!{{ Objective: }} To identify factors associated with a favorable vaccine response to tozinameran. !!{{ Design, setting, and participants: }} This prospective cohort study was conducted in a specialized multiple sclerosis clinic at a university hospital from January 21 to December 1, 2021. Of 75 patients evaluated for participation who received a diagnosis of multiple sclerosis with planned or ongoing treatment with rituximab, 69 were included in the study, and data from 67 were analyzed. !!{{ Exposures: }} Sex, age, number of previous rituximab infusions, accumulated dose of rituximab, previous COVID-19 infection, time since last rituximab treatment, CD19+ B-cell count before vaccination, CD4+ T-cell count, and CD8+ T-cell count were considered potential factors associated with the main outcome. !!{{ Main outcomes and measures: }} Serological vaccine responses were measured by quantitation of anti-spike immunoglobulin G (IgG) antibodies, anti-receptor-binding domain (RBD) IgG antibodies, and their neutralizing capacities. Cellular responses to spike protein-derived SARS-CoV-2 peptide pools were assessed by counting interferon gamma spot-forming units in a FluoroSpot assay. !!{{ Results: }} Among 60 patients with ongoing rituximab treatment (49 women [82%]; mean (SD) age, 43 [10] years), the median (range) disease duration was 9 (1-29) years, and the median (range) dose of rituximab was 2750 (500-10 000) mg during a median (range) time of 2.8 (0.5-8.3) years. The median (range) follow-up from the first vaccination dose was 7.3 (4.3-10.0) months. Vaccine responses were determined before vaccination with tozinameran and 6 weeks after vaccination. By using established cutoff values for anti-spike IgG (264 binding antibody units/mL) and anti-RBD IgG (506 binding antibody units/mL), the proportion of patients with a positive response increased with the number of B cells, which was the only factor associated with these outcomes. A cutoff for the B-cell count of at least 40/μL was associated with an optimal serological response. At this cutoff, 26 of 29 patients (90%) had positive test results for anti-spike IgG and 21 of 29 patients (72%) for anti-RBD IgG, and 27 of 29 patients (93%) developed antibodies with greater than 90% inhibition of angiotensin-converting enzyme 2. No factor associated with the cellular response was identified. Depending on the peptide pool, 21 of 25 patients (84%) to 22 of 25 patients (88%) developed a T-cell response with interferon gamma production at the B-cell count cutoff of at least 40/μL. !!{{ Conclusions and relevance: }} This cohort study found that for an optimal vaccine response from tozinameran, rituximab-treated patients with multiple sclerosis may be vaccinated as soon as possible, with rituximab treatment delayed until B-cell counts have reached at least 40/μL. An additional vaccination with tozinameran should be considered at that point. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096596/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1115981 | 897 | 진단 | the median | Term | the median | abstract | None | 23613 | 10.1001/jamanetworkopen.2022.11497 | Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab | Andreas Tolf@@@Anna Wiberg@@@Malin M?ller@@@Faisal Hayat Nazir@@@Ivan Pavlovic@@@Ida Laur?n@@@Sara Mangsbo@@@Joachim Burman | 202205 | Article | PMC | {{{ Abstract }}} !!{{ Importance: }} B-cell-depleting monoclonal antibodies are widely used for treatment of multiple sclerosis but are associated with an impaired response to vaccines. !!{{ Objective: }} To identify factors associated with a favorable vaccine response to tozinameran. !!{{ Design, setting, and participants: }} This prospective cohort study was conducted in a specialized multiple sclerosis clinic at a university hospital from January 21 to December 1, 2021. Of 75 patients evaluated for participation who received a diagnosis of multiple sclerosis with planned or ongoing treatment with rituximab, 69 were included in the study, and data from 67 were analyzed. !!{{ Exposures: }} Sex, age, number of previous rituximab infusions, accumulated dose of rituximab, previous COVID-19 infection, time since last rituximab treatment, CD19+ B-cell count before vaccination, CD4+ T-cell count, and CD8+ T-cell count were considered potential factors associated with the main outcome. !!{{ Main outcomes and measures: }} Serological vaccine responses were measured by quantitation of anti-spike immunoglobulin G (IgG) antibodies, anti-receptor-binding domain (RBD) IgG antibodies, and their neutralizing capacities. Cellular responses to spike protein-derived SARS-CoV-2 peptide pools were assessed by counting interferon gamma spot-forming units in a FluoroSpot assay. !!{{ Results: }} Among 60 patients with ongoing rituximab treatment (49 women [82%]; mean (SD) age, 43 [10] years), the median (range) disease duration was 9 (1-29) years, and the median (range) dose of rituximab was 2750 (500-10 000) mg during a median (range) time of 2.8 (0.5-8.3) years. The median (range) follow-up from the first vaccination dose was 7.3 (4.3-10.0) months. Vaccine responses were determined before vaccination with tozinameran and 6 weeks after vaccination. By using established cutoff values for anti-spike IgG (264 binding antibody units/mL) and anti-RBD IgG (506 binding antibody units/mL), the proportion of patients with a positive response increased with the number of B cells, which was the only factor associated with these outcomes. A cutoff for the B-cell count of at least 40/μL was associated with an optimal serological response. At this cutoff, 26 of 29 patients (90%) had positive test results for anti-spike IgG and 21 of 29 patients (72%) for anti-RBD IgG, and 27 of 29 patients (93%) developed antibodies with greater than 90% inhibition of angiotensin-converting enzyme 2. No factor associated with the cellular response was identified. Depending on the peptide pool, 21 of 25 patients (84%) to 22 of 25 patients (88%) developed a T-cell response with interferon gamma production at the B-cell count cutoff of at least 40/μL. !!{{ Conclusions and relevance: }} This cohort study found that for an optimal vaccine response from tozinameran, rituximab-treated patients with multiple sclerosis may be vaccinated as soon as possible, with rituximab treatment delayed until B-cell counts have reached at least 40/μL. An additional vaccination with tozinameran should be considered at that point. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096596/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1111541 | 897 | 진단 | understanding | Term | understanding | abstract | 이해 | 23484 | 10.1001/jamanetworkopen.2022.21616 | Long-term Immune Response to SARS-CoV-2 Infection Among Children and Adults After Mild Infection | Costanza Di Chiara@@@Anna Cantarutti@@@Paola Costenaro@@@Daniele Don?@@@Francesco Bonfante@@@Chiara Cosma@@@Martina Ferrarese@@@Sandra Cozzani@@@Maria Raffaella Petrara@@@Francesco Carmona@@@Cecilia Liberati@@@Paolo Palma@@@Giovanni Di Salvo@@@Anita De Rossi@@@Mario Plebani@@@Andrea Padoan@@@Carlo Giaquinto | 202207 | Article | PMC | {{{ Abstract }}} !!{{ Importance: }} Understanding the long-term immune response against SARS-CoV-2 infection in children is crucial to optimize vaccination strategies. Although it is known that SARS-CoV-2 antibodies may persist in adults 12 months after infection, data are limited in the pediatric population. !!{{ Objective: }} To examine long-term anti-SARS-CoV-2 spike receptor-binding domain (S-RBD) IgG kinetics in children after SARS-CoV-2 infection. !!{{ Design, setting, and participants: }} In this single-center, prospective cohort study, patients were enrolled consecutively from April 1, 2020, to August 31, 2021, at the COVID-19 Family Cluster Follow-up Clinic, Department of Women's and Children's Health, University Hospital of Padua. A cohort of 252 COVID-19 family clusters underwent serologic follow-up at 1 to 4, 5 to 10, and more than 10 months after infection with quantification of anti-S-RBD IgG by chemiluminescent immunoassay. !!{{ Exposures: }} SARS-CoV-2 infection. !!{{ Results: }} Among 902 study participants, 697 had confirmed SARS-CoV-2 infection, including 351 children or older siblings (mean [SD] age, 8.6 [5.1] years) and 346 parents (mean [SD] age, 42.5 [7.1] years). Among 697 cases, 674 (96.7%) were asymptomatic or mild. Children had significantly higher S-RBD IgG titers than older patients across all follow-up time points, with an overall median S-RBD IgG titer in patients younger than 3 years 5-fold higher than adults (304.8 [IQR, 139.0-516.6] kBAU/L vs 55.6 [24.2-136.0] kBAU/L, P < .001). Longitudinal analysis of 56 study participants sampled at least twice during follow-up demonstrated the persistence of antibodies up to 10 months from infection in all age classes, despite a progressive decline over time. !!{{ Conclusions and relevance: }} In this cohort study of Italian children and adults following SARS-CoV-2 infection different kinetics of SARS-CoV-2 antibodies were found across several age classes of individuals with asymptomatic or mild COVID-19, which could help in optimizing COVID-19 vaccination strategies and prevention policies. This work provides further evidence of sustained immune response in children up to 1 year after primary SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280400/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1245369 | 897 | 진단 | convalescent plasma treatment | Treatment | convalescent plasma treatment | abstract | None | 2869 | 10.1186/s12879-021-06829-7 | Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials | Cathrine Axfors@@@Perrine Janiaud@@@Andreas M. Schmitt@@@Janneke van’t Hooft@@@Emily R. Smith@@@Noah A. Haber@@@Akin Abayomi@@@Manal Abduljalil@@@Abdulkarim Abdulrahman@@@Yeny Acosta-Ampudia@@@Manuela Aguilar-Guisado@@@Farah Al-Beidh@@@Marissa M. Alejandria@@@Rachelle N. Alfonso@@@Mohammad Ali@@@Manaf AlQahtani@@@Alaa AlZamrooni@@@Juan-Manuel Anaya@@@Mark Angelo C. Ang@@@Ismael F. Aomar@@@Luis E. Argumanis@@@Alexander Averyanov@@@Vladimir P. Baklaushev@@@Olga Balionis@@@Thomas Benfield@@@Scott Berry@@@Nadia Birocco@@@Lynn B. Bonifacio@@@Asha C. Bowen@@@Abbie Bown@@@Carlos Cabello-Gutierrez@@@Bernardo Camacho@@@Adrian Camacho-Ortiz@@@Sally Campbell-Lee@@@Damon H. Cao@@@Ana Cardesa@@@Jose M. Carnate@@@German Jr. J. Castillo@@@Rossana Cavallo@@@Fazle R. Chowdhury@@@Forhad U. H. Chowdhury@@@Giovannino Ciccone@@@Antonella Cingolani@@@Fresthel Monica M. Climacosa@@@Veerle Compernolle@@@Carlo Francisco N. Cortez@@@Abel Costa Neto@@@Sergio D’Antico@@@James Daly@@@Franca Danielle@@@Joshua S. Davis@@@Francesco Giuseppe De Rosa@@@Justin T. Denholm@@@Claudia M. Denkinger@@@Daniel Desmecht@@@Juan C. D?az-Coronado@@@Juan A. D?az Ponce-Medrano@@@Anne-Fran?oise Donneau@@@Teresita E. Dumagay@@@Susanna Dunachie@@@Cecile C. Dungog@@@Olufemi Erinoso@@@Ivy Mae S. Escasa@@@Lise J. Estcourt@@@Amy Evans@@@Agnes L. M. Evasan@@@Christian J. Fareli@@@Veronica Fernandez-Sanchez@@@Claudia Galassi@@@Juan E. Gallo@@@Patricia J. Garcia@@@Patricia L. Garcia@@@Jesus A. Garcia@@@Mutien Garigliany@@@Elvira Garza-Gonzalez@@@Deonne Thaddeus V. Gauiran@@@Paula A. Gaviria Garc?a@@@Jose-Antonio Giron-Gonzalez@@@David G?mez-Almaguer@@@Anthony C. Gordon@@@Andr? Gothot@@@Jeser Santiago Grass Guaqueta@@@Cameron Green@@@David Grimaldi@@@Naomi E. Hammond@@@Heli Harvala@@@Francisco M. Heralde@@@Jesica Herrick@@@Alisa M. Higgins@@@Thomas E. Hills@@@Jennifer Hines@@@Karin Holm@@@Ashraful Hoque@@@Eric Hoste@@@Jose M. Ignacio@@@Alexander V. Ivanov@@@Maike Janssen@@@Jeffrey H. Jennings@@@Vivekanand Jha@@@Ruby Anne N. King@@@Jens Kjeldsen-Kragh@@@Paul Klenerman@@@Aditya Kotecha@@@Fiorella Krapp@@@Luciana Labanca@@@Emma Laing@@@Mona Landin-Olsson@@@Pierre-Fran?ois Laterre@@@Lyn-Li Lim@@@Jodor Lim@@@Oskar Ljungquist@@@Jorge M. Llaca-D?az@@@Concepci?n L?pez-Robles@@@Salvador L?pez-C?rdenas@@@Ileana Lopez-Plaza@@@Josephine Anne C. Lucero@@@Maria Lundgren@@@Juan Mac?as@@@Sandy C. Maganito@@@Anna Flor G. Malundo@@@Rub?n D. Manrique@@@Paola M. Manzini@@@Miguel Marcos@@@Ignacio Marquez@@@Francisco Javier Mart?nez-Marcos@@@Ana M. Mata@@@Colin J. McArthur@@@Zoe K. McQuilten@@@Bryan J. McVerry@@@David K. Menon@@@Geert Meyfroidt@@@Ma. Angelina L. Mirasol@@@Beno?t Misset@@@James S. Molton@@@Alric V. Mondragon@@@Diana M. Monsalve@@@Parastoo Moradi Choghakabodi@@@Susan C. Morpeth@@@Paul R. Mouncey@@@Michel Moutschen@@@Carsten M?ller-Tidow@@@Erin Murphy@@@Tome Najdovski@@@Alistair D. Nichol@@@Henrik Nielsen@@@Richard M. Novak@@@Matthew V. N. O’Sullivan@@@Julian Olalla@@@Akin Osibogun@@@Bodunrin Osikomaiya@@@Salvador Oyonarte@@@Juan M. Pardo-Oviedo@@@Mahesh C. Patel@@@David L. Paterson@@@Carlos A. Pe?a-Perez@@@Angel A. Perez-Calatayud@@@Eduardo P?rez-Alba@@@Anastasia Perkina@@@Naomi Perry@@@Mandana Pouladzadeh@@@Inmaculada Poyato@@@David J. Price@@@Anne Kristine H. Quero@@@Md. M. Rahman@@@Md. S. Rahman@@@Mayur Ramesh@@@Carolina Ram?rez-Santana@@@Magnus Rasmussen@@@Megan A. Rees@@@Eduardo Rego@@@Jason A. Roberts@@@David J. Roberts@@@Yhojan Rodr?guez@@@Jes?s Rodr?guez-Ba?o@@@Benjamin A. Rogers@@@Manuel Rojas@@@Alberto Romero@@@Kathryn M. Rowan@@@Fabio Saccona@@@Mehdi Safdarian@@@Maria Clariza M. Santos@@@Joe Sasadeusz@@@Gitana Scozzari@@@Manu Shankar-Hari@@@Gorav Sharma@@@Thomas Snelling@@@Alonso Soto@@@Pedrito Y. Tagayuna@@@Amy Tang@@@Geneva Tatem@@@Luciana Teofili@@@Steven Y. C. Tong@@@Alexis F. Turgeon@@@Januario D. Veloso@@@Balasubramanian Venkatesh@@@Yanet Ventura-Enriquez@@@Steve A. Webb@@@Lothar Wiese@@@Christian Wik?n@@@Erica M. Wood@@@Gaukhar M. Yusubalieva@@@Kai Zacharowski@@@Ryan Zarycha | 202111 | Meta-Analysis | PMC | Background Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials (Open Science Framework, https://doi.org/10.17605/OSF.IO/GEHFX ). Methods In this collaborative systematic review and meta-analysis, clinical trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform), the Cochrane COVID-19 register, the LOVE database, and PubMed were searched until April 8, 2021. Investigators of trials registered by March 1, 2021, without published results were contacted via email. Eligible were ongoing, discontinued and completed randomized clinical trials that compared convalescent plasma with placebo or no treatment in COVID-19 patients, regardless of setting or treatment schedule. Aggregated mortality data were extracted from publications or provided by investigators of unpublished trials and combined using the Hartung?Knapp?Sidik?Jonkman random effects model. We investigated the contribution of unpublished trials to the overall evidence. Results A total of 16,477 patients were included in 33 trials (20 unpublished with 3190 patients, 13 published with 13,287 patients). 32 trials enrolled only hospitalized patients (including 3 with only intensive care unit patients). Risk of bias was low for 29/33 trials. Of 8495 patients who received convalescent plasma, 1997 died (23%), and of 7982 control patients, 1952 died (24%). The combined risk ratio for all-cause mortality was 0.97 (95% confidence interval: 0.92; 1.02) with between-study heterogeneity not beyond chance (I 2 =?0%). The RECOVERY trial had 69.8% and the unpublished evidence 25.3% of the weight in the meta-analysis. Conclusions Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care. Supplementary Information The online version contains supplementary material available at 10.1186/s12879-021-06829-7. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605464/ | 2 | 1471-2334 | BMC Infectious Diseases | London : BioMed Central | |
| 1116050 | 897 | 진단 | Cell | Term | cell | abstract | abnormality | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1116051 | 897 | 진단 | cellular response | Action | cellular response | abstract | None | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1111542 | 897 | 진단 | university | Term | university | abstract | 대학교 | 23484 | 10.1001/jamanetworkopen.2022.21616 | Long-term Immune Response to SARS-CoV-2 Infection Among Children and Adults After Mild Infection | Costanza Di Chiara@@@Anna Cantarutti@@@Paola Costenaro@@@Daniele Don?@@@Francesco Bonfante@@@Chiara Cosma@@@Martina Ferrarese@@@Sandra Cozzani@@@Maria Raffaella Petrara@@@Francesco Carmona@@@Cecilia Liberati@@@Paolo Palma@@@Giovanni Di Salvo@@@Anita De Rossi@@@Mario Plebani@@@Andrea Padoan@@@Carlo Giaquinto | 202207 | Article | PMC | {{{ Abstract }}} !!{{ Importance: }} Understanding the long-term immune response against SARS-CoV-2 infection in children is crucial to optimize vaccination strategies. Although it is known that SARS-CoV-2 antibodies may persist in adults 12 months after infection, data are limited in the pediatric population. !!{{ Objective: }} To examine long-term anti-SARS-CoV-2 spike receptor-binding domain (S-RBD) IgG kinetics in children after SARS-CoV-2 infection. !!{{ Design, setting, and participants: }} In this single-center, prospective cohort study, patients were enrolled consecutively from April 1, 2020, to August 31, 2021, at the COVID-19 Family Cluster Follow-up Clinic, Department of Women's and Children's Health, University Hospital of Padua. A cohort of 252 COVID-19 family clusters underwent serologic follow-up at 1 to 4, 5 to 10, and more than 10 months after infection with quantification of anti-S-RBD IgG by chemiluminescent immunoassay. !!{{ Exposures: }} SARS-CoV-2 infection. !!{{ Results: }} Among 902 study participants, 697 had confirmed SARS-CoV-2 infection, including 351 children or older siblings (mean [SD] age, 8.6 [5.1] years) and 346 parents (mean [SD] age, 42.5 [7.1] years). Among 697 cases, 674 (96.7%) were asymptomatic or mild. Children had significantly higher S-RBD IgG titers than older patients across all follow-up time points, with an overall median S-RBD IgG titer in patients younger than 3 years 5-fold higher than adults (304.8 [IQR, 139.0-516.6] kBAU/L vs 55.6 [24.2-136.0] kBAU/L, P < .001). Longitudinal analysis of 56 study participants sampled at least twice during follow-up demonstrated the persistence of antibodies up to 10 months from infection in all age classes, despite a progressive decline over time. !!{{ Conclusions and relevance: }} In this cohort study of Italian children and adults following SARS-CoV-2 infection different kinetics of SARS-CoV-2 antibodies were found across several age classes of individuals with asymptomatic or mild COVID-19, which could help in optimizing COVID-19 vaccination strategies and prevention policies. This work provides further evidence of sustained immune response in children up to 1 year after primary SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280400/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1116052 | 897 | 진단 | Characteristics | Term | characteristic | abstract | 특징 | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1116053 | 897 | 진단 | controls | Term | control | abstract | abnormality | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1116054 | 897 | 진단 | correlation | Term | correlation | abstract | 상관 | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1229834 | 897 | 진단 | during pregnancy | Term | during pregnancy | abstract | None | 22292 | 10.1001/jamanetworkopen.2020.29256 | Pregnancy Outcomes Among Women With and Without Severe Acute Respiratory Syndrome Coronavirus 2 Infection | Emily H. Adhikari@@@Wilmer Moreno@@@Amanda C. Zofkie@@@Lorre MacDonald@@@Donald D. McIntire@@@Rebecca R. J. Collins@@@Catherine Y. Spong | 202011 | Research | PMC | Key Points Question In a large county health care system with access to inpatient and outpatient testing, is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection associated with pregnancy outcomes, maternal illness severity, placental pathology, and neonatal infections? Findings In this cohort study of 252 SARS-CoV-2?positive and 3122 negative pregnant women tested in outpatient and inpatient settings at a large county medical center, adverse pregnancy outcomes were similar, and neonatal infection occurred in 3% of infants, predominantly among infants born to asymptomatic or mildly symptomatic women. Placental abnormalities were not associated with disease severity, and the rate of hospitalization was similar to rates among nonpregnant women. Meaning These findings suggest that SARS-CoV-2 infection in pregnancy is not associated with adverse pregnancy outcomes. This cohort study evaluates the adverse outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among pregnant women and describes clinical management, disease progression, hospital admission, placental abnormalities, and neonatal outcomes. Importance Published data suggest that there are increased hospitalizations, placental abnormalities, and rare neonatal transmission among pregnant women with coronavirus disease 2019 (COVID-19). Objectives To evaluate adverse outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pregnancy and to describe clinical management, disease progression, hospital admission, placental abnormalities, and neonatal outcomes. Design, Setting, and Participants This observational cohort study of maternal and neonatal outcomes among delivered women with and without SARS-CoV-2 during pregnancy was conducted from March 18 through August 22, 2020, at Parkland Health and Hospital System (Dallas, Texas), a high-volume prenatal clinic system and public maternity hospital with widespread access to SARS-CoV-2 testing in outpatient, emergency department, and inpatient settings. Women were included if they were tested for SARS-CoV-2 during pregnancy and delivered. For placental analysis, the pathologist was blinded to illness severity. Exposures SARS-CoV-2 infection during pregnancy. Main Outcomes and Measures The primary outcome was a composite of preterm birth, preeclampsia with severe features, or cesarean delivery for abnormal fetal heart rate among women delivered after 20 weeks of gestation. Maternal illness severity, neonatal infection, and placental abnormalities were described. Results From March 18 through August 22, 2020, 3374 pregnant women (mean [SD] age, 27.6?[6] years) tested for SARS-CoV-2 were delivered, including 252 who tested positive for SARS-CoV-2 and 3122 who tested negative. The cohort included 2520 Hispanic (75%), 619 Black (18%), and 125 White (4%) women. There were no differences in age, parity, body mass index, or diabetes among women with or without SARS-CoV-2. SARS-CoV-2 positivity was more common among Hispanic women (230 [91%] positive vs 2290 [73%] negative; difference, 17.9%; 95% CI, 12.3%-23.5%; P <?.001). There was no difference in the composite primary outcome (52 women [21%] vs 684 women [23%]; relative risk, 0.94; 95% CI, 0.73-1.21; P =?.64). Early neonatal SARS-CoV-2 infection occurred in 6 of 188 tested infants (3%), primarily born to asymptomatic or mildly symptomatic women. There were no placental pathologic differences by illness severity. Maternal illness at initial presentation was asymptomatic or mild in 239 women (95%), and 6 of those women (3%) developed severe or critical illness. Fourteen women (6%) were hospitalized for the indication of COVID-19. Conclusions and Relevance In a large, single-institution cohort study, SARS-CoV-2 infection during pregnancy was not associated with adverse pregnancy outcomes. Neonatal infection may be as high as 3% and may occur predominantly among asymptomatic or mildly symptomatic women. Placental abnormalities were not associated with disease severity, and hospitalization frequency was similar to rates among nonpregnant women. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677755/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1116055 | 897 | 진단 | CoV | Virus | cov | abstract | 코로나바이러스 | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1123369 | 897 | 진단 | FIVE | Term | FIVE | abstract | abnormality | 23912 | 10.3389/fimmu.2022.919762 | Factors that predict severity of infection and seroconversion in immunocompromised children and adolescents with COVID-19 infection | Mayada Abu Shanap@@@Maher Sughayer@@@Osama Alsmadi@@@Ismail Elzayat@@@Abeer Al-Nuirat@@@Abdelghani Tbakhi@@@Iyad Sultan | 202208 | Observational Study | PMC | {{{ Abstract }}} !!{{ Objectives: }} We aimed to study the outcomes, severity, and seroconversion post SARS-CoV-2 infection in immunocompromised children and adolescents treated at our center. !!{{ Method: }} For this observational study, all pediatric patients who had COVID-19 infection from Sep-22-2020 to Nov-10-2021were identified by reviewing our laboratory records. Their charts were reviewed to determine clinical severity and outcome. Blood samples were drawn for anti-SARS-CoV-2 antibody assay. Serious COVID-19 infection (SVI) was defined if the patient had moderate, severe, or critical illness. A cutoff of 100 U/mL anti-SARS-CoV-2 antibodies was used to categorize low and high titer seroconversion. !!{{ Results: }} We identified 263 pediatric patients with COVID-19; most (68%) were symptomatic: 5% had severe or critical infection, 25% were hospitalized, 12 required respiratory support, 12 were admitted to the ICU, and five patients (2%) died. Multivariable analysis revealed several factors that predict SVI: Age above 12 years (p=0.035), body mass index above 95 th percentile (p=0.034), comorbid conditions (p=0.025), absolute neutrophil count ≤500(p=0.014) and absolute lymphocyte count ≤300 (p=0.022). Levels of anti-SARS-CoV-2 spike antibodies were obtained for 173 patients at a median of 94 days (range, 14-300) after PCR diagnosis; of them 142 (82%) patients seroconverted; the lowest seroconversion rate was observed in patients with hematological malignancies (79%). Our univariable model showed that the following factors were predictive of low titer: lower ANC, p=0.01; hematologic malignancy, p=0.023; receiving steroids in the last 14 days, p=0.032; time since last chemotherapy or immunosuppressive therapy less than 30 days, p=0.002; and being on active chemotherapy in the last 3 months prior to infection, p<0.001. !!{{ Conclusions: }} SARS-CoV-2 antibodies developed in most immunocompromised patients with COVID-19 infection in our study. Mortality was relatively low in our patients. Our univariable and multivariable models showed multiple variables that predict severity of infections and antibody response post COVID-19 infection. These observations may guide choice of active therapy during infection and the best timing of vaccination in this high-risk population. !!{{ Keywords: }} COVID 19; SARS-CoV-2; cancer; chemotherapy; children; immunocompromised; seroconversion; stem cell transplant. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381983/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1229848 | 897 | 진단 | Hispanic | Term | hispanic | abstract | 라티노 | 22292 | 10.1001/jamanetworkopen.2020.29256 | Pregnancy Outcomes Among Women With and Without Severe Acute Respiratory Syndrome Coronavirus 2 Infection | Emily H. Adhikari@@@Wilmer Moreno@@@Amanda C. Zofkie@@@Lorre MacDonald@@@Donald D. McIntire@@@Rebecca R. J. Collins@@@Catherine Y. Spong | 202011 | Research | PMC | Key Points Question In a large county health care system with access to inpatient and outpatient testing, is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection associated with pregnancy outcomes, maternal illness severity, placental pathology, and neonatal infections? Findings In this cohort study of 252 SARS-CoV-2?positive and 3122 negative pregnant women tested in outpatient and inpatient settings at a large county medical center, adverse pregnancy outcomes were similar, and neonatal infection occurred in 3% of infants, predominantly among infants born to asymptomatic or mildly symptomatic women. Placental abnormalities were not associated with disease severity, and the rate of hospitalization was similar to rates among nonpregnant women. Meaning These findings suggest that SARS-CoV-2 infection in pregnancy is not associated with adverse pregnancy outcomes. This cohort study evaluates the adverse outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among pregnant women and describes clinical management, disease progression, hospital admission, placental abnormalities, and neonatal outcomes. Importance Published data suggest that there are increased hospitalizations, placental abnormalities, and rare neonatal transmission among pregnant women with coronavirus disease 2019 (COVID-19). Objectives To evaluate adverse outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pregnancy and to describe clinical management, disease progression, hospital admission, placental abnormalities, and neonatal outcomes. Design, Setting, and Participants This observational cohort study of maternal and neonatal outcomes among delivered women with and without SARS-CoV-2 during pregnancy was conducted from March 18 through August 22, 2020, at Parkland Health and Hospital System (Dallas, Texas), a high-volume prenatal clinic system and public maternity hospital with widespread access to SARS-CoV-2 testing in outpatient, emergency department, and inpatient settings. Women were included if they were tested for SARS-CoV-2 during pregnancy and delivered. For placental analysis, the pathologist was blinded to illness severity. Exposures SARS-CoV-2 infection during pregnancy. Main Outcomes and Measures The primary outcome was a composite of preterm birth, preeclampsia with severe features, or cesarean delivery for abnormal fetal heart rate among women delivered after 20 weeks of gestation. Maternal illness severity, neonatal infection, and placental abnormalities were described. Results From March 18 through August 22, 2020, 3374 pregnant women (mean [SD] age, 27.6?[6] years) tested for SARS-CoV-2 were delivered, including 252 who tested positive for SARS-CoV-2 and 3122 who tested negative. The cohort included 2520 Hispanic (75%), 619 Black (18%), and 125 White (4%) women. There were no differences in age, parity, body mass index, or diabetes among women with or without SARS-CoV-2. SARS-CoV-2 positivity was more common among Hispanic women (230 [91%] positive vs 2290 [73%] negative; difference, 17.9%; 95% CI, 12.3%-23.5%; P <?.001). There was no difference in the composite primary outcome (52 women [21%] vs 684 women [23%]; relative risk, 0.94; 95% CI, 0.73-1.21; P =?.64). Early neonatal SARS-CoV-2 infection occurred in 6 of 188 tested infants (3%), primarily born to asymptomatic or mildly symptomatic women. There were no placental pathologic differences by illness severity. Maternal illness at initial presentation was asymptomatic or mild in 239 women (95%), and 6 of those women (3%) developed severe or critical illness. Fourteen women (6%) were hospitalized for the indication of COVID-19. Conclusions and Relevance In a large, single-institution cohort study, SARS-CoV-2 infection during pregnancy was not associated with adverse pregnancy outcomes. Neonatal infection may be as high as 3% and may occur predominantly among asymptomatic or mildly symptomatic women. Placental abnormalities were not associated with disease severity, and hospitalization frequency was similar to rates among nonpregnant women. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677755/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1229851 | 897 | 진단 | Hospitalization | Term | hospitalization | abstract | 입원 | 22292 | 10.1001/jamanetworkopen.2020.29256 | Pregnancy Outcomes Among Women With and Without Severe Acute Respiratory Syndrome Coronavirus 2 Infection | Emily H. Adhikari@@@Wilmer Moreno@@@Amanda C. Zofkie@@@Lorre MacDonald@@@Donald D. McIntire@@@Rebecca R. J. Collins@@@Catherine Y. Spong | 202011 | Research | PMC | Key Points Question In a large county health care system with access to inpatient and outpatient testing, is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection associated with pregnancy outcomes, maternal illness severity, placental pathology, and neonatal infections? Findings In this cohort study of 252 SARS-CoV-2?positive and 3122 negative pregnant women tested in outpatient and inpatient settings at a large county medical center, adverse pregnancy outcomes were similar, and neonatal infection occurred in 3% of infants, predominantly among infants born to asymptomatic or mildly symptomatic women. Placental abnormalities were not associated with disease severity, and the rate of hospitalization was similar to rates among nonpregnant women. Meaning These findings suggest that SARS-CoV-2 infection in pregnancy is not associated with adverse pregnancy outcomes. This cohort study evaluates the adverse outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among pregnant women and describes clinical management, disease progression, hospital admission, placental abnormalities, and neonatal outcomes. Importance Published data suggest that there are increased hospitalizations, placental abnormalities, and rare neonatal transmission among pregnant women with coronavirus disease 2019 (COVID-19). Objectives To evaluate adverse outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pregnancy and to describe clinical management, disease progression, hospital admission, placental abnormalities, and neonatal outcomes. Design, Setting, and Participants This observational cohort study of maternal and neonatal outcomes among delivered women with and without SARS-CoV-2 during pregnancy was conducted from March 18 through August 22, 2020, at Parkland Health and Hospital System (Dallas, Texas), a high-volume prenatal clinic system and public maternity hospital with widespread access to SARS-CoV-2 testing in outpatient, emergency department, and inpatient settings. Women were included if they were tested for SARS-CoV-2 during pregnancy and delivered. For placental analysis, the pathologist was blinded to illness severity. Exposures SARS-CoV-2 infection during pregnancy. Main Outcomes and Measures The primary outcome was a composite of preterm birth, preeclampsia with severe features, or cesarean delivery for abnormal fetal heart rate among women delivered after 20 weeks of gestation. Maternal illness severity, neonatal infection, and placental abnormalities were described. Results From March 18 through August 22, 2020, 3374 pregnant women (mean [SD] age, 27.6?[6] years) tested for SARS-CoV-2 were delivered, including 252 who tested positive for SARS-CoV-2 and 3122 who tested negative. The cohort included 2520 Hispanic (75%), 619 Black (18%), and 125 White (4%) women. There were no differences in age, parity, body mass index, or diabetes among women with or without SARS-CoV-2. SARS-CoV-2 positivity was more common among Hispanic women (230 [91%] positive vs 2290 [73%] negative; difference, 17.9%; 95% CI, 12.3%-23.5%; P <?.001). There was no difference in the composite primary outcome (52 women [21%] vs 684 women [23%]; relative risk, 0.94; 95% CI, 0.73-1.21; P =?.64). Early neonatal SARS-CoV-2 infection occurred in 6 of 188 tested infants (3%), primarily born to asymptomatic or mildly symptomatic women. There were no placental pathologic differences by illness severity. Maternal illness at initial presentation was asymptomatic or mild in 239 women (95%), and 6 of those women (3%) developed severe or critical illness. Fourteen women (6%) were hospitalized for the indication of COVID-19. Conclusions and Relevance In a large, single-institution cohort study, SARS-CoV-2 infection during pregnancy was not associated with adverse pregnancy outcomes. Neonatal infection may be as high as 3% and may occur predominantly among asymptomatic or mildly symptomatic women. Placental abnormalities were not associated with disease severity, and hospitalization frequency was similar to rates among nonpregnant women. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677755/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1123391 | 897 | 진단 | PCR | Action | pcr | abstract | 중합효소 연쇄반응 | 23912 | 10.3389/fimmu.2022.919762 | Factors that predict severity of infection and seroconversion in immunocompromised children and adolescents with COVID-19 infection | Mayada Abu Shanap@@@Maher Sughayer@@@Osama Alsmadi@@@Ismail Elzayat@@@Abeer Al-Nuirat@@@Abdelghani Tbakhi@@@Iyad Sultan | 202208 | Observational Study | PMC | {{{ Abstract }}} !!{{ Objectives: }} We aimed to study the outcomes, severity, and seroconversion post SARS-CoV-2 infection in immunocompromised children and adolescents treated at our center. !!{{ Method: }} For this observational study, all pediatric patients who had COVID-19 infection from Sep-22-2020 to Nov-10-2021were identified by reviewing our laboratory records. Their charts were reviewed to determine clinical severity and outcome. Blood samples were drawn for anti-SARS-CoV-2 antibody assay. Serious COVID-19 infection (SVI) was defined if the patient had moderate, severe, or critical illness. A cutoff of 100 U/mL anti-SARS-CoV-2 antibodies was used to categorize low and high titer seroconversion. !!{{ Results: }} We identified 263 pediatric patients with COVID-19; most (68%) were symptomatic: 5% had severe or critical infection, 25% were hospitalized, 12 required respiratory support, 12 were admitted to the ICU, and five patients (2%) died. Multivariable analysis revealed several factors that predict SVI: Age above 12 years (p=0.035), body mass index above 95 th percentile (p=0.034), comorbid conditions (p=0.025), absolute neutrophil count ≤500(p=0.014) and absolute lymphocyte count ≤300 (p=0.022). Levels of anti-SARS-CoV-2 spike antibodies were obtained for 173 patients at a median of 94 days (range, 14-300) after PCR diagnosis; of them 142 (82%) patients seroconverted; the lowest seroconversion rate was observed in patients with hematological malignancies (79%). Our univariable model showed that the following factors were predictive of low titer: lower ANC, p=0.01; hematologic malignancy, p=0.023; receiving steroids in the last 14 days, p=0.032; time since last chemotherapy or immunosuppressive therapy less than 30 days, p=0.002; and being on active chemotherapy in the last 3 months prior to infection, p<0.001. !!{{ Conclusions: }} SARS-CoV-2 antibodies developed in most immunocompromised patients with COVID-19 infection in our study. Mortality was relatively low in our patients. Our univariable and multivariable models showed multiple variables that predict severity of infections and antibody response post COVID-19 infection. These observations may guide choice of active therapy during infection and the best timing of vaccination in this high-risk population. !!{{ Keywords: }} COVID 19; SARS-CoV-2; cancer; chemotherapy; children; immunocompromised; seroconversion; stem cell transplant. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381983/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1116056 | 897 | 진단 | CXCR5 | Gene | CXCR5 | abstract | None | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1229868 | 897 | 진단 | no differences | Action | no difference | abstract | None | 22292 | 10.1001/jamanetworkopen.2020.29256 | Pregnancy Outcomes Among Women With and Without Severe Acute Respiratory Syndrome Coronavirus 2 Infection | Emily H. Adhikari@@@Wilmer Moreno@@@Amanda C. Zofkie@@@Lorre MacDonald@@@Donald D. McIntire@@@Rebecca R. J. Collins@@@Catherine Y. Spong | 202011 | Research | PMC | Key Points Question In a large county health care system with access to inpatient and outpatient testing, is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection associated with pregnancy outcomes, maternal illness severity, placental pathology, and neonatal infections? Findings In this cohort study of 252 SARS-CoV-2?positive and 3122 negative pregnant women tested in outpatient and inpatient settings at a large county medical center, adverse pregnancy outcomes were similar, and neonatal infection occurred in 3% of infants, predominantly among infants born to asymptomatic or mildly symptomatic women. Placental abnormalities were not associated with disease severity, and the rate of hospitalization was similar to rates among nonpregnant women. Meaning These findings suggest that SARS-CoV-2 infection in pregnancy is not associated with adverse pregnancy outcomes. This cohort study evaluates the adverse outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among pregnant women and describes clinical management, disease progression, hospital admission, placental abnormalities, and neonatal outcomes. Importance Published data suggest that there are increased hospitalizations, placental abnormalities, and rare neonatal transmission among pregnant women with coronavirus disease 2019 (COVID-19). Objectives To evaluate adverse outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pregnancy and to describe clinical management, disease progression, hospital admission, placental abnormalities, and neonatal outcomes. Design, Setting, and Participants This observational cohort study of maternal and neonatal outcomes among delivered women with and without SARS-CoV-2 during pregnancy was conducted from March 18 through August 22, 2020, at Parkland Health and Hospital System (Dallas, Texas), a high-volume prenatal clinic system and public maternity hospital with widespread access to SARS-CoV-2 testing in outpatient, emergency department, and inpatient settings. Women were included if they were tested for SARS-CoV-2 during pregnancy and delivered. For placental analysis, the pathologist was blinded to illness severity. Exposures SARS-CoV-2 infection during pregnancy. Main Outcomes and Measures The primary outcome was a composite of preterm birth, preeclampsia with severe features, or cesarean delivery for abnormal fetal heart rate among women delivered after 20 weeks of gestation. Maternal illness severity, neonatal infection, and placental abnormalities were described. Results From March 18 through August 22, 2020, 3374 pregnant women (mean [SD] age, 27.6?[6] years) tested for SARS-CoV-2 were delivered, including 252 who tested positive for SARS-CoV-2 and 3122 who tested negative. The cohort included 2520 Hispanic (75%), 619 Black (18%), and 125 White (4%) women. There were no differences in age, parity, body mass index, or diabetes among women with or without SARS-CoV-2. SARS-CoV-2 positivity was more common among Hispanic women (230 [91%] positive vs 2290 [73%] negative; difference, 17.9%; 95% CI, 12.3%-23.5%; P <?.001). There was no difference in the composite primary outcome (52 women [21%] vs 684 women [23%]; relative risk, 0.94; 95% CI, 0.73-1.21; P =?.64). Early neonatal SARS-CoV-2 infection occurred in 6 of 188 tested infants (3%), primarily born to asymptomatic or mildly symptomatic women. There were no placental pathologic differences by illness severity. Maternal illness at initial presentation was asymptomatic or mild in 239 women (95%), and 6 of those women (3%) developed severe or critical illness. Fourteen women (6%) were hospitalized for the indication of COVID-19. Conclusions and Relevance In a large, single-institution cohort study, SARS-CoV-2 infection during pregnancy was not associated with adverse pregnancy outcomes. Neonatal infection may be as high as 3% and may occur predominantly among asymptomatic or mildly symptomatic women. Placental abnormalities were not associated with disease severity, and hospitalization frequency was similar to rates among nonpregnant women. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677755/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1116057 | 897 | 진단 | distribution | Term | distribution | abstract | 분포 | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1123392 | 897 | 진단 | Pediatric patient | Term | pediatric patient | abstract | None | 23912 | 10.3389/fimmu.2022.919762 | Factors that predict severity of infection and seroconversion in immunocompromised children and adolescents with COVID-19 infection | Mayada Abu Shanap@@@Maher Sughayer@@@Osama Alsmadi@@@Ismail Elzayat@@@Abeer Al-Nuirat@@@Abdelghani Tbakhi@@@Iyad Sultan | 202208 | Observational Study | PMC | {{{ Abstract }}} !!{{ Objectives: }} We aimed to study the outcomes, severity, and seroconversion post SARS-CoV-2 infection in immunocompromised children and adolescents treated at our center. !!{{ Method: }} For this observational study, all pediatric patients who had COVID-19 infection from Sep-22-2020 to Nov-10-2021were identified by reviewing our laboratory records. Their charts were reviewed to determine clinical severity and outcome. Blood samples were drawn for anti-SARS-CoV-2 antibody assay. Serious COVID-19 infection (SVI) was defined if the patient had moderate, severe, or critical illness. A cutoff of 100 U/mL anti-SARS-CoV-2 antibodies was used to categorize low and high titer seroconversion. !!{{ Results: }} We identified 263 pediatric patients with COVID-19; most (68%) were symptomatic: 5% had severe or critical infection, 25% were hospitalized, 12 required respiratory support, 12 were admitted to the ICU, and five patients (2%) died. Multivariable analysis revealed several factors that predict SVI: Age above 12 years (p=0.035), body mass index above 95 th percentile (p=0.034), comorbid conditions (p=0.025), absolute neutrophil count ≤500(p=0.014) and absolute lymphocyte count ≤300 (p=0.022). Levels of anti-SARS-CoV-2 spike antibodies were obtained for 173 patients at a median of 94 days (range, 14-300) after PCR diagnosis; of them 142 (82%) patients seroconverted; the lowest seroconversion rate was observed in patients with hematological malignancies (79%). Our univariable model showed that the following factors were predictive of low titer: lower ANC, p=0.01; hematologic malignancy, p=0.023; receiving steroids in the last 14 days, p=0.032; time since last chemotherapy or immunosuppressive therapy less than 30 days, p=0.002; and being on active chemotherapy in the last 3 months prior to infection, p<0.001. !!{{ Conclusions: }} SARS-CoV-2 antibodies developed in most immunocompromised patients with COVID-19 infection in our study. Mortality was relatively low in our patients. Our univariable and multivariable models showed multiple variables that predict severity of infections and antibody response post COVID-19 infection. These observations may guide choice of active therapy during infection and the best timing of vaccination in this high-risk population. !!{{ Keywords: }} COVID 19; SARS-CoV-2; cancer; chemotherapy; children; immunocompromised; seroconversion; stem cell transplant. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381983/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1116058 | 897 | 진단 | double negative | Term | double negative | abstract | abnormality | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1116059 | 897 | 진단 | evaluated | Action | evaluated | abstract | None | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1116060 | 897 | 진단 | expressing | Action | expressing | abstract | None | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1116061 | 897 | 진단 | expression | Action | expression | abstract | 표현 | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1229869 | 897 | 진단 | nonpregnant | Term | nonpregnant | abstract | None | 22292 | 10.1001/jamanetworkopen.2020.29256 | Pregnancy Outcomes Among Women With and Without Severe Acute Respiratory Syndrome Coronavirus 2 Infection | Emily H. Adhikari@@@Wilmer Moreno@@@Amanda C. Zofkie@@@Lorre MacDonald@@@Donald D. McIntire@@@Rebecca R. J. Collins@@@Catherine Y. Spong | 202011 | Research | PMC | Key Points Question In a large county health care system with access to inpatient and outpatient testing, is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection associated with pregnancy outcomes, maternal illness severity, placental pathology, and neonatal infections? Findings In this cohort study of 252 SARS-CoV-2?positive and 3122 negative pregnant women tested in outpatient and inpatient settings at a large county medical center, adverse pregnancy outcomes were similar, and neonatal infection occurred in 3% of infants, predominantly among infants born to asymptomatic or mildly symptomatic women. Placental abnormalities were not associated with disease severity, and the rate of hospitalization was similar to rates among nonpregnant women. Meaning These findings suggest that SARS-CoV-2 infection in pregnancy is not associated with adverse pregnancy outcomes. This cohort study evaluates the adverse outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among pregnant women and describes clinical management, disease progression, hospital admission, placental abnormalities, and neonatal outcomes. Importance Published data suggest that there are increased hospitalizations, placental abnormalities, and rare neonatal transmission among pregnant women with coronavirus disease 2019 (COVID-19). Objectives To evaluate adverse outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pregnancy and to describe clinical management, disease progression, hospital admission, placental abnormalities, and neonatal outcomes. Design, Setting, and Participants This observational cohort study of maternal and neonatal outcomes among delivered women with and without SARS-CoV-2 during pregnancy was conducted from March 18 through August 22, 2020, at Parkland Health and Hospital System (Dallas, Texas), a high-volume prenatal clinic system and public maternity hospital with widespread access to SARS-CoV-2 testing in outpatient, emergency department, and inpatient settings. Women were included if they were tested for SARS-CoV-2 during pregnancy and delivered. For placental analysis, the pathologist was blinded to illness severity. Exposures SARS-CoV-2 infection during pregnancy. Main Outcomes and Measures The primary outcome was a composite of preterm birth, preeclampsia with severe features, or cesarean delivery for abnormal fetal heart rate among women delivered after 20 weeks of gestation. Maternal illness severity, neonatal infection, and placental abnormalities were described. Results From March 18 through August 22, 2020, 3374 pregnant women (mean [SD] age, 27.6?[6] years) tested for SARS-CoV-2 were delivered, including 252 who tested positive for SARS-CoV-2 and 3122 who tested negative. The cohort included 2520 Hispanic (75%), 619 Black (18%), and 125 White (4%) women. There were no differences in age, parity, body mass index, or diabetes among women with or without SARS-CoV-2. SARS-CoV-2 positivity was more common among Hispanic women (230 [91%] positive vs 2290 [73%] negative; difference, 17.9%; 95% CI, 12.3%-23.5%; P <?.001). There was no difference in the composite primary outcome (52 women [21%] vs 684 women [23%]; relative risk, 0.94; 95% CI, 0.73-1.21; P =?.64). Early neonatal SARS-CoV-2 infection occurred in 6 of 188 tested infants (3%), primarily born to asymptomatic or mildly symptomatic women. There were no placental pathologic differences by illness severity. Maternal illness at initial presentation was asymptomatic or mild in 239 women (95%), and 6 of those women (3%) developed severe or critical illness. Fourteen women (6%) were hospitalized for the indication of COVID-19. Conclusions and Relevance In a large, single-institution cohort study, SARS-CoV-2 infection during pregnancy was not associated with adverse pregnancy outcomes. Neonatal infection may be as high as 3% and may occur predominantly among asymptomatic or mildly symptomatic women. Placental abnormalities were not associated with disease severity, and hospitalization frequency was similar to rates among nonpregnant women. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677755/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1123405 | 897 | 진단 | stem cell transplant. | Term | stem cell transplant | author | None | 23912 | 10.3389/fimmu.2022.919762 | Factors that predict severity of infection and seroconversion in immunocompromised children and adolescents with COVID-19 infection | Mayada Abu Shanap@@@Maher Sughayer@@@Osama Alsmadi@@@Ismail Elzayat@@@Abeer Al-Nuirat@@@Abdelghani Tbakhi@@@Iyad Sultan | 202208 | Observational Study | PMC | {{{ Abstract }}} !!{{ Objectives: }} We aimed to study the outcomes, severity, and seroconversion post SARS-CoV-2 infection in immunocompromised children and adolescents treated at our center. !!{{ Method: }} For this observational study, all pediatric patients who had COVID-19 infection from Sep-22-2020 to Nov-10-2021were identified by reviewing our laboratory records. Their charts were reviewed to determine clinical severity and outcome. Blood samples were drawn for anti-SARS-CoV-2 antibody assay. Serious COVID-19 infection (SVI) was defined if the patient had moderate, severe, or critical illness. A cutoff of 100 U/mL anti-SARS-CoV-2 antibodies was used to categorize low and high titer seroconversion. !!{{ Results: }} We identified 263 pediatric patients with COVID-19; most (68%) were symptomatic: 5% had severe or critical infection, 25% were hospitalized, 12 required respiratory support, 12 were admitted to the ICU, and five patients (2%) died. Multivariable analysis revealed several factors that predict SVI: Age above 12 years (p=0.035), body mass index above 95 th percentile (p=0.034), comorbid conditions (p=0.025), absolute neutrophil count ≤500(p=0.014) and absolute lymphocyte count ≤300 (p=0.022). Levels of anti-SARS-CoV-2 spike antibodies were obtained for 173 patients at a median of 94 days (range, 14-300) after PCR diagnosis; of them 142 (82%) patients seroconverted; the lowest seroconversion rate was observed in patients with hematological malignancies (79%). Our univariable model showed that the following factors were predictive of low titer: lower ANC, p=0.01; hematologic malignancy, p=0.023; receiving steroids in the last 14 days, p=0.032; time since last chemotherapy or immunosuppressive therapy less than 30 days, p=0.002; and being on active chemotherapy in the last 3 months prior to infection, p<0.001. !!{{ Conclusions: }} SARS-CoV-2 antibodies developed in most immunocompromised patients with COVID-19 infection in our study. Mortality was relatively low in our patients. Our univariable and multivariable models showed multiple variables that predict severity of infections and antibody response post COVID-19 infection. These observations may guide choice of active therapy during infection and the best timing of vaccination in this high-risk population. !!{{ Keywords: }} COVID 19; SARS-CoV-2; cancer; chemotherapy; children; immunocompromised; seroconversion; stem cell transplant. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381983/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1116062 | 897 | 진단 | group | Term | group | abstract | 집단 | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1116040 | 897 | 진단 | Algorithm | Term | algorithm | abstract | 연산법 | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1116041 | 897 | 진단 | Analysis | Term | analysis | abstract | 분석 | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1123370 | 897 | 진단 | Hematological malignancy | Disease | hematological malignancy | abstract | 혈액 악성 악성 | 23912 | 10.3389/fimmu.2022.919762 | Factors that predict severity of infection and seroconversion in immunocompromised children and adolescents with COVID-19 infection | Mayada Abu Shanap@@@Maher Sughayer@@@Osama Alsmadi@@@Ismail Elzayat@@@Abeer Al-Nuirat@@@Abdelghani Tbakhi@@@Iyad Sultan | 202208 | Observational Study | PMC | {{{ Abstract }}} !!{{ Objectives: }} We aimed to study the outcomes, severity, and seroconversion post SARS-CoV-2 infection in immunocompromised children and adolescents treated at our center. !!{{ Method: }} For this observational study, all pediatric patients who had COVID-19 infection from Sep-22-2020 to Nov-10-2021were identified by reviewing our laboratory records. Their charts were reviewed to determine clinical severity and outcome. Blood samples were drawn for anti-SARS-CoV-2 antibody assay. Serious COVID-19 infection (SVI) was defined if the patient had moderate, severe, or critical illness. A cutoff of 100 U/mL anti-SARS-CoV-2 antibodies was used to categorize low and high titer seroconversion. !!{{ Results: }} We identified 263 pediatric patients with COVID-19; most (68%) were symptomatic: 5% had severe or critical infection, 25% were hospitalized, 12 required respiratory support, 12 were admitted to the ICU, and five patients (2%) died. Multivariable analysis revealed several factors that predict SVI: Age above 12 years (p=0.035), body mass index above 95 th percentile (p=0.034), comorbid conditions (p=0.025), absolute neutrophil count ≤500(p=0.014) and absolute lymphocyte count ≤300 (p=0.022). Levels of anti-SARS-CoV-2 spike antibodies were obtained for 173 patients at a median of 94 days (range, 14-300) after PCR diagnosis; of them 142 (82%) patients seroconverted; the lowest seroconversion rate was observed in patients with hematological malignancies (79%). Our univariable model showed that the following factors were predictive of low titer: lower ANC, p=0.01; hematologic malignancy, p=0.023; receiving steroids in the last 14 days, p=0.032; time since last chemotherapy or immunosuppressive therapy less than 30 days, p=0.002; and being on active chemotherapy in the last 3 months prior to infection, p<0.001. !!{{ Conclusions: }} SARS-CoV-2 antibodies developed in most immunocompromised patients with COVID-19 infection in our study. Mortality was relatively low in our patients. Our univariable and multivariable models showed multiple variables that predict severity of infections and antibody response post COVID-19 infection. These observations may guide choice of active therapy during infection and the best timing of vaccination in this high-risk population. !!{{ Keywords: }} COVID 19; SARS-CoV-2; cancer; chemotherapy; children; immunocompromised; seroconversion; stem cell transplant. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381983/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1116042 | 897 | 진단 | Antigen presentation | Action | antigen presentation | abstract | 항원제시 | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1116043 | 897 | 진단 | Autoimmune | Disease | autoimmune | abstract | 자가면역 | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1116044 | 897 | 진단 | baseline | Term | baseline | abstract | None | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1116045 | 897 | 진단 | B cell | Cell | b cell | abstract | B세포 | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1116046 | 897 | 진단 | B cells | Cell | b cell | abstract | B세포 | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1111543 | 897 | 진단 | Vaccination strategies | Term | vaccination strategy | abstract | 예방 접종 전략 | 23484 | 10.1001/jamanetworkopen.2022.21616 | Long-term Immune Response to SARS-CoV-2 Infection Among Children and Adults After Mild Infection | Costanza Di Chiara@@@Anna Cantarutti@@@Paola Costenaro@@@Daniele Don?@@@Francesco Bonfante@@@Chiara Cosma@@@Martina Ferrarese@@@Sandra Cozzani@@@Maria Raffaella Petrara@@@Francesco Carmona@@@Cecilia Liberati@@@Paolo Palma@@@Giovanni Di Salvo@@@Anita De Rossi@@@Mario Plebani@@@Andrea Padoan@@@Carlo Giaquinto | 202207 | Article | PMC | {{{ Abstract }}} !!{{ Importance: }} Understanding the long-term immune response against SARS-CoV-2 infection in children is crucial to optimize vaccination strategies. Although it is known that SARS-CoV-2 antibodies may persist in adults 12 months after infection, data are limited in the pediatric population. !!{{ Objective: }} To examine long-term anti-SARS-CoV-2 spike receptor-binding domain (S-RBD) IgG kinetics in children after SARS-CoV-2 infection. !!{{ Design, setting, and participants: }} In this single-center, prospective cohort study, patients were enrolled consecutively from April 1, 2020, to August 31, 2021, at the COVID-19 Family Cluster Follow-up Clinic, Department of Women's and Children's Health, University Hospital of Padua. A cohort of 252 COVID-19 family clusters underwent serologic follow-up at 1 to 4, 5 to 10, and more than 10 months after infection with quantification of anti-S-RBD IgG by chemiluminescent immunoassay. !!{{ Exposures: }} SARS-CoV-2 infection. !!{{ Results: }} Among 902 study participants, 697 had confirmed SARS-CoV-2 infection, including 351 children or older siblings (mean [SD] age, 8.6 [5.1] years) and 346 parents (mean [SD] age, 42.5 [7.1] years). Among 697 cases, 674 (96.7%) were asymptomatic or mild. Children had significantly higher S-RBD IgG titers than older patients across all follow-up time points, with an overall median S-RBD IgG titer in patients younger than 3 years 5-fold higher than adults (304.8 [IQR, 139.0-516.6] kBAU/L vs 55.6 [24.2-136.0] kBAU/L, P < .001). Longitudinal analysis of 56 study participants sampled at least twice during follow-up demonstrated the persistence of antibodies up to 10 months from infection in all age classes, despite a progressive decline over time. !!{{ Conclusions and relevance: }} In this cohort study of Italian children and adults following SARS-CoV-2 infection different kinetics of SARS-CoV-2 antibodies were found across several age classes of individuals with asymptomatic or mild COVID-19, which could help in optimizing COVID-19 vaccination strategies and prevention policies. This work provides further evidence of sustained immune response in children up to 1 year after primary SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280400/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1111491 | 897 | 진단 | age | Term | age | abstract | 오랫동안 | 23484 | 10.1001/jamanetworkopen.2022.21616 | Long-term Immune Response to SARS-CoV-2 Infection Among Children and Adults After Mild Infection | Costanza Di Chiara@@@Anna Cantarutti@@@Paola Costenaro@@@Daniele Don?@@@Francesco Bonfante@@@Chiara Cosma@@@Martina Ferrarese@@@Sandra Cozzani@@@Maria Raffaella Petrara@@@Francesco Carmona@@@Cecilia Liberati@@@Paolo Palma@@@Giovanni Di Salvo@@@Anita De Rossi@@@Mario Plebani@@@Andrea Padoan@@@Carlo Giaquinto | 202207 | Article | PMC | {{{ Abstract }}} !!{{ Importance: }} Understanding the long-term immune response against SARS-CoV-2 infection in children is crucial to optimize vaccination strategies. Although it is known that SARS-CoV-2 antibodies may persist in adults 12 months after infection, data are limited in the pediatric population. !!{{ Objective: }} To examine long-term anti-SARS-CoV-2 spike receptor-binding domain (S-RBD) IgG kinetics in children after SARS-CoV-2 infection. !!{{ Design, setting, and participants: }} In this single-center, prospective cohort study, patients were enrolled consecutively from April 1, 2020, to August 31, 2021, at the COVID-19 Family Cluster Follow-up Clinic, Department of Women's and Children's Health, University Hospital of Padua. A cohort of 252 COVID-19 family clusters underwent serologic follow-up at 1 to 4, 5 to 10, and more than 10 months after infection with quantification of anti-S-RBD IgG by chemiluminescent immunoassay. !!{{ Exposures: }} SARS-CoV-2 infection. !!{{ Results: }} Among 902 study participants, 697 had confirmed SARS-CoV-2 infection, including 351 children or older siblings (mean [SD] age, 8.6 [5.1] years) and 346 parents (mean [SD] age, 42.5 [7.1] years). Among 697 cases, 674 (96.7%) were asymptomatic or mild. Children had significantly higher S-RBD IgG titers than older patients across all follow-up time points, with an overall median S-RBD IgG titer in patients younger than 3 years 5-fold higher than adults (304.8 [IQR, 139.0-516.6] kBAU/L vs 55.6 [24.2-136.0] kBAU/L, P < .001). Longitudinal analysis of 56 study participants sampled at least twice during follow-up demonstrated the persistence of antibodies up to 10 months from infection in all age classes, despite a progressive decline over time. !!{{ Conclusions and relevance: }} In this cohort study of Italian children and adults following SARS-CoV-2 infection different kinetics of SARS-CoV-2 antibodies were found across several age classes of individuals with asymptomatic or mild COVID-19, which could help in optimizing COVID-19 vaccination strategies and prevention policies. This work provides further evidence of sustained immune response in children up to 1 year after primary SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280400/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1116047 | 897 | 진단 | B-cells | Cell | b-cell | author | None | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1111492 | 897 | 진단 | Analysis | Term | analysis | abstract | 분석 | 23484 | 10.1001/jamanetworkopen.2022.21616 | Long-term Immune Response to SARS-CoV-2 Infection Among Children and Adults After Mild Infection | Costanza Di Chiara@@@Anna Cantarutti@@@Paola Costenaro@@@Daniele Don?@@@Francesco Bonfante@@@Chiara Cosma@@@Martina Ferrarese@@@Sandra Cozzani@@@Maria Raffaella Petrara@@@Francesco Carmona@@@Cecilia Liberati@@@Paolo Palma@@@Giovanni Di Salvo@@@Anita De Rossi@@@Mario Plebani@@@Andrea Padoan@@@Carlo Giaquinto | 202207 | Article | PMC | {{{ Abstract }}} !!{{ Importance: }} Understanding the long-term immune response against SARS-CoV-2 infection in children is crucial to optimize vaccination strategies. Although it is known that SARS-CoV-2 antibodies may persist in adults 12 months after infection, data are limited in the pediatric population. !!{{ Objective: }} To examine long-term anti-SARS-CoV-2 spike receptor-binding domain (S-RBD) IgG kinetics in children after SARS-CoV-2 infection. !!{{ Design, setting, and participants: }} In this single-center, prospective cohort study, patients were enrolled consecutively from April 1, 2020, to August 31, 2021, at the COVID-19 Family Cluster Follow-up Clinic, Department of Women's and Children's Health, University Hospital of Padua. A cohort of 252 COVID-19 family clusters underwent serologic follow-up at 1 to 4, 5 to 10, and more than 10 months after infection with quantification of anti-S-RBD IgG by chemiluminescent immunoassay. !!{{ Exposures: }} SARS-CoV-2 infection. !!{{ Results: }} Among 902 study participants, 697 had confirmed SARS-CoV-2 infection, including 351 children or older siblings (mean [SD] age, 8.6 [5.1] years) and 346 parents (mean [SD] age, 42.5 [7.1] years). Among 697 cases, 674 (96.7%) were asymptomatic or mild. Children had significantly higher S-RBD IgG titers than older patients across all follow-up time points, with an overall median S-RBD IgG titer in patients younger than 3 years 5-fold higher than adults (304.8 [IQR, 139.0-516.6] kBAU/L vs 55.6 [24.2-136.0] kBAU/L, P < .001). Longitudinal analysis of 56 study participants sampled at least twice during follow-up demonstrated the persistence of antibodies up to 10 months from infection in all age classes, despite a progressive decline over time. !!{{ Conclusions and relevance: }} In this cohort study of Italian children and adults following SARS-CoV-2 infection different kinetics of SARS-CoV-2 antibodies were found across several age classes of individuals with asymptomatic or mild COVID-19, which could help in optimizing COVID-19 vaccination strategies and prevention policies. This work provides further evidence of sustained immune response in children up to 1 year after primary SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280400/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1116048 | 897 | 진단 | B cell subset | Term | B cell subset | abstract | None | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1111493 | 897 | 진단 | antibody | Protein | antibody | abstract | 항체 | 23484 | 10.1001/jamanetworkopen.2022.21616 | Long-term Immune Response to SARS-CoV-2 Infection Among Children and Adults After Mild Infection | Costanza Di Chiara@@@Anna Cantarutti@@@Paola Costenaro@@@Daniele Don?@@@Francesco Bonfante@@@Chiara Cosma@@@Martina Ferrarese@@@Sandra Cozzani@@@Maria Raffaella Petrara@@@Francesco Carmona@@@Cecilia Liberati@@@Paolo Palma@@@Giovanni Di Salvo@@@Anita De Rossi@@@Mario Plebani@@@Andrea Padoan@@@Carlo Giaquinto | 202207 | Article | PMC | {{{ Abstract }}} !!{{ Importance: }} Understanding the long-term immune response against SARS-CoV-2 infection in children is crucial to optimize vaccination strategies. Although it is known that SARS-CoV-2 antibodies may persist in adults 12 months after infection, data are limited in the pediatric population. !!{{ Objective: }} To examine long-term anti-SARS-CoV-2 spike receptor-binding domain (S-RBD) IgG kinetics in children after SARS-CoV-2 infection. !!{{ Design, setting, and participants: }} In this single-center, prospective cohort study, patients were enrolled consecutively from April 1, 2020, to August 31, 2021, at the COVID-19 Family Cluster Follow-up Clinic, Department of Women's and Children's Health, University Hospital of Padua. A cohort of 252 COVID-19 family clusters underwent serologic follow-up at 1 to 4, 5 to 10, and more than 10 months after infection with quantification of anti-S-RBD IgG by chemiluminescent immunoassay. !!{{ Exposures: }} SARS-CoV-2 infection. !!{{ Results: }} Among 902 study participants, 697 had confirmed SARS-CoV-2 infection, including 351 children or older siblings (mean [SD] age, 8.6 [5.1] years) and 346 parents (mean [SD] age, 42.5 [7.1] years). Among 697 cases, 674 (96.7%) were asymptomatic or mild. Children had significantly higher S-RBD IgG titers than older patients across all follow-up time points, with an overall median S-RBD IgG titer in patients younger than 3 years 5-fold higher than adults (304.8 [IQR, 139.0-516.6] kBAU/L vs 55.6 [24.2-136.0] kBAU/L, P < .001). Longitudinal analysis of 56 study participants sampled at least twice during follow-up demonstrated the persistence of antibodies up to 10 months from infection in all age classes, despite a progressive decline over time. !!{{ Conclusions and relevance: }} In this cohort study of Italian children and adults following SARS-CoV-2 infection different kinetics of SARS-CoV-2 antibodies were found across several age classes of individuals with asymptomatic or mild COVID-19, which could help in optimizing COVID-19 vaccination strategies and prevention policies. This work provides further evidence of sustained immune response in children up to 1 year after primary SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280400/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1229870 | 897 | 진단 | objective | Term | objective | abstract | abnormality | 22292 | 10.1001/jamanetworkopen.2020.29256 | Pregnancy Outcomes Among Women With and Without Severe Acute Respiratory Syndrome Coronavirus 2 Infection | Emily H. Adhikari@@@Wilmer Moreno@@@Amanda C. Zofkie@@@Lorre MacDonald@@@Donald D. McIntire@@@Rebecca R. J. Collins@@@Catherine Y. Spong | 202011 | Research | PMC | Key Points Question In a large county health care system with access to inpatient and outpatient testing, is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection associated with pregnancy outcomes, maternal illness severity, placental pathology, and neonatal infections? Findings In this cohort study of 252 SARS-CoV-2?positive and 3122 negative pregnant women tested in outpatient and inpatient settings at a large county medical center, adverse pregnancy outcomes were similar, and neonatal infection occurred in 3% of infants, predominantly among infants born to asymptomatic or mildly symptomatic women. Placental abnormalities were not associated with disease severity, and the rate of hospitalization was similar to rates among nonpregnant women. Meaning These findings suggest that SARS-CoV-2 infection in pregnancy is not associated with adverse pregnancy outcomes. This cohort study evaluates the adverse outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among pregnant women and describes clinical management, disease progression, hospital admission, placental abnormalities, and neonatal outcomes. Importance Published data suggest that there are increased hospitalizations, placental abnormalities, and rare neonatal transmission among pregnant women with coronavirus disease 2019 (COVID-19). Objectives To evaluate adverse outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pregnancy and to describe clinical management, disease progression, hospital admission, placental abnormalities, and neonatal outcomes. Design, Setting, and Participants This observational cohort study of maternal and neonatal outcomes among delivered women with and without SARS-CoV-2 during pregnancy was conducted from March 18 through August 22, 2020, at Parkland Health and Hospital System (Dallas, Texas), a high-volume prenatal clinic system and public maternity hospital with widespread access to SARS-CoV-2 testing in outpatient, emergency department, and inpatient settings. Women were included if they were tested for SARS-CoV-2 during pregnancy and delivered. For placental analysis, the pathologist was blinded to illness severity. Exposures SARS-CoV-2 infection during pregnancy. Main Outcomes and Measures The primary outcome was a composite of preterm birth, preeclampsia with severe features, or cesarean delivery for abnormal fetal heart rate among women delivered after 20 weeks of gestation. Maternal illness severity, neonatal infection, and placental abnormalities were described. Results From March 18 through August 22, 2020, 3374 pregnant women (mean [SD] age, 27.6?[6] years) tested for SARS-CoV-2 were delivered, including 252 who tested positive for SARS-CoV-2 and 3122 who tested negative. The cohort included 2520 Hispanic (75%), 619 Black (18%), and 125 White (4%) women. There were no differences in age, parity, body mass index, or diabetes among women with or without SARS-CoV-2. SARS-CoV-2 positivity was more common among Hispanic women (230 [91%] positive vs 2290 [73%] negative; difference, 17.9%; 95% CI, 12.3%-23.5%; P <?.001). There was no difference in the composite primary outcome (52 women [21%] vs 684 women [23%]; relative risk, 0.94; 95% CI, 0.73-1.21; P =?.64). Early neonatal SARS-CoV-2 infection occurred in 6 of 188 tested infants (3%), primarily born to asymptomatic or mildly symptomatic women. There were no placental pathologic differences by illness severity. Maternal illness at initial presentation was asymptomatic or mild in 239 women (95%), and 6 of those women (3%) developed severe or critical illness. Fourteen women (6%) were hospitalized for the indication of COVID-19. Conclusions and Relevance In a large, single-institution cohort study, SARS-CoV-2 infection during pregnancy was not associated with adverse pregnancy outcomes. Neonatal infection may be as high as 3% and may occur predominantly among asymptomatic or mildly symptomatic women. Placental abnormalities were not associated with disease severity, and hospitalization frequency was similar to rates among nonpregnant women. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677755/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1116049 | 897 | 진단 | carried | Action | carried | abstract | None | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1154948 | 897 | 진단 | administration | Treatment | administration | abstract | 행정 | 25010 | 10.1186/s12879-022-07513-0 | Anti-SARS-CoV2 antibody-mediated cytokine release syndrome in a patient with acute promyelocytic leukemia | Ahmed N Hegazy@@@Jan Kr?nke@@@Stefan Angermair@@@Stefan Schwartz@@@Carl Weidinger@@@Ulrich Keller@@@Sascha Treskatsch@@@Britta Siegmund@@@Thomas Schneider | 202206 | Case Reports | PMC | {{{ Abstract }}} !!{{ Background: }} Passive immunization against SARS-CoV-2 limits viral burden and death from COVID-19; however, it poses a theoretical risk of disease exacerbation through antibody-dependent enhancement (ADE). ADE after anti-SARS-CoV2 antibody treatment has not been reported, and therefore the potential risk and promoting factors remain unknown. !!{{ Case presentation: }} A 75-year-old female was admitted to the emergency room with recurrent, unexplained bruises and leukocytopenia, anemia, and thrombocytopenia. Evaluation of a bone marrow biopsy established the diagnosis of an acute promyelocytic leukemia (APL). SARS-CoV-2 RT-PCR testing of nasal and throat swabs on admission was negative. During the routine SARS-CoV-2 testing of inpatients, our patient tested positive for SARS-CoV-2 on day 14 after admission without typical COVID-19 symptoms. Due to disease- and therapy-related immunosuppression and advanced age conferring a high risk of progressing to severe COVID-19, casirivimab and imdevimab were administered as a preemptive approach. The patient developed immune activation and cytokine release syndrome (CRS) occurring within four hours of preemptive anti-SARS-CoV2 antibody (casirivimab/imdevimab) infusion. Immune activation and CRS were evidenced by a rapid increase in serum cytokines (IL-6, TNFα, IL-8, IL-10), acute respiratory insufficiency, and progressive acute respiratory distress syndrome. !!{{ Discussion and conclusion: }} The temporal relationship between therapeutic antibody administration and the rapid laboratory, radiological, and clinical deterioration suggests that CRS was an antibody-related adverse event, potentially exacerbated by APL treatment-mediated differentiation of leukemic blasts and promyelocytes. This case highlights the need for careful assessment of life-threatening adverse events after passive SARS-CoV-2 immunization, especially in the clinical context of patients with complex immune and hematological landscapes. !!{{ Keywords: }} Acute promyelocytic leukemia; Antibody-dependent enhancement; Case report; Coronavirus disease 2019; Cytokine release syndrome; SARS-CoV2; Viral infection. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188919/ | 2 | 1471-2334 | BMC Infectious Diseases | London : BioMed Central | |
| 1116063 | 897 | 진단 | healthy control | Patient | healthy control | abstract | None | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1195454 | 897 | 진단 | consequence | Term | consequence | abstract | abnormality | 26243 | 10.1186/s12879-022-07599-6 | A fatal SARS-coronavirus-2 induced bone marrow aplasia complicated with invasive fungal infection and severe neutropenic enterocolitis | Ali Amanati@@@Seyyed Bozorgmehr Hedayati@@@Mazyar Ziyaeyan@@@Alireza Honar@@@Reyhaneh Dashtianeh@@@Negin Rabiei@@@Nasrin Saki@@@Leila Karami | 202208 | Case Reports | PMC | {{{ Abstract }}} !!{{ Background: }} Immunization against the coronavirus disease 2019 (COVID-19) began in January 2021 in Iran; nonetheless, due to a lack of vaccination among children under 12, this age group is still at risk of SARS-CoV-2 infection and its complications. !!{{ Case presentation: }} SARS-CoV-2 infection was diagnosed in a 6-year-old girl who had previously been healthy but had developed a fever and pancytopenia. The bone marrow aspiration/biopsy demonstrated just hypocellular marrow without signs of leukemia. She was worked up for primary and secondary causes of pancytopenia. Except for a repeated reactive HIV antibody/Ag P24 assay, all test results were inconclusive. After a thorough diagnostic investigation, the cross-reactivity of the HIV antibody/Ag P24 test with SARS-CoV-2 antibodies was confirmed. The patient did not develop any COVID-19-related signs and symptoms, but she did get a severe invasive fungal infection and neutropenic enterocolitis. She died as a result of disseminated intravascular coagulopathy. !!{{ Conclusion: }} It is critical to recognize children infected with SARS-CoV-2 who exhibit atypical clinical manifestations of COVID-19, such as persistent pancytopenia. SARS-CoV-2 infection can cause severe and deadly consequences in children; thus, pediatricians should be aware of COVID-19's unusual signs and symptoms mimicking other conditions such as aplastic anemia. !!{{ Keywords: }} Aplastic anemia; Bone marrow-induced aplasia; Pancytopenia; Prognosis; SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361242/ | 2 | 1471-2334 | BMC Infectious Diseases | London : BioMed Central | |
| 1116064 | 897 | 진단 | HLA-DR | Term | hla-dr | abstract | None | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1195469 | 897 | 진단 | Inconclusive | Term | inconclusive | abstract | abnormality | 26243 | 10.1186/s12879-022-07599-6 | A fatal SARS-coronavirus-2 induced bone marrow aplasia complicated with invasive fungal infection and severe neutropenic enterocolitis | Ali Amanati@@@Seyyed Bozorgmehr Hedayati@@@Mazyar Ziyaeyan@@@Alireza Honar@@@Reyhaneh Dashtianeh@@@Negin Rabiei@@@Nasrin Saki@@@Leila Karami | 202208 | Case Reports | PMC | {{{ Abstract }}} !!{{ Background: }} Immunization against the coronavirus disease 2019 (COVID-19) began in January 2021 in Iran; nonetheless, due to a lack of vaccination among children under 12, this age group is still at risk of SARS-CoV-2 infection and its complications. !!{{ Case presentation: }} SARS-CoV-2 infection was diagnosed in a 6-year-old girl who had previously been healthy but had developed a fever and pancytopenia. The bone marrow aspiration/biopsy demonstrated just hypocellular marrow without signs of leukemia. She was worked up for primary and secondary causes of pancytopenia. Except for a repeated reactive HIV antibody/Ag P24 assay, all test results were inconclusive. After a thorough diagnostic investigation, the cross-reactivity of the HIV antibody/Ag P24 test with SARS-CoV-2 antibodies was confirmed. The patient did not develop any COVID-19-related signs and symptoms, but she did get a severe invasive fungal infection and neutropenic enterocolitis. She died as a result of disseminated intravascular coagulopathy. !!{{ Conclusion: }} It is critical to recognize children infected with SARS-CoV-2 who exhibit atypical clinical manifestations of COVID-19, such as persistent pancytopenia. SARS-CoV-2 infection can cause severe and deadly consequences in children; thus, pediatricians should be aware of COVID-19's unusual signs and symptoms mimicking other conditions such as aplastic anemia. !!{{ Keywords: }} Aplastic anemia; Bone marrow-induced aplasia; Pancytopenia; Prognosis; SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361242/ | 2 | 1471-2334 | BMC Infectious Diseases | London : BioMed Central | |
| 1195447 | 897 | 진단 | Bone marrow | Organ | bone marrow | title,abstract | 골수 | 26243 | 10.1186/s12879-022-07599-6 | A fatal SARS-coronavirus-2 induced bone marrow aplasia complicated with invasive fungal infection and severe neutropenic enterocolitis | Ali Amanati@@@Seyyed Bozorgmehr Hedayati@@@Mazyar Ziyaeyan@@@Alireza Honar@@@Reyhaneh Dashtianeh@@@Negin Rabiei@@@Nasrin Saki@@@Leila Karami | 202208 | Case Reports | PMC | {{{ Abstract }}} !!{{ Background: }} Immunization against the coronavirus disease 2019 (COVID-19) began in January 2021 in Iran; nonetheless, due to a lack of vaccination among children under 12, this age group is still at risk of SARS-CoV-2 infection and its complications. !!{{ Case presentation: }} SARS-CoV-2 infection was diagnosed in a 6-year-old girl who had previously been healthy but had developed a fever and pancytopenia. The bone marrow aspiration/biopsy demonstrated just hypocellular marrow without signs of leukemia. She was worked up for primary and secondary causes of pancytopenia. Except for a repeated reactive HIV antibody/Ag P24 assay, all test results were inconclusive. After a thorough diagnostic investigation, the cross-reactivity of the HIV antibody/Ag P24 test with SARS-CoV-2 antibodies was confirmed. The patient did not develop any COVID-19-related signs and symptoms, but she did get a severe invasive fungal infection and neutropenic enterocolitis. She died as a result of disseminated intravascular coagulopathy. !!{{ Conclusion: }} It is critical to recognize children infected with SARS-CoV-2 who exhibit atypical clinical manifestations of COVID-19, such as persistent pancytopenia. SARS-CoV-2 infection can cause severe and deadly consequences in children; thus, pediatricians should be aware of COVID-19's unusual signs and symptoms mimicking other conditions such as aplastic anemia. !!{{ Keywords: }} Aplastic anemia; Bone marrow-induced aplasia; Pancytopenia; Prognosis; SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361242/ | 2 | 1471-2334 | BMC Infectious Diseases | London : BioMed Central | |
| 1212082 | 897 | 진단 | receptor | Term | receptor | abstract | 수용기 | 77309 | 10.3389/fimmu.2022.956369 | Serum peptidome profiles immune response of COVID-19 Vaccine administration | Wenjia Zhang@@@Dandan Li@@@Bin Xu@@@Lanlan Xu@@@Qian Lyu@@@Xiangyi Liu@@@Zhijie Li@@@Jian Zhang@@@Wei Sun@@@Qingwei Ma@@@Liang Qiao@@@Pu Liao | 202208 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused significant loss of life and property. In response to the serious pandemic, recently developed vaccines against SARS-CoV-2 have been administrated to the public. Nevertheless, the research on human immunization response against COVID-19 vaccines is insufficient. Although much information associated with vaccine efficacy, safety and immunogenicity has been reported by pharmaceutical companies based on laboratory studies and clinical trials, vaccine evaluation needs to be extended further to better understand the effect of COVID-19 vaccines on human beings. !!{{ Methods: }} We performed a comparative peptidome analysis on serum samples from 95 participants collected at four time points before and after receiving CoronaVac. The collected serum samples were analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to profile the serum peptides, and also subjected to humoral and cellular immune response analyses to obtain typical immunogenicity information. !!{{ Results: }} Significant difference in serum peptidome profiles by MALDI-TOF MS was observed after vaccination. By supervised statistical analysis, a total of 13 serum MALDI-TOF MS feature peaks were obtained on day 28 and day 42 of vaccination. The feature peaks were identified as component C1q receptor, CD59 glycoprotein, mannose-binding protein C, platelet basic protein, CD99 antigen, Leucine-rich alpha-2-glycoprotein, integral membrane protein 2B, platelet factor 4 and hemoglobin subunits. Combining with immunogenicity analysis, the study provided evidence for the humoral and cellular immune responses activated by CoronaVac. Furthermore, we found that it is possible to distinguish neutralizing antibody (NAbs)-positive from NAbs-negative individuals after complete vaccination using the serum peptidome profiles by MALDI-TOF MS together with machine learning methods, including random forest (RF), partial least squares-discriminant analysis (PLS-DA), linear support vector machine (SVM) and logistic regression (LR). !!{{ Conclusions: }} The study shows the promise of MALDI-TOF MS-based serum peptidome analysis for the assessment of immune responses activated by COVID-19 vaccination, and discovered a panel of serum peptides biomarkers for COVID-19 vaccination and for NAbs generation. The method developed in this study can help not only in the development of new vaccines, but also in the post-marketing evaluation of developed vaccines. !!{{ Keywords: }} COVID-19; MALDI-TOF; immune response; peptidome; serum; vaccine. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450691/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1116065 | 897 | 진단 | humoral | Term | humoral | abstract | None | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1116066 | 897 | 진단 | identify | Action | identify | abstract | None | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1212093 | 897 | 진단 | vaccination | Term | vaccination | abstract | 백신 접종 | 77309 | 10.3389/fimmu.2022.956369 | Serum peptidome profiles immune response of COVID-19 Vaccine administration | Wenjia Zhang@@@Dandan Li@@@Bin Xu@@@Lanlan Xu@@@Qian Lyu@@@Xiangyi Liu@@@Zhijie Li@@@Jian Zhang@@@Wei Sun@@@Qingwei Ma@@@Liang Qiao@@@Pu Liao | 202208 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused significant loss of life and property. In response to the serious pandemic, recently developed vaccines against SARS-CoV-2 have been administrated to the public. Nevertheless, the research on human immunization response against COVID-19 vaccines is insufficient. Although much information associated with vaccine efficacy, safety and immunogenicity has been reported by pharmaceutical companies based on laboratory studies and clinical trials, vaccine evaluation needs to be extended further to better understand the effect of COVID-19 vaccines on human beings. !!{{ Methods: }} We performed a comparative peptidome analysis on serum samples from 95 participants collected at four time points before and after receiving CoronaVac. The collected serum samples were analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to profile the serum peptides, and also subjected to humoral and cellular immune response analyses to obtain typical immunogenicity information. !!{{ Results: }} Significant difference in serum peptidome profiles by MALDI-TOF MS was observed after vaccination. By supervised statistical analysis, a total of 13 serum MALDI-TOF MS feature peaks were obtained on day 28 and day 42 of vaccination. The feature peaks were identified as component C1q receptor, CD59 glycoprotein, mannose-binding protein C, platelet basic protein, CD99 antigen, Leucine-rich alpha-2-glycoprotein, integral membrane protein 2B, platelet factor 4 and hemoglobin subunits. Combining with immunogenicity analysis, the study provided evidence for the humoral and cellular immune responses activated by CoronaVac. Furthermore, we found that it is possible to distinguish neutralizing antibody (NAbs)-positive from NAbs-negative individuals after complete vaccination using the serum peptidome profiles by MALDI-TOF MS together with machine learning methods, including random forest (RF), partial least squares-discriminant analysis (PLS-DA), linear support vector machine (SVM) and logistic regression (LR). !!{{ Conclusions: }} The study shows the promise of MALDI-TOF MS-based serum peptidome analysis for the assessment of immune responses activated by COVID-19 vaccination, and discovered a panel of serum peptides biomarkers for COVID-19 vaccination and for NAbs generation. The method developed in this study can help not only in the development of new vaccines, but also in the post-marketing evaluation of developed vaccines. !!{{ Keywords: }} COVID-19; MALDI-TOF; immune response; peptidome; serum; vaccine. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450691/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1212094 | 897 | 진단 | vaccine. | Term | vaccine | author | 백신 | 77309 | 10.3389/fimmu.2022.956369 | Serum peptidome profiles immune response of COVID-19 Vaccine administration | Wenjia Zhang@@@Dandan Li@@@Bin Xu@@@Lanlan Xu@@@Qian Lyu@@@Xiangyi Liu@@@Zhijie Li@@@Jian Zhang@@@Wei Sun@@@Qingwei Ma@@@Liang Qiao@@@Pu Liao | 202208 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused significant loss of life and property. In response to the serious pandemic, recently developed vaccines against SARS-CoV-2 have been administrated to the public. Nevertheless, the research on human immunization response against COVID-19 vaccines is insufficient. Although much information associated with vaccine efficacy, safety and immunogenicity has been reported by pharmaceutical companies based on laboratory studies and clinical trials, vaccine evaluation needs to be extended further to better understand the effect of COVID-19 vaccines on human beings. !!{{ Methods: }} We performed a comparative peptidome analysis on serum samples from 95 participants collected at four time points before and after receiving CoronaVac. The collected serum samples were analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to profile the serum peptides, and also subjected to humoral and cellular immune response analyses to obtain typical immunogenicity information. !!{{ Results: }} Significant difference in serum peptidome profiles by MALDI-TOF MS was observed after vaccination. By supervised statistical analysis, a total of 13 serum MALDI-TOF MS feature peaks were obtained on day 28 and day 42 of vaccination. The feature peaks were identified as component C1q receptor, CD59 glycoprotein, mannose-binding protein C, platelet basic protein, CD99 antigen, Leucine-rich alpha-2-glycoprotein, integral membrane protein 2B, platelet factor 4 and hemoglobin subunits. Combining with immunogenicity analysis, the study provided evidence for the humoral and cellular immune responses activated by CoronaVac. Furthermore, we found that it is possible to distinguish neutralizing antibody (NAbs)-positive from NAbs-negative individuals after complete vaccination using the serum peptidome profiles by MALDI-TOF MS together with machine learning methods, including random forest (RF), partial least squares-discriminant analysis (PLS-DA), linear support vector machine (SVM) and logistic regression (LR). !!{{ Conclusions: }} The study shows the promise of MALDI-TOF MS-based serum peptidome analysis for the assessment of immune responses activated by COVID-19 vaccination, and discovered a panel of serum peptides biomarkers for COVID-19 vaccination and for NAbs generation. The method developed in this study can help not only in the development of new vaccines, but also in the post-marketing evaluation of developed vaccines. !!{{ Keywords: }} COVID-19; MALDI-TOF; immune response; peptidome; serum; vaccine. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450691/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1116067 | 897 | 진단 | Immunosuppression | Treatment | immunosuppression | abstract | 면역억제 | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1111494 | 897 | 진단 | anti-SARS-CoV-2 | Term | anti-sars-cov-2 | abstract | 항 -SARS-COV-2 | 23484 | 10.1001/jamanetworkopen.2022.21616 | Long-term Immune Response to SARS-CoV-2 Infection Among Children and Adults After Mild Infection | Costanza Di Chiara@@@Anna Cantarutti@@@Paola Costenaro@@@Daniele Don?@@@Francesco Bonfante@@@Chiara Cosma@@@Martina Ferrarese@@@Sandra Cozzani@@@Maria Raffaella Petrara@@@Francesco Carmona@@@Cecilia Liberati@@@Paolo Palma@@@Giovanni Di Salvo@@@Anita De Rossi@@@Mario Plebani@@@Andrea Padoan@@@Carlo Giaquinto | 202207 | Article | PMC | {{{ Abstract }}} !!{{ Importance: }} Understanding the long-term immune response against SARS-CoV-2 infection in children is crucial to optimize vaccination strategies. Although it is known that SARS-CoV-2 antibodies may persist in adults 12 months after infection, data are limited in the pediatric population. !!{{ Objective: }} To examine long-term anti-SARS-CoV-2 spike receptor-binding domain (S-RBD) IgG kinetics in children after SARS-CoV-2 infection. !!{{ Design, setting, and participants: }} In this single-center, prospective cohort study, patients were enrolled consecutively from April 1, 2020, to August 31, 2021, at the COVID-19 Family Cluster Follow-up Clinic, Department of Women's and Children's Health, University Hospital of Padua. A cohort of 252 COVID-19 family clusters underwent serologic follow-up at 1 to 4, 5 to 10, and more than 10 months after infection with quantification of anti-S-RBD IgG by chemiluminescent immunoassay. !!{{ Exposures: }} SARS-CoV-2 infection. !!{{ Results: }} Among 902 study participants, 697 had confirmed SARS-CoV-2 infection, including 351 children or older siblings (mean [SD] age, 8.6 [5.1] years) and 346 parents (mean [SD] age, 42.5 [7.1] years). Among 697 cases, 674 (96.7%) were asymptomatic or mild. Children had significantly higher S-RBD IgG titers than older patients across all follow-up time points, with an overall median S-RBD IgG titer in patients younger than 3 years 5-fold higher than adults (304.8 [IQR, 139.0-516.6] kBAU/L vs 55.6 [24.2-136.0] kBAU/L, P < .001). Longitudinal analysis of 56 study participants sampled at least twice during follow-up demonstrated the persistence of antibodies up to 10 months from infection in all age classes, despite a progressive decline over time. !!{{ Conclusions and relevance: }} In this cohort study of Italian children and adults following SARS-CoV-2 infection different kinetics of SARS-CoV-2 antibodies were found across several age classes of individuals with asymptomatic or mild COVID-19, which could help in optimizing COVID-19 vaccination strategies and prevention policies. This work provides further evidence of sustained immune response in children up to 1 year after primary SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280400/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1212095 | 897 | 진단 | Vaccine | Drug | vaccine | abstract | 백신 | 77309 | 10.3389/fimmu.2022.956369 | Serum peptidome profiles immune response of COVID-19 Vaccine administration | Wenjia Zhang@@@Dandan Li@@@Bin Xu@@@Lanlan Xu@@@Qian Lyu@@@Xiangyi Liu@@@Zhijie Li@@@Jian Zhang@@@Wei Sun@@@Qingwei Ma@@@Liang Qiao@@@Pu Liao | 202208 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused significant loss of life and property. In response to the serious pandemic, recently developed vaccines against SARS-CoV-2 have been administrated to the public. Nevertheless, the research on human immunization response against COVID-19 vaccines is insufficient. Although much information associated with vaccine efficacy, safety and immunogenicity has been reported by pharmaceutical companies based on laboratory studies and clinical trials, vaccine evaluation needs to be extended further to better understand the effect of COVID-19 vaccines on human beings. !!{{ Methods: }} We performed a comparative peptidome analysis on serum samples from 95 participants collected at four time points before and after receiving CoronaVac. The collected serum samples were analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to profile the serum peptides, and also subjected to humoral and cellular immune response analyses to obtain typical immunogenicity information. !!{{ Results: }} Significant difference in serum peptidome profiles by MALDI-TOF MS was observed after vaccination. By supervised statistical analysis, a total of 13 serum MALDI-TOF MS feature peaks were obtained on day 28 and day 42 of vaccination. The feature peaks were identified as component C1q receptor, CD59 glycoprotein, mannose-binding protein C, platelet basic protein, CD99 antigen, Leucine-rich alpha-2-glycoprotein, integral membrane protein 2B, platelet factor 4 and hemoglobin subunits. Combining with immunogenicity analysis, the study provided evidence for the humoral and cellular immune responses activated by CoronaVac. Furthermore, we found that it is possible to distinguish neutralizing antibody (NAbs)-positive from NAbs-negative individuals after complete vaccination using the serum peptidome profiles by MALDI-TOF MS together with machine learning methods, including random forest (RF), partial least squares-discriminant analysis (PLS-DA), linear support vector machine (SVM) and logistic regression (LR). !!{{ Conclusions: }} The study shows the promise of MALDI-TOF MS-based serum peptidome analysis for the assessment of immune responses activated by COVID-19 vaccination, and discovered a panel of serum peptides biomarkers for COVID-19 vaccination and for NAbs generation. The method developed in this study can help not only in the development of new vaccines, but also in the post-marketing evaluation of developed vaccines. !!{{ Keywords: }} COVID-19; MALDI-TOF; immune response; peptidome; serum; vaccine. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450691/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1212096 | 897 | 진단 | Vaccines | Drug | vaccine | abstract | 백신 | 77309 | 10.3389/fimmu.2022.956369 | Serum peptidome profiles immune response of COVID-19 Vaccine administration | Wenjia Zhang@@@Dandan Li@@@Bin Xu@@@Lanlan Xu@@@Qian Lyu@@@Xiangyi Liu@@@Zhijie Li@@@Jian Zhang@@@Wei Sun@@@Qingwei Ma@@@Liang Qiao@@@Pu Liao | 202208 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused significant loss of life and property. In response to the serious pandemic, recently developed vaccines against SARS-CoV-2 have been administrated to the public. Nevertheless, the research on human immunization response against COVID-19 vaccines is insufficient. Although much information associated with vaccine efficacy, safety and immunogenicity has been reported by pharmaceutical companies based on laboratory studies and clinical trials, vaccine evaluation needs to be extended further to better understand the effect of COVID-19 vaccines on human beings. !!{{ Methods: }} We performed a comparative peptidome analysis on serum samples from 95 participants collected at four time points before and after receiving CoronaVac. The collected serum samples were analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to profile the serum peptides, and also subjected to humoral and cellular immune response analyses to obtain typical immunogenicity information. !!{{ Results: }} Significant difference in serum peptidome profiles by MALDI-TOF MS was observed after vaccination. By supervised statistical analysis, a total of 13 serum MALDI-TOF MS feature peaks were obtained on day 28 and day 42 of vaccination. The feature peaks were identified as component C1q receptor, CD59 glycoprotein, mannose-binding protein C, platelet basic protein, CD99 antigen, Leucine-rich alpha-2-glycoprotein, integral membrane protein 2B, platelet factor 4 and hemoglobin subunits. Combining with immunogenicity analysis, the study provided evidence for the humoral and cellular immune responses activated by CoronaVac. Furthermore, we found that it is possible to distinguish neutralizing antibody (NAbs)-positive from NAbs-negative individuals after complete vaccination using the serum peptidome profiles by MALDI-TOF MS together with machine learning methods, including random forest (RF), partial least squares-discriminant analysis (PLS-DA), linear support vector machine (SVM) and logistic regression (LR). !!{{ Conclusions: }} The study shows the promise of MALDI-TOF MS-based serum peptidome analysis for the assessment of immune responses activated by COVID-19 vaccination, and discovered a panel of serum peptides biomarkers for COVID-19 vaccination and for NAbs generation. The method developed in this study can help not only in the development of new vaccines, but also in the post-marketing evaluation of developed vaccines. !!{{ Keywords: }} COVID-19; MALDI-TOF; immune response; peptidome; serum; vaccine. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450691/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1229884 | 897 | 진단 | preeclampsia | Term | preeclampsia | abstract | 자간전증 | 22292 | 10.1001/jamanetworkopen.2020.29256 | Pregnancy Outcomes Among Women With and Without Severe Acute Respiratory Syndrome Coronavirus 2 Infection | Emily H. Adhikari@@@Wilmer Moreno@@@Amanda C. Zofkie@@@Lorre MacDonald@@@Donald D. McIntire@@@Rebecca R. J. Collins@@@Catherine Y. Spong | 202011 | Research | PMC | Key Points Question In a large county health care system with access to inpatient and outpatient testing, is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection associated with pregnancy outcomes, maternal illness severity, placental pathology, and neonatal infections? Findings In this cohort study of 252 SARS-CoV-2?positive and 3122 negative pregnant women tested in outpatient and inpatient settings at a large county medical center, adverse pregnancy outcomes were similar, and neonatal infection occurred in 3% of infants, predominantly among infants born to asymptomatic or mildly symptomatic women. Placental abnormalities were not associated with disease severity, and the rate of hospitalization was similar to rates among nonpregnant women. Meaning These findings suggest that SARS-CoV-2 infection in pregnancy is not associated with adverse pregnancy outcomes. This cohort study evaluates the adverse outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among pregnant women and describes clinical management, disease progression, hospital admission, placental abnormalities, and neonatal outcomes. Importance Published data suggest that there are increased hospitalizations, placental abnormalities, and rare neonatal transmission among pregnant women with coronavirus disease 2019 (COVID-19). Objectives To evaluate adverse outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pregnancy and to describe clinical management, disease progression, hospital admission, placental abnormalities, and neonatal outcomes. Design, Setting, and Participants This observational cohort study of maternal and neonatal outcomes among delivered women with and without SARS-CoV-2 during pregnancy was conducted from March 18 through August 22, 2020, at Parkland Health and Hospital System (Dallas, Texas), a high-volume prenatal clinic system and public maternity hospital with widespread access to SARS-CoV-2 testing in outpatient, emergency department, and inpatient settings. Women were included if they were tested for SARS-CoV-2 during pregnancy and delivered. For placental analysis, the pathologist was blinded to illness severity. Exposures SARS-CoV-2 infection during pregnancy. Main Outcomes and Measures The primary outcome was a composite of preterm birth, preeclampsia with severe features, or cesarean delivery for abnormal fetal heart rate among women delivered after 20 weeks of gestation. Maternal illness severity, neonatal infection, and placental abnormalities were described. Results From March 18 through August 22, 2020, 3374 pregnant women (mean [SD] age, 27.6?[6] years) tested for SARS-CoV-2 were delivered, including 252 who tested positive for SARS-CoV-2 and 3122 who tested negative. The cohort included 2520 Hispanic (75%), 619 Black (18%), and 125 White (4%) women. There were no differences in age, parity, body mass index, or diabetes among women with or without SARS-CoV-2. SARS-CoV-2 positivity was more common among Hispanic women (230 [91%] positive vs 2290 [73%] negative; difference, 17.9%; 95% CI, 12.3%-23.5%; P <?.001). There was no difference in the composite primary outcome (52 women [21%] vs 684 women [23%]; relative risk, 0.94; 95% CI, 0.73-1.21; P =?.64). Early neonatal SARS-CoV-2 infection occurred in 6 of 188 tested infants (3%), primarily born to asymptomatic or mildly symptomatic women. There were no placental pathologic differences by illness severity. Maternal illness at initial presentation was asymptomatic or mild in 239 women (95%), and 6 of those women (3%) developed severe or critical illness. Fourteen women (6%) were hospitalized for the indication of COVID-19. Conclusions and Relevance In a large, single-institution cohort study, SARS-CoV-2 infection during pregnancy was not associated with adverse pregnancy outcomes. Neonatal infection may be as high as 3% and may occur predominantly among asymptomatic or mildly symptomatic women. Placental abnormalities were not associated with disease severity, and hospitalization frequency was similar to rates among nonpregnant women. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677755/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1123371 | 897 | 진단 | Hematologic malignancy | Term | hematologic malignancy | abstract | 혈액암 | 23912 | 10.3389/fimmu.2022.919762 | Factors that predict severity of infection and seroconversion in immunocompromised children and adolescents with COVID-19 infection | Mayada Abu Shanap@@@Maher Sughayer@@@Osama Alsmadi@@@Ismail Elzayat@@@Abeer Al-Nuirat@@@Abdelghani Tbakhi@@@Iyad Sultan | 202208 | Observational Study | PMC | {{{ Abstract }}} !!{{ Objectives: }} We aimed to study the outcomes, severity, and seroconversion post SARS-CoV-2 infection in immunocompromised children and adolescents treated at our center. !!{{ Method: }} For this observational study, all pediatric patients who had COVID-19 infection from Sep-22-2020 to Nov-10-2021were identified by reviewing our laboratory records. Their charts were reviewed to determine clinical severity and outcome. Blood samples were drawn for anti-SARS-CoV-2 antibody assay. Serious COVID-19 infection (SVI) was defined if the patient had moderate, severe, or critical illness. A cutoff of 100 U/mL anti-SARS-CoV-2 antibodies was used to categorize low and high titer seroconversion. !!{{ Results: }} We identified 263 pediatric patients with COVID-19; most (68%) were symptomatic: 5% had severe or critical infection, 25% were hospitalized, 12 required respiratory support, 12 were admitted to the ICU, and five patients (2%) died. Multivariable analysis revealed several factors that predict SVI: Age above 12 years (p=0.035), body mass index above 95 th percentile (p=0.034), comorbid conditions (p=0.025), absolute neutrophil count ≤500(p=0.014) and absolute lymphocyte count ≤300 (p=0.022). Levels of anti-SARS-CoV-2 spike antibodies were obtained for 173 patients at a median of 94 days (range, 14-300) after PCR diagnosis; of them 142 (82%) patients seroconverted; the lowest seroconversion rate was observed in patients with hematological malignancies (79%). Our univariable model showed that the following factors were predictive of low titer: lower ANC, p=0.01; hematologic malignancy, p=0.023; receiving steroids in the last 14 days, p=0.032; time since last chemotherapy or immunosuppressive therapy less than 30 days, p=0.002; and being on active chemotherapy in the last 3 months prior to infection, p<0.001. !!{{ Conclusions: }} SARS-CoV-2 antibodies developed in most immunocompromised patients with COVID-19 infection in our study. Mortality was relatively low in our patients. Our univariable and multivariable models showed multiple variables that predict severity of infections and antibody response post COVID-19 infection. These observations may guide choice of active therapy during infection and the best timing of vaccination in this high-risk population. !!{{ Keywords: }} COVID 19; SARS-CoV-2; cancer; chemotherapy; children; immunocompromised; seroconversion; stem cell transplant. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381983/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1212041 | 897 | 진단 | Cellular immune response | Term | cellular immune response | abstract | 세포 면역 반응 | 77309 | 10.3389/fimmu.2022.956369 | Serum peptidome profiles immune response of COVID-19 Vaccine administration | Wenjia Zhang@@@Dandan Li@@@Bin Xu@@@Lanlan Xu@@@Qian Lyu@@@Xiangyi Liu@@@Zhijie Li@@@Jian Zhang@@@Wei Sun@@@Qingwei Ma@@@Liang Qiao@@@Pu Liao | 202208 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused significant loss of life and property. In response to the serious pandemic, recently developed vaccines against SARS-CoV-2 have been administrated to the public. Nevertheless, the research on human immunization response against COVID-19 vaccines is insufficient. Although much information associated with vaccine efficacy, safety and immunogenicity has been reported by pharmaceutical companies based on laboratory studies and clinical trials, vaccine evaluation needs to be extended further to better understand the effect of COVID-19 vaccines on human beings. !!{{ Methods: }} We performed a comparative peptidome analysis on serum samples from 95 participants collected at four time points before and after receiving CoronaVac. The collected serum samples were analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to profile the serum peptides, and also subjected to humoral and cellular immune response analyses to obtain typical immunogenicity information. !!{{ Results: }} Significant difference in serum peptidome profiles by MALDI-TOF MS was observed after vaccination. By supervised statistical analysis, a total of 13 serum MALDI-TOF MS feature peaks were obtained on day 28 and day 42 of vaccination. The feature peaks were identified as component C1q receptor, CD59 glycoprotein, mannose-binding protein C, platelet basic protein, CD99 antigen, Leucine-rich alpha-2-glycoprotein, integral membrane protein 2B, platelet factor 4 and hemoglobin subunits. Combining with immunogenicity analysis, the study provided evidence for the humoral and cellular immune responses activated by CoronaVac. Furthermore, we found that it is possible to distinguish neutralizing antibody (NAbs)-positive from NAbs-negative individuals after complete vaccination using the serum peptidome profiles by MALDI-TOF MS together with machine learning methods, including random forest (RF), partial least squares-discriminant analysis (PLS-DA), linear support vector machine (SVM) and logistic regression (LR). !!{{ Conclusions: }} The study shows the promise of MALDI-TOF MS-based serum peptidome analysis for the assessment of immune responses activated by COVID-19 vaccination, and discovered a panel of serum peptides biomarkers for COVID-19 vaccination and for NAbs generation. The method developed in this study can help not only in the development of new vaccines, but also in the post-marketing evaluation of developed vaccines. !!{{ Keywords: }} COVID-19; MALDI-TOF; immune response; peptidome; serum; vaccine. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450691/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1212042 | 897 | 진단 | clinical trials | Term | clinical trial | abstract | 임상시험 | 77309 | 10.3389/fimmu.2022.956369 | Serum peptidome profiles immune response of COVID-19 Vaccine administration | Wenjia Zhang@@@Dandan Li@@@Bin Xu@@@Lanlan Xu@@@Qian Lyu@@@Xiangyi Liu@@@Zhijie Li@@@Jian Zhang@@@Wei Sun@@@Qingwei Ma@@@Liang Qiao@@@Pu Liao | 202208 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused significant loss of life and property. In response to the serious pandemic, recently developed vaccines against SARS-CoV-2 have been administrated to the public. Nevertheless, the research on human immunization response against COVID-19 vaccines is insufficient. Although much information associated with vaccine efficacy, safety and immunogenicity has been reported by pharmaceutical companies based on laboratory studies and clinical trials, vaccine evaluation needs to be extended further to better understand the effect of COVID-19 vaccines on human beings. !!{{ Methods: }} We performed a comparative peptidome analysis on serum samples from 95 participants collected at four time points before and after receiving CoronaVac. The collected serum samples were analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to profile the serum peptides, and also subjected to humoral and cellular immune response analyses to obtain typical immunogenicity information. !!{{ Results: }} Significant difference in serum peptidome profiles by MALDI-TOF MS was observed after vaccination. By supervised statistical analysis, a total of 13 serum MALDI-TOF MS feature peaks were obtained on day 28 and day 42 of vaccination. The feature peaks were identified as component C1q receptor, CD59 glycoprotein, mannose-binding protein C, platelet basic protein, CD99 antigen, Leucine-rich alpha-2-glycoprotein, integral membrane protein 2B, platelet factor 4 and hemoglobin subunits. Combining with immunogenicity analysis, the study provided evidence for the humoral and cellular immune responses activated by CoronaVac. Furthermore, we found that it is possible to distinguish neutralizing antibody (NAbs)-positive from NAbs-negative individuals after complete vaccination using the serum peptidome profiles by MALDI-TOF MS together with machine learning methods, including random forest (RF), partial least squares-discriminant analysis (PLS-DA), linear support vector machine (SVM) and logistic regression (LR). !!{{ Conclusions: }} The study shows the promise of MALDI-TOF MS-based serum peptidome analysis for the assessment of immune responses activated by COVID-19 vaccination, and discovered a panel of serum peptides biomarkers for COVID-19 vaccination and for NAbs generation. The method developed in this study can help not only in the development of new vaccines, but also in the post-marketing evaluation of developed vaccines. !!{{ Keywords: }} COVID-19; MALDI-TOF; immune response; peptidome; serum; vaccine. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450691/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1212043 | 897 | 진단 | collected | Action | collected | abstract | None | 77309 | 10.3389/fimmu.2022.956369 | Serum peptidome profiles immune response of COVID-19 Vaccine administration | Wenjia Zhang@@@Dandan Li@@@Bin Xu@@@Lanlan Xu@@@Qian Lyu@@@Xiangyi Liu@@@Zhijie Li@@@Jian Zhang@@@Wei Sun@@@Qingwei Ma@@@Liang Qiao@@@Pu Liao | 202208 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused significant loss of life and property. In response to the serious pandemic, recently developed vaccines against SARS-CoV-2 have been administrated to the public. Nevertheless, the research on human immunization response against COVID-19 vaccines is insufficient. Although much information associated with vaccine efficacy, safety and immunogenicity has been reported by pharmaceutical companies based on laboratory studies and clinical trials, vaccine evaluation needs to be extended further to better understand the effect of COVID-19 vaccines on human beings. !!{{ Methods: }} We performed a comparative peptidome analysis on serum samples from 95 participants collected at four time points before and after receiving CoronaVac. The collected serum samples were analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to profile the serum peptides, and also subjected to humoral and cellular immune response analyses to obtain typical immunogenicity information. !!{{ Results: }} Significant difference in serum peptidome profiles by MALDI-TOF MS was observed after vaccination. By supervised statistical analysis, a total of 13 serum MALDI-TOF MS feature peaks were obtained on day 28 and day 42 of vaccination. The feature peaks were identified as component C1q receptor, CD59 glycoprotein, mannose-binding protein C, platelet basic protein, CD99 antigen, Leucine-rich alpha-2-glycoprotein, integral membrane protein 2B, platelet factor 4 and hemoglobin subunits. Combining with immunogenicity analysis, the study provided evidence for the humoral and cellular immune responses activated by CoronaVac. Furthermore, we found that it is possible to distinguish neutralizing antibody (NAbs)-positive from NAbs-negative individuals after complete vaccination using the serum peptidome profiles by MALDI-TOF MS together with machine learning methods, including random forest (RF), partial least squares-discriminant analysis (PLS-DA), linear support vector machine (SVM) and logistic regression (LR). !!{{ Conclusions: }} The study shows the promise of MALDI-TOF MS-based serum peptidome analysis for the assessment of immune responses activated by COVID-19 vaccination, and discovered a panel of serum peptides biomarkers for COVID-19 vaccination and for NAbs generation. The method developed in this study can help not only in the development of new vaccines, but also in the post-marketing evaluation of developed vaccines. !!{{ Keywords: }} COVID-19; MALDI-TOF; immune response; peptidome; serum; vaccine. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450691/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1212044 | 897 | 진단 | Complete | Term | complete | abstract | abnormality | 77309 | 10.3389/fimmu.2022.956369 | Serum peptidome profiles immune response of COVID-19 Vaccine administration | Wenjia Zhang@@@Dandan Li@@@Bin Xu@@@Lanlan Xu@@@Qian Lyu@@@Xiangyi Liu@@@Zhijie Li@@@Jian Zhang@@@Wei Sun@@@Qingwei Ma@@@Liang Qiao@@@Pu Liao | 202208 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused significant loss of life and property. In response to the serious pandemic, recently developed vaccines against SARS-CoV-2 have been administrated to the public. Nevertheless, the research on human immunization response against COVID-19 vaccines is insufficient. Although much information associated with vaccine efficacy, safety and immunogenicity has been reported by pharmaceutical companies based on laboratory studies and clinical trials, vaccine evaluation needs to be extended further to better understand the effect of COVID-19 vaccines on human beings. !!{{ Methods: }} We performed a comparative peptidome analysis on serum samples from 95 participants collected at four time points before and after receiving CoronaVac. The collected serum samples were analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to profile the serum peptides, and also subjected to humoral and cellular immune response analyses to obtain typical immunogenicity information. !!{{ Results: }} Significant difference in serum peptidome profiles by MALDI-TOF MS was observed after vaccination. By supervised statistical analysis, a total of 13 serum MALDI-TOF MS feature peaks were obtained on day 28 and day 42 of vaccination. The feature peaks were identified as component C1q receptor, CD59 glycoprotein, mannose-binding protein C, platelet basic protein, CD99 antigen, Leucine-rich alpha-2-glycoprotein, integral membrane protein 2B, platelet factor 4 and hemoglobin subunits. Combining with immunogenicity analysis, the study provided evidence for the humoral and cellular immune responses activated by CoronaVac. Furthermore, we found that it is possible to distinguish neutralizing antibody (NAbs)-positive from NAbs-negative individuals after complete vaccination using the serum peptidome profiles by MALDI-TOF MS together with machine learning methods, including random forest (RF), partial least squares-discriminant analysis (PLS-DA), linear support vector machine (SVM) and logistic regression (LR). !!{{ Conclusions: }} The study shows the promise of MALDI-TOF MS-based serum peptidome analysis for the assessment of immune responses activated by COVID-19 vaccination, and discovered a panel of serum peptides biomarkers for COVID-19 vaccination and for NAbs generation. The method developed in this study can help not only in the development of new vaccines, but also in the post-marketing evaluation of developed vaccines. !!{{ Keywords: }} COVID-19; MALDI-TOF; immune response; peptidome; serum; vaccine. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450691/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1212045 | 897 | 진단 | CoronaVac | Drug | coronavac | abstract | 코로나 박 | 77309 | 10.3389/fimmu.2022.956369 | Serum peptidome profiles immune response of COVID-19 Vaccine administration | Wenjia Zhang@@@Dandan Li@@@Bin Xu@@@Lanlan Xu@@@Qian Lyu@@@Xiangyi Liu@@@Zhijie Li@@@Jian Zhang@@@Wei Sun@@@Qingwei Ma@@@Liang Qiao@@@Pu Liao | 202208 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused significant loss of life and property. In response to the serious pandemic, recently developed vaccines against SARS-CoV-2 have been administrated to the public. Nevertheless, the research on human immunization response against COVID-19 vaccines is insufficient. Although much information associated with vaccine efficacy, safety and immunogenicity has been reported by pharmaceutical companies based on laboratory studies and clinical trials, vaccine evaluation needs to be extended further to better understand the effect of COVID-19 vaccines on human beings. !!{{ Methods: }} We performed a comparative peptidome analysis on serum samples from 95 participants collected at four time points before and after receiving CoronaVac. The collected serum samples were analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to profile the serum peptides, and also subjected to humoral and cellular immune response analyses to obtain typical immunogenicity information. !!{{ Results: }} Significant difference in serum peptidome profiles by MALDI-TOF MS was observed after vaccination. By supervised statistical analysis, a total of 13 serum MALDI-TOF MS feature peaks were obtained on day 28 and day 42 of vaccination. The feature peaks were identified as component C1q receptor, CD59 glycoprotein, mannose-binding protein C, platelet basic protein, CD99 antigen, Leucine-rich alpha-2-glycoprotein, integral membrane protein 2B, platelet factor 4 and hemoglobin subunits. Combining with immunogenicity analysis, the study provided evidence for the humoral and cellular immune responses activated by CoronaVac. Furthermore, we found that it is possible to distinguish neutralizing antibody (NAbs)-positive from NAbs-negative individuals after complete vaccination using the serum peptidome profiles by MALDI-TOF MS together with machine learning methods, including random forest (RF), partial least squares-discriminant analysis (PLS-DA), linear support vector machine (SVM) and logistic regression (LR). !!{{ Conclusions: }} The study shows the promise of MALDI-TOF MS-based serum peptidome analysis for the assessment of immune responses activated by COVID-19 vaccination, and discovered a panel of serum peptides biomarkers for COVID-19 vaccination and for NAbs generation. The method developed in this study can help not only in the development of new vaccines, but also in the post-marketing evaluation of developed vaccines. !!{{ Keywords: }} COVID-19; MALDI-TOF; immune response; peptidome; serum; vaccine. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450691/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1212046 | 897 | 진단 | coronavirus | Virus | coronavirus | abstract | 코로나바이러스 | 77309 | 10.3389/fimmu.2022.956369 | Serum peptidome profiles immune response of COVID-19 Vaccine administration | Wenjia Zhang@@@Dandan Li@@@Bin Xu@@@Lanlan Xu@@@Qian Lyu@@@Xiangyi Liu@@@Zhijie Li@@@Jian Zhang@@@Wei Sun@@@Qingwei Ma@@@Liang Qiao@@@Pu Liao | 202208 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused significant loss of life and property. In response to the serious pandemic, recently developed vaccines against SARS-CoV-2 have been administrated to the public. Nevertheless, the research on human immunization response against COVID-19 vaccines is insufficient. Although much information associated with vaccine efficacy, safety and immunogenicity has been reported by pharmaceutical companies based on laboratory studies and clinical trials, vaccine evaluation needs to be extended further to better understand the effect of COVID-19 vaccines on human beings. !!{{ Methods: }} We performed a comparative peptidome analysis on serum samples from 95 participants collected at four time points before and after receiving CoronaVac. The collected serum samples were analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to profile the serum peptides, and also subjected to humoral and cellular immune response analyses to obtain typical immunogenicity information. !!{{ Results: }} Significant difference in serum peptidome profiles by MALDI-TOF MS was observed after vaccination. By supervised statistical analysis, a total of 13 serum MALDI-TOF MS feature peaks were obtained on day 28 and day 42 of vaccination. The feature peaks were identified as component C1q receptor, CD59 glycoprotein, mannose-binding protein C, platelet basic protein, CD99 antigen, Leucine-rich alpha-2-glycoprotein, integral membrane protein 2B, platelet factor 4 and hemoglobin subunits. Combining with immunogenicity analysis, the study provided evidence for the humoral and cellular immune responses activated by CoronaVac. Furthermore, we found that it is possible to distinguish neutralizing antibody (NAbs)-positive from NAbs-negative individuals after complete vaccination using the serum peptidome profiles by MALDI-TOF MS together with machine learning methods, including random forest (RF), partial least squares-discriminant analysis (PLS-DA), linear support vector machine (SVM) and logistic regression (LR). !!{{ Conclusions: }} The study shows the promise of MALDI-TOF MS-based serum peptidome analysis for the assessment of immune responses activated by COVID-19 vaccination, and discovered a panel of serum peptides biomarkers for COVID-19 vaccination and for NAbs generation. The method developed in this study can help not only in the development of new vaccines, but also in the post-marketing evaluation of developed vaccines. !!{{ Keywords: }} COVID-19; MALDI-TOF; immune response; peptidome; serum; vaccine. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450691/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1116068 | 897 | 진단 | increased risk | Action | increased risk | abstract | None | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1116069 | 897 | 진단 | Inflammatory | Term | inflammatory | abstract | None | 23617 | 10.3389/fimmu.2022.822885 | B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients | Ana-Luisa Stefanski@@@Hector Rincon-Arevalo@@@Eva Schrezenmeier@@@Kirsten Karberg@@@Franziska Szelinski@@@Jacob Ritter@@@Yidan Chen@@@Bernd Jahrsd?rfer@@@Carolin Ludwig@@@Hubert Schrezenmeier@@@Andreia C Lino@@@Thomas D?rner | 202204 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. !!{{ Methods: }} B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. !!{{ Results: }} Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were na?ve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. !!{{ Summary: }} Substantial repopulation of the na?ve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses. !!{{ Keywords: }} B-cells; RTX (rituximab); SARS ? CoV ? 2; prediction; vaccination. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063458/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1123345 | 897 | 진단 | absolute neutrophil count | Term | absolute neutrophil count | abstract | None | 23912 | 10.3389/fimmu.2022.919762 | Factors that predict severity of infection and seroconversion in immunocompromised children and adolescents with COVID-19 infection | Mayada Abu Shanap@@@Maher Sughayer@@@Osama Alsmadi@@@Ismail Elzayat@@@Abeer Al-Nuirat@@@Abdelghani Tbakhi@@@Iyad Sultan | 202208 | Observational Study | PMC | {{{ Abstract }}} !!{{ Objectives: }} We aimed to study the outcomes, severity, and seroconversion post SARS-CoV-2 infection in immunocompromised children and adolescents treated at our center. !!{{ Method: }} For this observational study, all pediatric patients who had COVID-19 infection from Sep-22-2020 to Nov-10-2021were identified by reviewing our laboratory records. Their charts were reviewed to determine clinical severity and outcome. Blood samples were drawn for anti-SARS-CoV-2 antibody assay. Serious COVID-19 infection (SVI) was defined if the patient had moderate, severe, or critical illness. A cutoff of 100 U/mL anti-SARS-CoV-2 antibodies was used to categorize low and high titer seroconversion. !!{{ Results: }} We identified 263 pediatric patients with COVID-19; most (68%) were symptomatic: 5% had severe or critical infection, 25% were hospitalized, 12 required respiratory support, 12 were admitted to the ICU, and five patients (2%) died. Multivariable analysis revealed several factors that predict SVI: Age above 12 years (p=0.035), body mass index above 95 th percentile (p=0.034), comorbid conditions (p=0.025), absolute neutrophil count ≤500(p=0.014) and absolute lymphocyte count ≤300 (p=0.022). Levels of anti-SARS-CoV-2 spike antibodies were obtained for 173 patients at a median of 94 days (range, 14-300) after PCR diagnosis; of them 142 (82%) patients seroconverted; the lowest seroconversion rate was observed in patients with hematological malignancies (79%). Our univariable model showed that the following factors were predictive of low titer: lower ANC, p=0.01; hematologic malignancy, p=0.023; receiving steroids in the last 14 days, p=0.032; time since last chemotherapy or immunosuppressive therapy less than 30 days, p=0.002; and being on active chemotherapy in the last 3 months prior to infection, p<0.001. !!{{ Conclusions: }} SARS-CoV-2 antibodies developed in most immunocompromised patients with COVID-19 infection in our study. Mortality was relatively low in our patients. Our univariable and multivariable models showed multiple variables that predict severity of infections and antibody response post COVID-19 infection. These observations may guide choice of active therapy during infection and the best timing of vaccination in this high-risk population. !!{{ Keywords: }} COVID 19; SARS-CoV-2; cancer; chemotherapy; children; immunocompromised; seroconversion; stem cell transplant. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381983/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1123346 | 897 | 진단 | Analysis | Term | analysis | abstract | 분석 | 23912 | 10.3389/fimmu.2022.919762 | Factors that predict severity of infection and seroconversion in immunocompromised children and adolescents with COVID-19 infection | Mayada Abu Shanap@@@Maher Sughayer@@@Osama Alsmadi@@@Ismail Elzayat@@@Abeer Al-Nuirat@@@Abdelghani Tbakhi@@@Iyad Sultan | 202208 | Observational Study | PMC | {{{ Abstract }}} !!{{ Objectives: }} We aimed to study the outcomes, severity, and seroconversion post SARS-CoV-2 infection in immunocompromised children and adolescents treated at our center. !!{{ Method: }} For this observational study, all pediatric patients who had COVID-19 infection from Sep-22-2020 to Nov-10-2021were identified by reviewing our laboratory records. Their charts were reviewed to determine clinical severity and outcome. Blood samples were drawn for anti-SARS-CoV-2 antibody assay. Serious COVID-19 infection (SVI) was defined if the patient had moderate, severe, or critical illness. A cutoff of 100 U/mL anti-SARS-CoV-2 antibodies was used to categorize low and high titer seroconversion. !!{{ Results: }} We identified 263 pediatric patients with COVID-19; most (68%) were symptomatic: 5% had severe or critical infection, 25% were hospitalized, 12 required respiratory support, 12 were admitted to the ICU, and five patients (2%) died. Multivariable analysis revealed several factors that predict SVI: Age above 12 years (p=0.035), body mass index above 95 th percentile (p=0.034), comorbid conditions (p=0.025), absolute neutrophil count ≤500(p=0.014) and absolute lymphocyte count ≤300 (p=0.022). Levels of anti-SARS-CoV-2 spike antibodies were obtained for 173 patients at a median of 94 days (range, 14-300) after PCR diagnosis; of them 142 (82%) patients seroconverted; the lowest seroconversion rate was observed in patients with hematological malignancies (79%). Our univariable model showed that the following factors were predictive of low titer: lower ANC, p=0.01; hematologic malignancy, p=0.023; receiving steroids in the last 14 days, p=0.032; time since last chemotherapy or immunosuppressive therapy less than 30 days, p=0.002; and being on active chemotherapy in the last 3 months prior to infection, p<0.001. !!{{ Conclusions: }} SARS-CoV-2 antibodies developed in most immunocompromised patients with COVID-19 infection in our study. Mortality was relatively low in our patients. Our univariable and multivariable models showed multiple variables that predict severity of infections and antibody response post COVID-19 infection. These observations may guide choice of active therapy during infection and the best timing of vaccination in this high-risk population. !!{{ Keywords: }} COVID 19; SARS-CoV-2; cancer; chemotherapy; children; immunocompromised; seroconversion; stem cell transplant. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381983/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1123347 | 897 | 진단 | ANC | Gene | ANC | abstract | None | 23912 | 10.3389/fimmu.2022.919762 | Factors that predict severity of infection and seroconversion in immunocompromised children and adolescents with COVID-19 infection | Mayada Abu Shanap@@@Maher Sughayer@@@Osama Alsmadi@@@Ismail Elzayat@@@Abeer Al-Nuirat@@@Abdelghani Tbakhi@@@Iyad Sultan | 202208 | Observational Study | PMC | {{{ Abstract }}} !!{{ Objectives: }} We aimed to study the outcomes, severity, and seroconversion post SARS-CoV-2 infection in immunocompromised children and adolescents treated at our center. !!{{ Method: }} For this observational study, all pediatric patients who had COVID-19 infection from Sep-22-2020 to Nov-10-2021were identified by reviewing our laboratory records. Their charts were reviewed to determine clinical severity and outcome. Blood samples were drawn for anti-SARS-CoV-2 antibody assay. Serious COVID-19 infection (SVI) was defined if the patient had moderate, severe, or critical illness. A cutoff of 100 U/mL anti-SARS-CoV-2 antibodies was used to categorize low and high titer seroconversion. !!{{ Results: }} We identified 263 pediatric patients with COVID-19; most (68%) were symptomatic: 5% had severe or critical infection, 25% were hospitalized, 12 required respiratory support, 12 were admitted to the ICU, and five patients (2%) died. Multivariable analysis revealed several factors that predict SVI: Age above 12 years (p=0.035), body mass index above 95 th percentile (p=0.034), comorbid conditions (p=0.025), absolute neutrophil count ≤500(p=0.014) and absolute lymphocyte count ≤300 (p=0.022). Levels of anti-SARS-CoV-2 spike antibodies were obtained for 173 patients at a median of 94 days (range, 14-300) after PCR diagnosis; of them 142 (82%) patients seroconverted; the lowest seroconversion rate was observed in patients with hematological malignancies (79%). Our univariable model showed that the following factors were predictive of low titer: lower ANC, p=0.01; hematologic malignancy, p=0.023; receiving steroids in the last 14 days, p=0.032; time since last chemotherapy or immunosuppressive therapy less than 30 days, p=0.002; and being on active chemotherapy in the last 3 months prior to infection, p<0.001. !!{{ Conclusions: }} SARS-CoV-2 antibodies developed in most immunocompromised patients with COVID-19 infection in our study. Mortality was relatively low in our patients. Our univariable and multivariable models showed multiple variables that predict severity of infections and antibody response post COVID-19 infection. These observations may guide choice of active therapy during infection and the best timing of vaccination in this high-risk population. !!{{ Keywords: }} COVID 19; SARS-CoV-2; cancer; chemotherapy; children; immunocompromised; seroconversion; stem cell transplant. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381983/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1229885 | 897 | 진단 | Pregnancy | Term | pregnancy | abstract | 임신 | 22292 | 10.1001/jamanetworkopen.2020.29256 | Pregnancy Outcomes Among Women With and Without Severe Acute Respiratory Syndrome Coronavirus 2 Infection | Emily H. Adhikari@@@Wilmer Moreno@@@Amanda C. Zofkie@@@Lorre MacDonald@@@Donald D. McIntire@@@Rebecca R. J. Collins@@@Catherine Y. Spong | 202011 | Research | PMC | Key Points Question In a large county health care system with access to inpatient and outpatient testing, is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection associated with pregnancy outcomes, maternal illness severity, placental pathology, and neonatal infections? Findings In this cohort study of 252 SARS-CoV-2?positive and 3122 negative pregnant women tested in outpatient and inpatient settings at a large county medical center, adverse pregnancy outcomes were similar, and neonatal infection occurred in 3% of infants, predominantly among infants born to asymptomatic or mildly symptomatic women. Placental abnormalities were not associated with disease severity, and the rate of hospitalization was similar to rates among nonpregnant women. Meaning These findings suggest that SARS-CoV-2 infection in pregnancy is not associated with adverse pregnancy outcomes. This cohort study evaluates the adverse outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among pregnant women and describes clinical management, disease progression, hospital admission, placental abnormalities, and neonatal outcomes. Importance Published data suggest that there are increased hospitalizations, placental abnormalities, and rare neonatal transmission among pregnant women with coronavirus disease 2019 (COVID-19). Objectives To evaluate adverse outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pregnancy and to describe clinical management, disease progression, hospital admission, placental abnormalities, and neonatal outcomes. Design, Setting, and Participants This observational cohort study of maternal and neonatal outcomes among delivered women with and without SARS-CoV-2 during pregnancy was conducted from March 18 through August 22, 2020, at Parkland Health and Hospital System (Dallas, Texas), a high-volume prenatal clinic system and public maternity hospital with widespread access to SARS-CoV-2 testing in outpatient, emergency department, and inpatient settings. Women were included if they were tested for SARS-CoV-2 during pregnancy and delivered. For placental analysis, the pathologist was blinded to illness severity. Exposures SARS-CoV-2 infection during pregnancy. Main Outcomes and Measures The primary outcome was a composite of preterm birth, preeclampsia with severe features, or cesarean delivery for abnormal fetal heart rate among women delivered after 20 weeks of gestation. Maternal illness severity, neonatal infection, and placental abnormalities were described. Results From March 18 through August 22, 2020, 3374 pregnant women (mean [SD] age, 27.6?[6] years) tested for SARS-CoV-2 were delivered, including 252 who tested positive for SARS-CoV-2 and 3122 who tested negative. The cohort included 2520 Hispanic (75%), 619 Black (18%), and 125 White (4%) women. There were no differences in age, parity, body mass index, or diabetes among women with or without SARS-CoV-2. SARS-CoV-2 positivity was more common among Hispanic women (230 [91%] positive vs 2290 [73%] negative; difference, 17.9%; 95% CI, 12.3%-23.5%; P <?.001). There was no difference in the composite primary outcome (52 women [21%] vs 684 women [23%]; relative risk, 0.94; 95% CI, 0.73-1.21; P =?.64). Early neonatal SARS-CoV-2 infection occurred in 6 of 188 tested infants (3%), primarily born to asymptomatic or mildly symptomatic women. There were no placental pathologic differences by illness severity. Maternal illness at initial presentation was asymptomatic or mild in 239 women (95%), and 6 of those women (3%) developed severe or critical illness. Fourteen women (6%) were hospitalized for the indication of COVID-19. Conclusions and Relevance In a large, single-institution cohort study, SARS-CoV-2 infection during pregnancy was not associated with adverse pregnancy outcomes. Neonatal infection may be as high as 3% and may occur predominantly among asymptomatic or mildly symptomatic women. Placental abnormalities were not associated with disease severity, and hospitalization frequency was similar to rates among nonpregnant women. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677755/ | 71 | 2574-3805 | JAMA Network Open | Chicago, IL : American Medical Association | |
| 1123348 | 897 | 진단 | antibody | Protein | antibody | abstract | 항체 | 23912 | 10.3389/fimmu.2022.919762 | Factors that predict severity of infection and seroconversion in immunocompromised children and adolescents with COVID-19 infection | Mayada Abu Shanap@@@Maher Sughayer@@@Osama Alsmadi@@@Ismail Elzayat@@@Abeer Al-Nuirat@@@Abdelghani Tbakhi@@@Iyad Sultan | 202208 | Observational Study | PMC | {{{ Abstract }}} !!{{ Objectives: }} We aimed to study the outcomes, severity, and seroconversion post SARS-CoV-2 infection in immunocompromised children and adolescents treated at our center. !!{{ Method: }} For this observational study, all pediatric patients who had COVID-19 infection from Sep-22-2020 to Nov-10-2021were identified by reviewing our laboratory records. Their charts were reviewed to determine clinical severity and outcome. Blood samples were drawn for anti-SARS-CoV-2 antibody assay. Serious COVID-19 infection (SVI) was defined if the patient had moderate, severe, or critical illness. A cutoff of 100 U/mL anti-SARS-CoV-2 antibodies was used to categorize low and high titer seroconversion. !!{{ Results: }} We identified 263 pediatric patients with COVID-19; most (68%) were symptomatic: 5% had severe or critical infection, 25% were hospitalized, 12 required respiratory support, 12 were admitted to the ICU, and five patients (2%) died. Multivariable analysis revealed several factors that predict SVI: Age above 12 years (p=0.035), body mass index above 95 th percentile (p=0.034), comorbid conditions (p=0.025), absolute neutrophil count ≤500(p=0.014) and absolute lymphocyte count ≤300 (p=0.022). Levels of anti-SARS-CoV-2 spike antibodies were obtained for 173 patients at a median of 94 days (range, 14-300) after PCR diagnosis; of them 142 (82%) patients seroconverted; the lowest seroconversion rate was observed in patients with hematological malignancies (79%). Our univariable model showed that the following factors were predictive of low titer: lower ANC, p=0.01; hematologic malignancy, p=0.023; receiving steroids in the last 14 days, p=0.032; time since last chemotherapy or immunosuppressive therapy less than 30 days, p=0.002; and being on active chemotherapy in the last 3 months prior to infection, p<0.001. !!{{ Conclusions: }} SARS-CoV-2 antibodies developed in most immunocompromised patients with COVID-19 infection in our study. Mortality was relatively low in our patients. Our univariable and multivariable models showed multiple variables that predict severity of infections and antibody response post COVID-19 infection. These observations may guide choice of active therapy during infection and the best timing of vaccination in this high-risk population. !!{{ Keywords: }} COVID 19; SARS-CoV-2; cancer; chemotherapy; children; immunocompromised; seroconversion; stem cell transplant. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381983/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. | |
| 1245363 | 897 | 진단 | chance | Term | chance | abstract | None | 2869 | 10.1186/s12879-021-06829-7 | Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials | Cathrine Axfors@@@Perrine Janiaud@@@Andreas M. Schmitt@@@Janneke van’t Hooft@@@Emily R. Smith@@@Noah A. Haber@@@Akin Abayomi@@@Manal Abduljalil@@@Abdulkarim Abdulrahman@@@Yeny Acosta-Ampudia@@@Manuela Aguilar-Guisado@@@Farah Al-Beidh@@@Marissa M. Alejandria@@@Rachelle N. Alfonso@@@Mohammad Ali@@@Manaf AlQahtani@@@Alaa AlZamrooni@@@Juan-Manuel Anaya@@@Mark Angelo C. Ang@@@Ismael F. Aomar@@@Luis E. Argumanis@@@Alexander Averyanov@@@Vladimir P. Baklaushev@@@Olga Balionis@@@Thomas Benfield@@@Scott Berry@@@Nadia Birocco@@@Lynn B. Bonifacio@@@Asha C. Bowen@@@Abbie Bown@@@Carlos Cabello-Gutierrez@@@Bernardo Camacho@@@Adrian Camacho-Ortiz@@@Sally Campbell-Lee@@@Damon H. Cao@@@Ana Cardesa@@@Jose M. Carnate@@@German Jr. J. Castillo@@@Rossana Cavallo@@@Fazle R. Chowdhury@@@Forhad U. H. Chowdhury@@@Giovannino Ciccone@@@Antonella Cingolani@@@Fresthel Monica M. Climacosa@@@Veerle Compernolle@@@Carlo Francisco N. Cortez@@@Abel Costa Neto@@@Sergio D’Antico@@@James Daly@@@Franca Danielle@@@Joshua S. Davis@@@Francesco Giuseppe De Rosa@@@Justin T. Denholm@@@Claudia M. Denkinger@@@Daniel Desmecht@@@Juan C. D?az-Coronado@@@Juan A. D?az Ponce-Medrano@@@Anne-Fran?oise Donneau@@@Teresita E. Dumagay@@@Susanna Dunachie@@@Cecile C. Dungog@@@Olufemi Erinoso@@@Ivy Mae S. Escasa@@@Lise J. Estcourt@@@Amy Evans@@@Agnes L. M. Evasan@@@Christian J. Fareli@@@Veronica Fernandez-Sanchez@@@Claudia Galassi@@@Juan E. Gallo@@@Patricia J. Garcia@@@Patricia L. Garcia@@@Jesus A. Garcia@@@Mutien Garigliany@@@Elvira Garza-Gonzalez@@@Deonne Thaddeus V. Gauiran@@@Paula A. Gaviria Garc?a@@@Jose-Antonio Giron-Gonzalez@@@David G?mez-Almaguer@@@Anthony C. Gordon@@@Andr? Gothot@@@Jeser Santiago Grass Guaqueta@@@Cameron Green@@@David Grimaldi@@@Naomi E. Hammond@@@Heli Harvala@@@Francisco M. Heralde@@@Jesica Herrick@@@Alisa M. Higgins@@@Thomas E. Hills@@@Jennifer Hines@@@Karin Holm@@@Ashraful Hoque@@@Eric Hoste@@@Jose M. Ignacio@@@Alexander V. Ivanov@@@Maike Janssen@@@Jeffrey H. Jennings@@@Vivekanand Jha@@@Ruby Anne N. King@@@Jens Kjeldsen-Kragh@@@Paul Klenerman@@@Aditya Kotecha@@@Fiorella Krapp@@@Luciana Labanca@@@Emma Laing@@@Mona Landin-Olsson@@@Pierre-Fran?ois Laterre@@@Lyn-Li Lim@@@Jodor Lim@@@Oskar Ljungquist@@@Jorge M. Llaca-D?az@@@Concepci?n L?pez-Robles@@@Salvador L?pez-C?rdenas@@@Ileana Lopez-Plaza@@@Josephine Anne C. Lucero@@@Maria Lundgren@@@Juan Mac?as@@@Sandy C. Maganito@@@Anna Flor G. Malundo@@@Rub?n D. Manrique@@@Paola M. Manzini@@@Miguel Marcos@@@Ignacio Marquez@@@Francisco Javier Mart?nez-Marcos@@@Ana M. Mata@@@Colin J. McArthur@@@Zoe K. McQuilten@@@Bryan J. McVerry@@@David K. Menon@@@Geert Meyfroidt@@@Ma. Angelina L. Mirasol@@@Beno?t Misset@@@James S. Molton@@@Alric V. Mondragon@@@Diana M. Monsalve@@@Parastoo Moradi Choghakabodi@@@Susan C. Morpeth@@@Paul R. Mouncey@@@Michel Moutschen@@@Carsten M?ller-Tidow@@@Erin Murphy@@@Tome Najdovski@@@Alistair D. Nichol@@@Henrik Nielsen@@@Richard M. Novak@@@Matthew V. N. O’Sullivan@@@Julian Olalla@@@Akin Osibogun@@@Bodunrin Osikomaiya@@@Salvador Oyonarte@@@Juan M. Pardo-Oviedo@@@Mahesh C. Patel@@@David L. Paterson@@@Carlos A. Pe?a-Perez@@@Angel A. Perez-Calatayud@@@Eduardo P?rez-Alba@@@Anastasia Perkina@@@Naomi Perry@@@Mandana Pouladzadeh@@@Inmaculada Poyato@@@David J. Price@@@Anne Kristine H. Quero@@@Md. M. Rahman@@@Md. S. Rahman@@@Mayur Ramesh@@@Carolina Ram?rez-Santana@@@Magnus Rasmussen@@@Megan A. Rees@@@Eduardo Rego@@@Jason A. Roberts@@@David J. Roberts@@@Yhojan Rodr?guez@@@Jes?s Rodr?guez-Ba?o@@@Benjamin A. Rogers@@@Manuel Rojas@@@Alberto Romero@@@Kathryn M. Rowan@@@Fabio Saccona@@@Mehdi Safdarian@@@Maria Clariza M. Santos@@@Joe Sasadeusz@@@Gitana Scozzari@@@Manu Shankar-Hari@@@Gorav Sharma@@@Thomas Snelling@@@Alonso Soto@@@Pedrito Y. Tagayuna@@@Amy Tang@@@Geneva Tatem@@@Luciana Teofili@@@Steven Y. C. Tong@@@Alexis F. Turgeon@@@Januario D. Veloso@@@Balasubramanian Venkatesh@@@Yanet Ventura-Enriquez@@@Steve A. Webb@@@Lothar Wiese@@@Christian Wik?n@@@Erica M. Wood@@@Gaukhar M. Yusubalieva@@@Kai Zacharowski@@@Ryan Zarycha | 202111 | Meta-Analysis | PMC | Background Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials (Open Science Framework, https://doi.org/10.17605/OSF.IO/GEHFX ). Methods In this collaborative systematic review and meta-analysis, clinical trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform), the Cochrane COVID-19 register, the LOVE database, and PubMed were searched until April 8, 2021. Investigators of trials registered by March 1, 2021, without published results were contacted via email. Eligible were ongoing, discontinued and completed randomized clinical trials that compared convalescent plasma with placebo or no treatment in COVID-19 patients, regardless of setting or treatment schedule. Aggregated mortality data were extracted from publications or provided by investigators of unpublished trials and combined using the Hartung?Knapp?Sidik?Jonkman random effects model. We investigated the contribution of unpublished trials to the overall evidence. Results A total of 16,477 patients were included in 33 trials (20 unpublished with 3190 patients, 13 published with 13,287 patients). 32 trials enrolled only hospitalized patients (including 3 with only intensive care unit patients). Risk of bias was low for 29/33 trials. Of 8495 patients who received convalescent plasma, 1997 died (23%), and of 7982 control patients, 1952 died (24%). The combined risk ratio for all-cause mortality was 0.97 (95% confidence interval: 0.92; 1.02) with between-study heterogeneity not beyond chance (I 2 =?0%). The RECOVERY trial had 69.8% and the unpublished evidence 25.3% of the weight in the meta-analysis. Conclusions Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care. Supplementary Information The online version contains supplementary material available at 10.1186/s12879-021-06829-7. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605464/ | 2 | 1471-2334 | BMC Infectious Diseases | London : BioMed Central | |
| 1242350 | 897 | 진단 | group | Term | group | abstract | 집단 | 2818 | 10.1186/s12879-021-06065-z | Development and validation of a simple-to-use nomogram to predict the deterioration and survival of patients with COVID-19 | Zhiyong Zeng@@@Chaohui Wu@@@Zhenlv Lin@@@Yong Ye@@@Shaodan Feng@@@Yingying Fang@@@Yanmei Huang@@@Minhua Li@@@Debing Du@@@Gongping Chen@@@Dezhi Kang | 202104 | Research | PMC | Background COVID-19 pandemic has forced physicians to quickly determine the patient’s condition and choose treatment strategies. This study aimed to build and validate a simple tool that can quickly predict the deterioration and survival of COVID-19 patients. Methods A total of 351 COVID-19 patients admitted to the Third People’s Hospital of Yichang between 9 January to 25 March 2020 were retrospectively analyzed. Patients were randomly grouped into training ( n =?246) or a validation ( n =?105) dataset. Risk factors associated with deterioration were identified using univariate logistic regression and least absolute shrinkage and selection operator (LASSO) regression. The factors were then incorporated into the nomogram. Kaplan-Meier analysis was used to compare the survival of patients between the low- and high-risk groups divided by the cut-off point. Results The least absolute shrinkage and selection operator (LASSO) regression was used to construct the nomogram via four parameters (white blood cells, C-reactive protein, lymphocyte≥0.8?×?10 9 /L, and lactate dehydrogenase ≥400?U/L). The nomogram showed good discriminative performance with the area under the receiver operating characteristic (AUROC) of 0.945 (95% confidence interval: 0.91?0.98), and good calibration ( P =?0.539). Besides, the nomogram showed good discrimination performance and good calibration in the validation and total cohorts (AUROC?=?0.979 and AUROC?=?0.954, respectively). Decision curve analysis demonstrated that the model had clinical application value. Kaplan-Meier analysis illustrated that low-risk patients had a significantly higher 8-week survival rate than those in the high-risk group (100% vs 71.41% and P <?0.0001). Conclusion A simple-to-use nomogram with excellent performance in predicting deterioration risk and survival of COVID-19 patients was developed and validated. However, it is necessary to verify this nomogram using a large-scale multicenter study. Supplementary Information The online version contains supplementary material available at 10.1186/s12879-021-06065-z. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050645/ | 2 | 1471-2334 | BMC Infectious Diseases | London : BioMed Central | |
| 1242333 | 897 | 진단 | build | Term | build | abstract | None | 2818 | 10.1186/s12879-021-06065-z | Development and validation of a simple-to-use nomogram to predict the deterioration and survival of patients with COVID-19 | Zhiyong Zeng@@@Chaohui Wu@@@Zhenlv Lin@@@Yong Ye@@@Shaodan Feng@@@Yingying Fang@@@Yanmei Huang@@@Minhua Li@@@Debing Du@@@Gongping Chen@@@Dezhi Kang | 202104 | Research | PMC | Background COVID-19 pandemic has forced physicians to quickly determine the patient’s condition and choose treatment strategies. This study aimed to build and validate a simple tool that can quickly predict the deterioration and survival of COVID-19 patients. Methods A total of 351 COVID-19 patients admitted to the Third People’s Hospital of Yichang between 9 January to 25 March 2020 were retrospectively analyzed. Patients were randomly grouped into training ( n =?246) or a validation ( n =?105) dataset. Risk factors associated with deterioration were identified using univariate logistic regression and least absolute shrinkage and selection operator (LASSO) regression. The factors were then incorporated into the nomogram. Kaplan-Meier analysis was used to compare the survival of patients between the low- and high-risk groups divided by the cut-off point. Results The least absolute shrinkage and selection operator (LASSO) regression was used to construct the nomogram via four parameters (white blood cells, C-reactive protein, lymphocyte≥0.8?×?10 9 /L, and lactate dehydrogenase ≥400?U/L). The nomogram showed good discriminative performance with the area under the receiver operating characteristic (AUROC) of 0.945 (95% confidence interval: 0.91?0.98), and good calibration ( P =?0.539). Besides, the nomogram showed good discrimination performance and good calibration in the validation and total cohorts (AUROC?=?0.979 and AUROC?=?0.954, respectively). Decision curve analysis demonstrated that the model had clinical application value. Kaplan-Meier analysis illustrated that low-risk patients had a significantly higher 8-week survival rate than those in the high-risk group (100% vs 71.41% and P <?0.0001). Conclusion A simple-to-use nomogram with excellent performance in predicting deterioration risk and survival of COVID-19 patients was developed and validated. However, it is necessary to verify this nomogram using a large-scale multicenter study. Supplementary Information The online version contains supplementary material available at 10.1186/s12879-021-06065-z. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050645/ | 2 | 1471-2334 | BMC Infectious Diseases | London : BioMed Central | |
| 1243748 | 897 | 진단 | Septic shock | Disease | septic shock | abstract | 패혈성 쇼크 | 2844 | 10.1186/s12879-021-05814-4 | Identification of risk factors for in-hospital death of COVID - 19 pneumonia -- lessions from the early outbreak | Zhigang Wang@@@Zhiqiang Wang | 202101 | Research Article | PMC | Background To examine the clinical characteristics and identify independent risk factors for in-hospital mortality of 2019 novel coronavirus (COVID-19) pneumonia. Methods A total of 156 patients diagnosed with COVID-19 pneumonia at the Central Hospital of Wuhan from January 29, 2020, to March 20, 2020, and 20 healthy individuals were enrolled in this single-centered retrospective study. The epidemiological parameters, clinical presentations, underlying diseases, laboratory test results, and disease outcomes were collected and analyzed. Results The median age of all enrolled patients was 66?years. At least one underlying disease was identified in 101 COVID-19 patients, with hypertension being the most common one, followed by cardiovascular disease and diabetes. The most common symptoms identified upon admission were fever, cough, dyspnea, and fatigue. Compared to survival cases, patients who died during hospitalization had higher plasma levels of D-dimer, creatinine, creatine kinase, lactate dehydrogenase, lactate, and lower percentage of lymphocytes (LYM [%]), platelet count and albumin levels. Most enrolled patients received antibiotics and anti-viral treatment. In addition, 60 patients received corticosteroids, and 51 received intravenous immunoglobulin infusion. Forty-four patients received noninvasive ventilation and 19 received invasive ventilation. Respiratory failure was the most frequently observed complication (106 [67.9%]), followed by sepsis (103 [66.0%]), acute respiratory distress syndrome (ARDS) (67 [42.9%]), and septic shock (50 [32.1%]). Multivariable regression suggested that advanced age (OR [odds ratio]?=?1.098, 95% CI [confidence interval]: 1.006?1.199, P =?0.037), shorter duration from onset to admission (OR?=?0.853, 95% CI: 0.750?0.969, P =?0.015) and elevated lactate level upon admission (OR?=?2.689, 95% CI: 1.044?6.926, P =?0.040) were independent risk factors for in-hospital mortality for COVID-19 infection. Meanwhile, increased LYM (%) at admission (OR?=?0.787, 95% CI: 0.686?0.903, P =?0.001) indicated a better prognosis. Conclusions In this study, we discovered that age, duration from onset to admission, LYM (%), and lactate level upon admission were independent factors that affecting the in-hospital mortality rate. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829622/ | 2 | 1471-2334 | BMC Infectious Diseases | London : BioMed Central | |
| 1242330 | 897 | 진단 | analyzed | Action | analyzed | abstract | None | 2818 | 10.1186/s12879-021-06065-z | Development and validation of a simple-to-use nomogram to predict the deterioration and survival of patients with COVID-19 | Zhiyong Zeng@@@Chaohui Wu@@@Zhenlv Lin@@@Yong Ye@@@Shaodan Feng@@@Yingying Fang@@@Yanmei Huang@@@Minhua Li@@@Debing Du@@@Gongping Chen@@@Dezhi Kang | 202104 | Research | PMC | Background COVID-19 pandemic has forced physicians to quickly determine the patient’s condition and choose treatment strategies. This study aimed to build and validate a simple tool that can quickly predict the deterioration and survival of COVID-19 patients. Methods A total of 351 COVID-19 patients admitted to the Third People’s Hospital of Yichang between 9 January to 25 March 2020 were retrospectively analyzed. Patients were randomly grouped into training ( n =?246) or a validation ( n =?105) dataset. Risk factors associated with deterioration were identified using univariate logistic regression and least absolute shrinkage and selection operator (LASSO) regression. The factors were then incorporated into the nomogram. Kaplan-Meier analysis was used to compare the survival of patients between the low- and high-risk groups divided by the cut-off point. Results The least absolute shrinkage and selection operator (LASSO) regression was used to construct the nomogram via four parameters (white blood cells, C-reactive protein, lymphocyte≥0.8?×?10 9 /L, and lactate dehydrogenase ≥400?U/L). The nomogram showed good discriminative performance with the area under the receiver operating characteristic (AUROC) of 0.945 (95% confidence interval: 0.91?0.98), and good calibration ( P =?0.539). Besides, the nomogram showed good discrimination performance and good calibration in the validation and total cohorts (AUROC?=?0.979 and AUROC?=?0.954, respectively). Decision curve analysis demonstrated that the model had clinical application value. Kaplan-Meier analysis illustrated that low-risk patients had a significantly higher 8-week survival rate than those in the high-risk group (100% vs 71.41% and P <?0.0001). Conclusion A simple-to-use nomogram with excellent performance in predicting deterioration risk and survival of COVID-19 patients was developed and validated. However, it is necessary to verify this nomogram using a large-scale multicenter study. Supplementary Information The online version contains supplementary material available at 10.1186/s12879-021-06065-z. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050645/ | 2 | 1471-2334 | BMC Infectious Diseases | London : BioMed Central | |
| 1242506 | 897 | 진단 | aPTT | Term | aPTT | abstract | None | 2821 | 10.1186/s12879-021-05975-2 | Clinical characteristics and outcome of influenza virus infection among adults hospitalized with severe COVID-19: a retrospective cohort study from Wuhan, China | Xunliang Tong@@@Xiaomao Xu@@@Guoyue Lv@@@He Wang@@@Anqi Cheng@@@Dingyi Wang@@@Guohui Fan@@@Yue Zhang@@@Yanming Li | 202104 | Research Article | PMC | Background Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that rapidly spreads worldwide and co-infection of COVID-19 and influenza may occur in some cases. We aimed to describe clinical features and outcomes of severe COVID-19 patients with co-infection of influenza virus. Methods Retrospective cohort study was performed and a total of 140 patients with severe COVID-19 were enrolled in designated wards of Sino-French New City Branch of Tongji Hospital between Feb 8th and March 15th in Wuhan city, Hubei province, China. The demographic, clinical features, laboratory indices, treatment and outcomes of these patients were collected. Results Of 140 severe COVID-19 hospitalized patients, including 73 patients (52.14%) with median age 62?years were influenza virus IgM-positive and 67 patients (47.86%) with median age 66?years were influenza virus IgM-negative. 76 (54.4%) of severe COVID-19 patients were males. Chronic comorbidities consisting mainly of hypertension (45.3%), diabetes (15.8%), chronic respiratory disease (7.2%), cardiovascular disease (5.8%), malignancy (4.3%) and chronic kidney disease (2.2%). Clinical features, including fever (≥38?°C), chill, cough, chest pain, dyspnea, diarrhea and fatigue or myalgia were collected. Fatigue or myalgia was less found in COVID-19 patients with IgM-positive (33.3% vs 50/7%, P =?0.0375). Higher proportion of prolonged activated partial thromboplastin time (APTT)?>?42?s was observed in COVID-19 patients with influenza virus IgM-negative (43.8% vs 23.6%, P =?0.0127). Severe COVID-19 Patients with influenza virus IgM positive have a higher cumulative survivor rate than that of patients with influenza virus IgM negative (Log-rank P =?0.0308). Considering age is a potential confounding variable, difference in age was adjusted between different influenza virus IgM status groups, the HR was 0.29 (95% CI, 0.081?1.100). Similarly, difference in gender was adjusted as above, the HR was 0.262 (95% CI, 0.072?0.952) in the COX regression model. Conclusions Influenza virus IgM positive may be associated with decreasing in-hospital death. Supplementary Information The online version contains supplementary material available at 10.1186/s12879-021-05975-2. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040362/ | 2 | 1471-2334 | BMC Infectious Diseases | London : BioMed Central | |
| 1242507 | 897 | 진단 | branch | Term | branch | abstract | None | 2821 | 10.1186/s12879-021-05975-2 | Clinical characteristics and outcome of influenza virus infection among adults hospitalized with severe COVID-19: a retrospective cohort study from Wuhan, China | Xunliang Tong@@@Xiaomao Xu@@@Guoyue Lv@@@He Wang@@@Anqi Cheng@@@Dingyi Wang@@@Guohui Fan@@@Yue Zhang@@@Yanming Li | 202104 | Research Article | PMC | Background Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that rapidly spreads worldwide and co-infection of COVID-19 and influenza may occur in some cases. We aimed to describe clinical features and outcomes of severe COVID-19 patients with co-infection of influenza virus. Methods Retrospective cohort study was performed and a total of 140 patients with severe COVID-19 were enrolled in designated wards of Sino-French New City Branch of Tongji Hospital between Feb 8th and March 15th in Wuhan city, Hubei province, China. The demographic, clinical features, laboratory indices, treatment and outcomes of these patients were collected. Results Of 140 severe COVID-19 hospitalized patients, including 73 patients (52.14%) with median age 62?years were influenza virus IgM-positive and 67 patients (47.86%) with median age 66?years were influenza virus IgM-negative. 76 (54.4%) of severe COVID-19 patients were males. Chronic comorbidities consisting mainly of hypertension (45.3%), diabetes (15.8%), chronic respiratory disease (7.2%), cardiovascular disease (5.8%), malignancy (4.3%) and chronic kidney disease (2.2%). Clinical features, including fever (≥38?°C), chill, cough, chest pain, dyspnea, diarrhea and fatigue or myalgia were collected. Fatigue or myalgia was less found in COVID-19 patients with IgM-positive (33.3% vs 50/7%, P =?0.0375). Higher proportion of prolonged activated partial thromboplastin time (APTT)?>?42?s was observed in COVID-19 patients with influenza virus IgM-negative (43.8% vs 23.6%, P =?0.0127). Severe COVID-19 Patients with influenza virus IgM positive have a higher cumulative survivor rate than that of patients with influenza virus IgM negative (Log-rank P =?0.0308). Considering age is a potential confounding variable, difference in age was adjusted between different influenza virus IgM status groups, the HR was 0.29 (95% CI, 0.081?1.100). Similarly, difference in gender was adjusted as above, the HR was 0.262 (95% CI, 0.072?0.952) in the COX regression model. Conclusions Influenza virus IgM positive may be associated with decreasing in-hospital death. Supplementary Information The online version contains supplementary material available at 10.1186/s12879-021-05975-2. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040362/ | 2 | 1471-2334 | BMC Infectious Diseases | London : BioMed Central | |
| 1243185 | 897 | 진단 | healthcare worker | Term | healthcare worker | abstract | 의료 종사자 | 2831 | 10.1186/s12879-021-06881-3 | Investigation of the impact of SARS-CoV infection on the immunologic status and lung function after 15?years | Jia Li@@@Yali Zheng@@@Lili Zhao@@@Zhihong Yue@@@Feng Pan@@@Yuehong Chen@@@Bing Yu@@@Yanwen Chen@@@Guangyu Zhao@@@Yusen Zhou@@@Zhancheng Gao | 202111 | Research | PMC | Background We investigate the long-term effects of SARS-CoV on patients’ lung and immune systems 15?years post-infection. SARS-CoV-2 pandemic is ongoing however, another genetically related beta-coronavirus SARS-CoV caused an epidemic in 2003?2004. Methods We enrolled 58 healthcare workers from Peking University People’s Hospital who were infected with SARS-CoV in 2003. We evaluated lung damage by mMRC score, pulmonary function tests, and chest CT. Immune function was assessed by their serum levels of globin, complete components, and peripheral T cell subsets. ELISA was used to detect SARS-CoV-specific IgG antibodies in sera. Results After 15?years of disease onset, 19 (36.5%), 8 (34.6%), and 19 (36.5%) subjects had impaired DL (CO), RV, and FEF 25?75 , respectively. 17 (30.4%) subjects had an mMRC score?≥?2. Fourteen (25.5%) cases had residual CT abnormalities. T regulatory cells were a bit higher in the SARS survivors. IgG antibodies against SARS S-RBD protein and N protein were detected in 11 (18.97%) and 12 (20.69%) subjects, respectively. Subgroup analysis revealed that small airway dysfunction and CT abnormalities were more common in the severe group than in the non-severe group (57.1% vs 22.6%, 54.5% vs 6.1%, respectively, p?<?0.05). Conclusions SARS-CoV could cause permanent damage to the lung, which requires early pulmonary rehabilitation. The long-lived immune memory response against coronavirus requires further studies to assess the potential benefit. Trial registration ClinicalTrials.gov, NCT03443102. Registered prospectively on 25 January 2018 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611627/ | 2 | 1471-2334 | BMC Infectious Diseases | London : BioMed Central | |
| 1243186 | 897 | 진단 | HRCT | Term | hrct | author | HRCT | 2831 | 10.1186/s12879-021-06881-3 | Investigation of the impact of SARS-CoV infection on the immunologic status and lung function after 15?years | Jia Li@@@Yali Zheng@@@Lili Zhao@@@Zhihong Yue@@@Feng Pan@@@Yuehong Chen@@@Bing Yu@@@Yanwen Chen@@@Guangyu Zhao@@@Yusen Zhou@@@Zhancheng Gao | 202111 | Research | PMC | Background We investigate the long-term effects of SARS-CoV on patients’ lung and immune systems 15?years post-infection. SARS-CoV-2 pandemic is ongoing however, another genetically related beta-coronavirus SARS-CoV caused an epidemic in 2003?2004. Methods We enrolled 58 healthcare workers from Peking University People’s Hospital who were infected with SARS-CoV in 2003. We evaluated lung damage by mMRC score, pulmonary function tests, and chest CT. Immune function was assessed by their serum levels of globin, complete components, and peripheral T cell subsets. ELISA was used to detect SARS-CoV-specific IgG antibodies in sera. Results After 15?years of disease onset, 19 (36.5%), 8 (34.6%), and 19 (36.5%) subjects had impaired DL (CO), RV, and FEF 25?75 , respectively. 17 (30.4%) subjects had an mMRC score?≥?2. Fourteen (25.5%) cases had residual CT abnormalities. T regulatory cells were a bit higher in the SARS survivors. IgG antibodies against SARS S-RBD protein and N protein were detected in 11 (18.97%) and 12 (20.69%) subjects, respectively. Subgroup analysis revealed that small airway dysfunction and CT abnormalities were more common in the severe group than in the non-severe group (57.1% vs 22.6%, 54.5% vs 6.1%, respectively, p?<?0.05). Conclusions SARS-CoV could cause permanent damage to the lung, which requires early pulmonary rehabilitation. The long-lived immune memory response against coronavirus requires further studies to assess the potential benefit. Trial registration ClinicalTrials.gov, NCT03443102. Registered prospectively on 25 January 2018 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611627/ | 2 | 1471-2334 | BMC Infectious Diseases | London : BioMed Central | |
| 1212049 | 897 | 진단 | COVID-19 vaccination | Treatment | covid-19 vaccination | abstract | Covid-19 백신 접종 | 77309 | 10.3389/fimmu.2022.956369 | Serum peptidome profiles immune response of COVID-19 Vaccine administration | Wenjia Zhang@@@Dandan Li@@@Bin Xu@@@Lanlan Xu@@@Qian Lyu@@@Xiangyi Liu@@@Zhijie Li@@@Jian Zhang@@@Wei Sun@@@Qingwei Ma@@@Liang Qiao@@@Pu Liao | 202208 | Article | PMC | {{{ Abstract }}} !!{{ Background: }} Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused significant loss of life and property. In response to the serious pandemic, recently developed vaccines against SARS-CoV-2 have been administrated to the public. Nevertheless, the research on human immunization response against COVID-19 vaccines is insufficient. Although much information associated with vaccine efficacy, safety and immunogenicity has been reported by pharmaceutical companies based on laboratory studies and clinical trials, vaccine evaluation needs to be extended further to better understand the effect of COVID-19 vaccines on human beings. !!{{ Methods: }} We performed a comparative peptidome analysis on serum samples from 95 participants collected at four time points before and after receiving CoronaVac. The collected serum samples were analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to profile the serum peptides, and also subjected to humoral and cellular immune response analyses to obtain typical immunogenicity information. !!{{ Results: }} Significant difference in serum peptidome profiles by MALDI-TOF MS was observed after vaccination. By supervised statistical analysis, a total of 13 serum MALDI-TOF MS feature peaks were obtained on day 28 and day 42 of vaccination. The feature peaks were identified as component C1q receptor, CD59 glycoprotein, mannose-binding protein C, platelet basic protein, CD99 antigen, Leucine-rich alpha-2-glycoprotein, integral membrane protein 2B, platelet factor 4 and hemoglobin subunits. Combining with immunogenicity analysis, the study provided evidence for the humoral and cellular immune responses activated by CoronaVac. Furthermore, we found that it is possible to distinguish neutralizing antibody (NAbs)-positive from NAbs-negative individuals after complete vaccination using the serum peptidome profiles by MALDI-TOF MS together with machine learning methods, including random forest (RF), partial least squares-discriminant analysis (PLS-DA), linear support vector machine (SVM) and logistic regression (LR). !!{{ Conclusions: }} The study shows the promise of MALDI-TOF MS-based serum peptidome analysis for the assessment of immune responses activated by COVID-19 vaccination, and discovered a panel of serum peptides biomarkers for COVID-19 vaccination and for NAbs generation. The method developed in this study can help not only in the development of new vaccines, but also in the post-marketing evaluation of developed vaccines. !!{{ Keywords: }} COVID-19; MALDI-TOF; immune response; peptidome; serum; vaccine. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450691/ | 109 | 1664-3224 | Frontiers in Immunology | [Lausanne : Frontiers Research Foundation]. |
| 판매제공처 홈페이지 | 판매담당자 | 연락처 | 이메일 |
|---|---|---|---|
| www.vinea.co.kr | (주)비네아 | 010-8703-2109 | bongbong@vinea.co.kr |
| 상품명 | 가격 |
|---|---|
| COVID19 데이터셋 | 3000000 |
| 진단 데이터셋 공개데이터 | 0 |
| 신종인플루엔자 데이터셋 | 2000000 |
| 홍역 데이터셋 | 3000000 |
| 제약 및 취소/환불 규정 안내 |
|---|
| 데이터 상품은 디지털화된 상품의 특성상 반품, 취소, 환불 되지 않으나 데이터의 심각한 오류, 상이한 데이터에 한하여 구매자가 요구하는 경우 환불을 진행할 수 있습니다. |
홈